TWI785583B - Monoclonal antibody against new coronavirus and use thereof - Google Patents

Abstract

The present invention relates to immunology and molecular virology, particularly relates to diagnosis, prevention and treatment of new coronaviruses. Specifically, the present invention relates to an anti-new coronavirus monoclonal antibody, and composition containing the antibody (for example, as a diagnostic agent and therapeutic agent). In addition, the present invention further relates to use of the antibody. The antibody of the present invention can be used to diagnose, prevent and/or treat a new coronavirus infection and/or diseases caused by the infection (for example, new coronavirus pneumonia).

Description

A kind of monoclonal antibody against novel coronavirus and application thereof

This paper relates to the fields of immunology and molecular virology, especially the diagnosis, prevention and treatment of novel coronaviruses. In particular, this document relates to antibodies against novel coronaviruses, and compositions (eg, diagnostic and therapeutic agents) comprising such antibodies. Furthermore, the present invention also relates to the use of said antibodies. The antibodies described herein can be used for diagnosing, preventing and/or treating infection by novel coronavirus and/or diseases caused by said infection (eg, novel coronavirus pneumonia).

Novel coronavirus (Severe acute respiratory syndrome coronavirus 2, 2019-nCoV or SARS-CoV-2), was discovered due to cases of viral pneumonia that appeared in Wuhan at the end of 2019. The new coronavirus is a coronavirus that has never been found in humans before. The new strain of the virus was subsequently named by the World Health Organization. From the end of 2019 to April 27, 2020, there were more than 80,000 confirmed cases in China and more than 3,000 cumulative deaths; outside China (South Korea, Iran, Italy, Thailand, the United States, Germany, Australia and other 213 countries) new coronary pneumonia The number of confirmed cases increased to 2,810,325, with a total of 193,825 deaths, posing a major threat to public life and health. As of now, there is still a lack of vaccines and specific therapeutic drugs for the treatment of new coronaviruses.

The novel coronavirus SARS-CoV-2, the causative agent of novel coronavirus pneumonia (COVID-19), is a single-stranded RNA virus that is related to the severe acute respiratory syndrome coronavirus (SARS-CoV) And the Middle East Respiratory Syndrome Coronavirus ( MERS -CoV) that caused the outbreak in 2012 belongs to the Coronaviridae family. Coronavirus particles are round or oval, also pleomorphic, with a diameter of 50-200 nm, belonging to larger viruses. Coronavirus is an enveloped virus. The viral capsid is covered with a lipid envelope, on which a wide spike protein (Spike, S protein, SEQ ID No: 1460) is arranged, shaped like a sun halo. Studies have confirmed that the virus surface of the new coronavirus SARS-CoV-2 has an S protein, which can bind the host cell receptor angiotensin through its receptor binding domain (RBD) during the process of virus infection of the host. Enzyme 2 (ACE2) molecule, which initiates the fusion of the viral membrane and the host cell membrane, causing the host cell to infect the virus.

So far, neutralizing antibodies have proven to be effective treatments for viral diseases. Generally speaking, after being stimulated by an antigen, the B lymphocytes in the patient's body will be activated, transform and differentiate into a variety of different cells, and produce antibodies. According to existing research reports, the anti-new coronavirus antibodies in the peripheral blood of patients with new coronavirus pneumonia are produced and secreted by activated B cells. However, there are many kinds of B cells in the plasma memory of convalescents, and the binding activity and neutralizing potency of antibodies produced by different B cells are also different. So far, no studies have reported antibodies against 2019-nCoV with high binding activity and/or high neutralizing activity.

Therefore, it is necessary to develop antibodies with high binding activity and/or high neutralizing activity against the novel coronavirus SARS-CoV-2, so as to provide effective means for diagnosing, preventing and/or treating novel coronavirus infection.

The following technical solutions provided herein meet the above needs and provide related advantages.

In one aspect, provided herein is an antigen binding unit comprising a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region comprising VH CDR1, VH CDR2 and VH CDR3, the light chain variable region comprising VH CDR1, VH CDR2 and VH CDR3, the light chain variable region comprising The chain variable region comprises VL CDR1, VL CDR2 and VL CDR3; wherein said VH CDR3 comprises a sequence selected from SEQ ID NO: 1-360 and 2971-3005 or compared to SEQ ID NO: 1-360 and 2971-3005 A sequence comprising one or more amino acid additions, deletions, or substitutions, and/or wherein said VL CDR3 comprises a sequence selected from SEQ ID NO: 361-720 and 3076-3110 or a sequence with SEQ ID NO: 361-720 and 3076 -3110 compared to sequences comprising one or more amino acid additions, deletions, or substitutions.

In some embodiments, the antigen binding unit is present at less than 100 nM, less than 50 nM, less than 20 nM, less than 15 nM, less than 10 nM, less than 5 nM, less than 4 nM, less than 3 nM, less than 2 nM, less than 1 nM, less than 0.5 nM, less than 0.1 nM , the equilibrium dissociation constant (KD) of less than 0.05 nM, or less than 0.01 nM binds to the receptor binding domain (RBD) of the novel coronavirus (SARS-CoV-2) S protein.

In some embodiments, the antigen binding unit is less than 20 µg/ml, less than 10 µg/ml, less than 9 µg/ml, less than 8 µg/ml, less than 7 µg/ml, less than 6 µg/ml, less than 5 µg/ml, less than 4 µg/ml, less than 3 µg/ml, less than 2 µg/ml, less than 1 µg/ml, less than 0.5 µg/ml, less than 0.25 µg/ml, less than 0.2 µg/ml, less than 0.1 µg /ml, less than 0.05 µg/ml, or less than 0.001 µg/ml IC ₅₀ neutralizes the novel coronavirus (SARS-CoV-2).

In some embodiments, said VH CDR1 of said antigen binding unit comprises a sequence selected from SEQ ID NO: 1461-1820 and 2901-2935 or comprises one or A sequence of multiple amino acid additions, deletions, or substitutions. In some embodiments, said VH CDR1 of said antigen binding unit comprises a sequence selected from SEQ ID NO: 1461-1820 and 2901-2935. In some embodiments, said VH CDR1 of said antigen binding unit comprises 5, 4, 3, 2 or 1 amino acid additions, deletions, or substitutions compared to SEQ ID NOs: 1461-1820 and 2901-2935 sequence. In some embodiments, the VH CDR1 of the antigen binding unit comprises the same sequence as the CDR1 comprised in SEQ ID NOs: 721-1080 and 3111-3145.

In some embodiments, said VH CDR2 of said antigen binding unit comprises a sequence selected from SEQ ID NO: 1821-2180 and 2936-2970 or comprises one or A sequence of multiple amino acid additions, deletions, or substitutions. In some embodiments, said VH CDR2 of said antigen binding unit comprises a sequence selected from SEQ ID NO: 1821-2180 and 2936-2970. In some embodiments, said VH CDR2 of said antigen binding unit comprises 5, 4, 3, 2 or 1 amino acid additions, deletions, or substitutions compared to SEQ ID NOs: 1821-2180 and 2936-2970 sequence. In some embodiments, the VH CDR2 of the antigen binding unit comprises the same sequence as the CDR2 comprised in SEQ ID NOs: 721-1080 and 3111-3145.

In some embodiments, said VL CDR1 of said antigen binding unit comprises a sequence selected from SEQ ID NO: 2181-2540 and 3006-3040 or comprises one or A sequence of multiple amino acid additions, deletions, or substitutions. In some embodiments, said VL CDR1 of said antigen binding unit comprises a sequence selected from SEQ ID NO: 2181-2540 and 3006-3040. In some embodiments, said VL CDR1 of said antigen binding unit comprises 5, 4, 3, 2 or 1 amino acid additions, deletions, or substitutions compared to SEQ ID NOs: 2181-2540 and 3006-3040 sequence. In some embodiments, the VL CDR1 of the antigen binding unit comprises the same sequence as the CDR1 comprised in SEQ ID NOs: 1081-1440 and 3146-3180.

In some embodiments, said VL CDR2 of said antigen binding unit comprises a sequence selected from SEQ ID NO: 2541-2900 and 3041-3075 or comprises one or A sequence of multiple amino acid additions, deletions, or substitutions. In some embodiments, said VL CDR2 of said antigen binding unit comprises a sequence selected from SEQ ID NO: 2541-2900 and 3041-3075. In some embodiments, said VL CDR2 of said antigen binding unit comprises 5, 4, 3, 2 or 1 amino acid additions, deletions, or substitutions compared to SEQ ID NOs: 2541-2900 and 3041-3075 sequence. In some embodiments, the VL CDR2 of the antigen binding unit comprises the same sequence as the CDR2 comprised in SEQ ID NOs: 1081-1440 and 3146-3180.

In some embodiments, said VH of said antigen binding unit comprises a sequence selected from SEQ ID NO: 721-1080 and 3111-3145 or comprises one or more of SEQ ID NO: 721-1080 and 3111-3145 A sequence of amino acid additions, deletions, or substitutions. In some embodiments, said VH of said antigen binding unit comprises a sequence selected from SEQ ID NO: 721-1080 and 3111-3145. In some embodiments, said VH of said antigen binding unit comprises 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 compared to SEQ ID NO: 721-1080 and 3111-3145 A sequence of amino acid additions, deletions, or substitutions. In some embodiments, said VH of said antigen binding unit comprises at least 80%, 85%, 90%, 91%, 92%, 93% of a sequence selected from SEQ ID NO: 721-1080 and 3111-3145 %, 94%, 95%, 96%, 97%, 98%, 99%, or 99% identical sequences.

In some embodiments, said VL of said antigen binding unit comprises a sequence selected from SEQ ID NO: 1081-1440 and 3146-3180 or comprises one or more of SEQ ID NO: 1081-1440 and 3146-3180 A sequence of amino acid additions, deletions, or substitutions. In some embodiments, said VL of said antigen binding unit comprises a sequence selected from SEQ ID NO: 1081-1440 and 3146-3180. In some embodiments, said VL of said antigen binding unit comprises 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 compared to SEQ ID NO: 1081-1440 and 3146-3180 A sequence of amino acid additions, deletions, or substitutions. In some embodiments, said VL of said antigen binding unit comprises at least 80%, 85%, 90%, 91%, 92%, 93% of a sequence selected from SEQ ID NO: 1081-1440 and 3146-3180 %, 94%, 95%, 96%, 97%, 98%, 99%, or 99% identical sequences.

In another aspect, provided herein is an antigen binding unit comprising a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region comprising VH CDR1, VH CDR2 and VH CDR3, said The light chain variable region comprises VL CDR1, VL CDR2 and VL CDR3; wherein said VH CDR1 comprises a sequence selected from SEQ ID NO: 1461-1820 and 2901-2935, corresponding to SEQ ID NO: 1461-1820 and 2901-2935 A sequence comprising one or more amino acid additions, deletions, or substitutions, or a sequence identical to the CDR1 contained in SEQ ID NO: 721-1080 and 3111-3145, wherein the VH CDR2 comprises a sequence selected from the group consisting of SEQ ID NO: The sequence of 1821-2180 and 2936-2970, the sequence comprising one or more amino acid additions, deletions, or substitutions compared to SEQ ID NO: 1821-2180 and 2936-2970, or the sequence compared to SEQ ID NO: 721-1080 and 3111 - the same sequence as the CDR2 contained in 3145, wherein said VH CDR3 comprises a sequence selected from SEQ ID NO: 1-360 and 2971-3005, compared to SEQ ID NO: 1-360 and 2971-3005 comprising one or A sequence of multiple amino acid additions, deletions, or substitutions, or the same sequence as the CDR3 contained in SEQ ID NO: 721-1080 and 3111-3145; and/or wherein the VL CDR1 comprises a sequence selected from SEQ ID NO: 2181 - a sequence of 2540 and 3006-3040, a sequence comprising one or more amino acid additions, deletions, or substitutions compared to SEQ ID NO: 2181-2540 and 3006-3040, or a sequence compared to SEQ ID NO: 1081-1440 and 3146- The same sequence as the CDR1 contained in 3180, the VL CDR2 comprising a sequence selected from SEQ ID NO: 2541-2900 and 3041-3075, compared with SEQ ID NO: 2541-2900 and 3041-3075 comprising one or more A sequence of amino acid additions, deletions, or substitutions, or a sequence identical to the CDR2 contained in SEQ ID NO: 1081-1440 and 3146-3180, the VL CDR3 comprising a sequence selected from the group consisting of SEQ ID NO: 361-720 and 3076-3110 The sequence comprising one or more amino acid additions, deletions, or substitutions compared to SEQ ID NO: 361-720 and 3076-3110, or the C contained in SEQ ID NO: 1081-1440 and 3146-3180 Same sequence as DR3.

In another aspect, provided herein is an antigen binding unit comprising a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region comprising VH CDR1, VH CDR2 and VH CDR3, said The light chain variable region comprises VL CDR1, VL CDR2 and VL CDR3; wherein said VH CDR1 comprises a sequence selected from SEQ ID NO: 1461-1820 and 2901-2935 or is the same as SEQ ID NO: 1461-1820 and 2901-2935 Compared to a sequence comprising one or more amino acid additions, deletions, or substitutions, wherein the VH CDR2 comprises a sequence selected from SEQ ID NO: 1821-2180 and 2936-2970 or is the same as SEQ ID NO: 1821-2180 and 2936-2970 Compared to a sequence comprising one or more amino acid additions, deletions, or substitutions, wherein the VH CDR3 comprises a sequence selected from SEQ ID NO: 1-360 and 2971-3005 or with SEQ ID NO: 1-360 and 2971- 3005 compared to a sequence comprising one or more amino acid additions, deletions, or substitutions; and/or wherein said VL CDR1 comprises a sequence selected from SEQ ID NO: 2181-2540 and 3006-3040 or with SEQ ID NO: 2181- Compared with 2540 and 3006-3040, the sequence comprising one or more amino acid additions, deletions, or substitutions, the VL CDR2 comprises a sequence selected from SEQ ID NO: 2541-2900 and 3041-3075 or a sequence with SEQ ID NO: 2541- Compared with 2900 and 3041-3075, the sequence comprising one or more amino acid additions, deletions, or substitutions, the VL CDR3 comprises a sequence selected from SEQ ID NO: 361-720 and 3076-3110 or a sequence with SEQ ID NO: 361- 720 is a sequence comprising one or more amino acid additions, deletions, or substitutions compared to 3076-3110.

In some embodiments, said VH of said antigen binding unit comprises a sequence selected from SEQ ID NO: 721-1080 and 3111-3145 or comprises one or more of SEQ ID NO: 721-1080 and 3111-3145 A sequence of amino acid additions, deletions, or substitutions. In some embodiments, said VH of said antigen binding unit comprises a sequence selected from SEQ ID NO: 721-1080 and 3111-3145. In some embodiments, said VH of said antigen binding unit comprises 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 compared to SEQ ID NO: 721-1080 and 3111-3145 A sequence of amino acid additions, deletions, or substitutions. In some embodiments, said VH of said antigen binding unit comprises at least 80%, 85%, 90%, 91%, 92%, 93% of a sequence selected from SEQ ID NO: 721-1080 and 3111-3145 %, 94%, 95%, 96%, 97%, 98%, 99%, or 99% identical sequences.

In some embodiments, said VL of said antigen binding unit comprises a sequence selected from SEQ ID NO: 1081-1440 and 3146-3180 or comprises one or more of SEQ ID NO: 1081-1440 and 3146-3180 A sequence of amino acid additions, deletions, or substitutions. In some embodiments, said VL of said antigen binding unit comprises a sequence selected from SEQ ID NO: 1081-1440 and 3146-3180. In some embodiments, said VL of said antigen binding unit comprises 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 compared to SEQ ID NO: 1081-1440 and 3146-3180 A sequence of amino acid additions, deletions, or substitutions. In some embodiments, said VL of said antigen binding unit comprises at least 80%, 85%, 90%, 91%, 92%, 93% of a sequence selected from SEQ ID NO: 1081-1440 and 3146-3180 %, 94%, 95%, 96%, 97%, 98%, 99%, or 99% identical sequences.

In some embodiments, the antigen binding unit is less than 100 nM, less than 50 nM, less than 20 nM, less than 15 nM, less than 10 nM, less than 5 nM, less than 4 nM, less than 3 nM, less than 2 nM, less than 1 nM, less than 0.5 nM, less than 0.1 nM The equilibrium dissociation constant (KD) of nM, less than 0.05 nM, or less than 0.01 nM binds to the receptor binding domain (RBD) of the novel coronavirus (SARS-CoV-2) S protein.

In some embodiments, the antigen binding unit is less than 20 µg/ml, less than 10 µg/ml, less than 9 µg/ml, less than 8 µg/ml, less than 7 µg/ml, less than 6 µg/ml, less than 5 µg/ml, less than 4 µg/ml, less than 3 µg/ml, less than 2 µg/ml, less than 1 µg/ml, less than 0.5 µg/ml, less than 0.25 µg/ml, less than 0.2 µg/ml, less than 0.1 µg /ml, less than 0.05 µg/ml, or less than 0.001 µg/ml IC50 neutralizes the novel coronavirus (SARS-CoV-2).

In another aspect, provided herein is an antigen binding unit comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises a compound selected from SEQ ID NO: 721-1080 and 3111-3145 A sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99% identity to the sequence, and/or Or wherein said VL comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96% of a sequence selected from SEQ ID NO: 1081-1440 and 3146-3180 , 97%, 98%, 99%, or 99% identical sequences.

In some embodiments, the antigen binding unit is less than 100 nM, less than 50 nM, less than 20 nM, less than 15 nM, less than 10 nM, less than 5 nM, less than 4 nM, less than 3 nM, less than 2 nM, less than 1 nM, less than 0.5 nM, less than 0.1 nM The equilibrium dissociation constant (KD) of nM, less than 0.05 nM, or less than 0.01 nM binds to the receptor binding domain (RBD) of the novel coronavirus (SARS-CoV-2) S protein.

In some embodiments, the antigen binding unit is less than 20 µg/ml, less than 10 µg/ml, less than 9 µg/ml, less than 8 µg/ml, less than 7 µg/ml, less than 6 µg/ml, less than 5 µg/ml, less than 4 µg/ml, less than 3 µg/ml, less than 2 µg/ml, less than 1 µg/ml, less than 0.5 µg/ml, less than 0.25 µg/ml, less than 0.2 µg/ml, less than 0.1 µg /ml, less than 0.05 µg/ml, or less than 0.001 µg/ml IC50 neutralizes the novel coronavirus (SARS-CoV-2).

In some embodiments, the antigen binding unit further comprises a heavy chain constant region (CH). In some embodiments, the CH of the antigen binding unit comprises the sequence of SEQ ID NO: 1457 or a sequence comprising one or more amino acid additions, deletions, or substitutions compared to SEQ ID NO: 1457. In some embodiments, said CH of said antigen binding unit comprises a sequence selected from SEQ ID NO: 1457. In some embodiments, said CH of said antigen binding unit comprises 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid addition, deletion, or substituted sequences. In some embodiments, said CH of said antigen binding unit comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of a sequence selected from SEQ ID NO: 1457. %, 96%, 97%, 98%, 99%, or 99% identical sequences.

In some embodiments, the antigen binding unit further comprises a light chain constant region (CL). In some embodiments, said CL of said antigen binding unit comprises the sequence of SEQ ID NO: 1458 or a sequence comprising one or more amino acid additions, deletions, or substitutions compared to SEQ ID NO: 1458. In some embodiments, said CL of said antigen binding unit comprises a sequence selected from SEQ ID NO: 1458. In some embodiments, said CL of said antigen binding unit comprises 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid addition, deletion, or substituted sequences. In some embodiments, said CL of said antigen binding unit comprises at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% of a sequence selected from SEQ ID NO: 1458 %, 96%, 97%, 98%, 99%, or 99% identical sequences.

In another aspect, provided herein is an isolated nucleic acid molecule encoding an antigen binding unit as defined herein above.

In another aspect, provided herein is a vector comprising an isolated nucleic acid molecule as defined above. The vector described herein can be a cloning vector or an expression vector. In some embodiments, the vectors described herein are, for example, plasmids, cosmids, or phage, among others.

In another aspect, a host cell comprising an isolated nucleic acid molecule or vector described herein is also provided. Such host cells include, but are not limited to, prokaryotic cells such as E. coli cells, and eukaryotic cells such as yeast cells, insect cells, plant cells, and animal cells (such as mammalian cells, such as mouse cells, human cells, etc.). The cells described herein can also be cell lines, such as HEK293 cells.

In another aspect, there is also provided a method for preparing the antigen-binding unit described herein, comprising culturing the host cell described herein under suitable conditions, and recovering the antigen-binding unit described herein from the cell culture.

In another aspect, provided herein is a composition comprising an antigen binding unit, isolated nucleic acid molecule, vector or host cell as described above.

In another aspect, provided herein is a kit comprising an antigen binding unit described herein. In some embodiments, an antigen binding unit described herein further comprises a detectable label. In some embodiments, the kit further includes a second antibody that specifically recognizes an antigen binding unit described herein. Preferably, said second antibody further comprises a detectable label. Such detectable labels are well known to those skilled in the art and include, but are not limited to, radioactive isotopes, fluorescent substances, luminescent substances, colored substances and enzymes (such as horseradish peroxidase) and the like.

In another aspect, provided herein is a method for detecting the presence or level of a novel coronavirus or its S protein or RBD of the S protein in a sample, which comprises using the antigen-binding unit described herein. In some embodiments, an antigen binding unit described herein further comprises a detectable label. In another preferred embodiment, the method further comprises detecting the antigen binding unit described herein using a second antibody carrying a detectable label. The methods can be used for diagnostic purposes (eg, the sample is a sample from a patient), or non-diagnostic purposes (eg, the sample is a sample of cells rather than a sample from a patient).

In another aspect, this paper provides a method for diagnosing whether a subject is infected with a new coronavirus, which includes: using the antigen binding unit described herein to detect whether the new coronavirus or its S protein or the RBD of the S protein is detected from the affected person. present in the subject's sample. In some embodiments, an antigen binding unit described herein further comprises a detectable label. In another preferred embodiment, the method further comprises detecting the antigen binding unit described herein using a second antibody carrying a detectable label.

In another aspect, the use of the antigen-binding unit described herein in the preparation of a kit for detecting the presence or level of a novel coronavirus or its S protein or RBD of the S protein in a sample is provided, Or for diagnosing whether the subject is infected with the new coronavirus.

In another aspect, provided herein is a pharmaceutical composition comprising an antigen-binding unit described herein, and a pharmaceutically acceptable carrier and/or excipient.

In another aspect, provided herein are methods for neutralizing the virulence of a novel coronavirus in a sample comprising contacting a sample comprising a novel coronavirus with an antigen binding unit described herein. Such methods may be used for therapeutic purposes, or non-therapeutic purposes (eg, the sample is a sample of cells rather than a patient or a sample from a patient).

In another aspect, a use of the antigen-binding unit described herein for the preparation of a medicament for neutralizing the virulence of the novel coronavirus in a sample is provided. In another aspect, provided herein is an antigen binding unit as described above for use in neutralizing the virulence of a novel coronavirus in a sample.

In another aspect, there is provided the use of the antigen-binding unit described herein in the preparation of a pharmaceutical composition for preventing or treating a novel coronavirus infection in a subject or a disease associated with a novel coronavirus infection (e.g. novel coronavirus pneumonia). In another aspect, provided herein is an antigen-binding unit as described above for use in preventing or treating novel coronavirus infection or a disease associated with novel coronavirus infection (eg novel coronavirus pneumonia) in a subject.

In another aspect, provided herein is a method for preventing or treating a novel coronavirus infection or a novel coronavirus infection-related disease (such as novel coronavirus pneumonia) in a subject, comprising, giving a subject in need thereof A prophylactically or therapeutically effective amount of an antigen binding unit described herein, or a pharmaceutical composition described herein is administered.

In some embodiments, the subject is a mammal, such as a human.

An antigen binding unit described herein or a pharmaceutical composition described herein can be administered to a subject by any suitable route of administration. Such routes of administration include, but are not limited to, oral, buccal, sublingual, topical, parenteral, rectal, intrathecal, or nasal routes.

The medicines and pharmaceutical compositions provided herein can be used alone or in combination, and can also be used in combination with other pharmaceutically active agents (such as antiviral drugs, such as Favipiravir, Remdesivir and Interferon, etc.). In some embodiments, the pharmaceutical composition further comprises pharmaceutically acceptable carriers and/or excipients.

In another aspect, provided herein is a conjugate comprising an antigen binding unit as described above, wherein the antigen binding unit is conjugated to a chemically functional moiety. In some embodiments, the chemically functional moiety is selected from radioisotopes, enzymes, fluorescent compounds, chemiluminescent compounds, bioluminescent compound substrate cofactors, and inhibitors.

While preferred embodiments described herein have been shown and described, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from what is described herein. It should be understood that various alternatives to the embodiments described herein may be employed in practicing the processes described herein. It is intended that the following claims define the scope described herein and that methods and structures within the scope of these claims and their equivalents be covered thereby.

When a range of values is provided, it is understood that each intervening value between the upper and lower limits of that range (to the nearest tenth of the unit of the lower limit unless the context clearly dictates otherwise) and any other value within that stated range Values indicated or in between are encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.

As used herein, the terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to a polymer of amino acids of any length. A polymer can be linear, cyclic, or branched, it can contain modified amino acids, and it can be interrupted by non-amino acids. The term also includes amino acid polymers that have been modified, for example, by sulfation, glycosylation, lipidation, acetylation, phosphorylation, iodination, methylation, oxidation, proteolytic treatment, phosphorylation, Prenylation, racemization, selenylation, transfer RNA-mediated addition of amino acids to proteins (eg, arginylation), ubiquitination, or any other manipulation, such as conjugation to a labeling component. As used herein, the term "amino acid" refers to natural and/or unnatural or synthetic amino acids, including glycine and D or L optical isomers, as well as amino acid analogs and peptidomimetics. A polypeptide or amino acid sequence "derived from" a given protein refers to the origin of the polypeptide. Preferably, the polypeptide has an amino acid sequence substantially identical to that of the polypeptide encoded in the sequence, or a portion thereof, wherein the portion consists of at least 10-20 amino acids or at least 20-30 amino acids or at least 30-50 amino acids, or It can be immunologically identified by the polypeptide encoded in the sequence. The term also includes polypeptides expressed from a specified nucleic acid sequence. As used herein, the term "domain" refers to a portion of a protein that is physically or functionally distinct from other portions of the protein or peptide. Physically defined domains include extremely hydrophobic or hydrophilic amino acid sequences, such as those membrane bound or cytoplasmic bound. Domains can also be defined by internal homology e.g. caused by gene duplication. Functionally defined domains have distinct biological functions. For example, an antigen-binding domain refers to an antigen-binding unit or the portion of an antibody that binds to an antigen. A functionally defined domain need not be encoded by a contiguous amino acid sequence, and a functionally defined domain may contain one or more physically defined domains.

As used herein, the term "amino acid" refers to natural and/or unnatural or synthetic amino acids, including but not limited to D or L optical isomers, as well as amino acid analogs and peptidomimetics. Standard one-letter or three-letter codes are used to designate amino acids. Herein, amino acids are generally referred to by one-letter and three-letter abbreviations well known in the art. For example, alanine can be represented by A or Ala.

As used herein, the term "antibody" refers to an immunoglobulin molecule generally composed of two pairs of polypeptide chains, each pair having a "light" (L) chain and a "heavy" (H) chain. Antibody light chains can be classified as kappa and lambda light chains. Heavy chains can be classified as mu, delta, gamma, alpha, or epsilon, and define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively. Within the light and heavy chains, the variable and constant regions are joined by a "J" region of about 12 or more amino acids, with the heavy chain also comprising a "D" region of about 3 or more amino acids. Each heavy chain is composed of a heavy chain variable region (VH) and a heavy chain constant region (CH). The heavy chain constant region consists of 3 domains (CH1, CH2 and CH3). Each light chain is composed of a light chain variable region (VL) and a light chain constant region (CL). The light chain constant region consists of one domain, CL. The constant regions of the antibodies mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (eg, effector cells) and the first component (Clq) of the classical complement system. The VH and VL regions can also be subdivided into regions of high variability called complementarity determining regions (CDRs) interspersed with more conserved regions called framework regions (FRs). Each VH and VL consists of 3 CDRs and 4 FRs arranged in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4, from amino-terminus to carboxy-terminus. The variable regions (VH and VL) of each heavy chain/light chain pair form the antibody binding site, respectively. Assignment of amino acids to regions or domains follows the Kabat Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)), or Chothia & Lesk (1987) J. Mol. Biol. 196:901 -917; as defined by Chothia et al. (1989) Nature 342:878-883. The allocation of each region or domain in this application can also be defined according to IMGT, AbM or Contact. Such nomenclature is well known to those skilled in the art, and the correspondence between various numbering systems is also well known to those skilled in the art. The term "antibody" is not limited to any particular method of producing antibodies. For example, it includes recombinant antibodies, monoclonal antibodies and polyclonal antibodies. The antibody can be of a different isotype, eg, an IgG (eg, IgG1, IgG2, IgG3 or IgG4 subtype), IgAl, IgA2, IgD, IgE or IgM antibody.

As used herein, the term "antigen-binding fragment" of an antibody refers to a polypeptide comprising a fragment of a full-length antibody that retains the ability to specifically bind to the same antigen to which the full-length antibody binds, and/or competes with the full-length antibody for antigen binding. specifically binds, which is also referred to as an "antigen-binding moiety". See generally, Fundamental Immunology, Ch. 7 (Paul, W., ed., 2nd ed., Raven Press, NY (1989), which is incorporated herein by reference in its entirety for all purposes. Can be obtained by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies to generate antigen-binding fragments of antibodies. In some cases, antigen-binding fragments include Fab, Fab', F(ab') ₂ , Fd, Fv, dAb, and complementarity determining regions (CDRs) Fragments, single chain antibodies (e.g., scFv), chimeric antibodies, diabodies (diabodies), and polypeptides comprising at least a portion of an antibody sufficient to confer specific antigen-binding ability on the polypeptide. In some cases, the antigen-binding capacity of the antibody Fragments are single-chain antibodies (e.g., scFv) in which the VL and VH domains are paired to form a monovalent molecule via a linker that enables production as a single polypeptide chain (see, e.g., Bird et al., Science 242:423 426 (1988) and Huston et al., Proc. Natl. Acad. Sci. USA 85:5879 5883 (1988)). Such scFv molecules may have the general structure: NH2-VL-linker-VH-COOH or NH2-VH-linker-VL- COOH. Suitable prior art linkers consist of the repeated GGGGS amino acid sequence or variants thereof. For example, linkers with the amino acid sequence (GGGGS) ₄ can be used, but variants thereof can also be used (Holliger et al. (1993), Proc. Natl. Acad. Sci. USA 90: 6444-6448). Can be used for other adapters described herein by Alfthan et al. (1995), Protein Eng. 8: 725-731, Choi et al. (2001), Eur. J. Immunol. 31:94-106, Hu et al. (1996), Cancer Res. 56:3055-3061, Kipriyanov et al. (1999), J. Mol. Biol. 293:41-56 and Roovers et al. (2001), Cancer Immunol. Description.

In some cases, the antigen-binding fragment of an antibody is a diabody, i.e., a diabody in which the VH and VL domains are expressed on a single polypeptide chain, but using a linker that is too short to allow for two structures on the same chain. pairing between domains, forcing the domain to pair with the complementary domain of another chain and creating two antigen-binding sites (see, e.g., Holliger P. et al., Proc. Natl. Acad. Sci. USA 90:6444 6448 ( 1993), and Poljak R. J. et al., Structure 2:1121 1123 (1994)).

Antigen-binding fragments of antibodies (e.g., the antibody fragments described above) can be obtained from a given antibody (e.g., the antibodies provided herein) using conventional techniques known to those of skill in the art (e.g., recombinant DNA techniques or enzymatic or chemical fragmentation methods). ), and antigen-binding fragments of antibodies are screened for specificity in the same manner as for whole antibodies.

Herein, unless the context clearly dictates otherwise, when the term "antibody" is referred to, it includes not only whole antibodies but also antigen-binding fragments of antibodies.

Herein, unless the context clearly indicates otherwise, the term "antigen-binding unit" includes antibodies and antigen-binding fragments thereof as defined above.

As used herein, the term "monoclonal antibody" refers to an antibody or a fragment of an antibody derived from a population of highly homogeneous antibody molecules, that is, a population of identical antibody molecule. mAbs are highly specific for a single epitope on an antigen. Compared with monoclonal antibodies, polyclonal antibodies usually contain at least two or more different antibodies, and these different antibodies usually recognize different epitopes on antigens. Monoclonal antibodies can usually be obtained using hybridoma technology first reported by Kohler et al. (Nature, 256:495, 1975), but can also be obtained using recombinant DNA technology (for example, see Journal of virological methods, 2009, 158(1-2): 171-179).

As used herein, "neutralizing antibody" refers to an antibody or antibody fragment that eliminates or significantly reduces the virulence (eg, ability to infect cells) of a target virus.

As used herein, "sequence" in the context of a polypeptide is the order of the amino acids in the polypeptide in the direction from the amino-terminus to the carboxy-terminus, wherein residues in the sequence that are adjacent to each other are in the primary structure of the polypeptide is continuous. The sequence may also be a linear sequence of a portion of a polypeptide known to contain additional residues in one or both directions.

As used herein, "identity", "homology" or "sequence identity" means between two or more polynucleotide sequences or between two or more polypeptide sequences sequence similarity or interchangeability. When using programs such as Emboss Needle or BestFit to determine sequence identity, similarity or homology between two different amino acid sequences, you can use the default settings, or you can choose an appropriate scoring matrix, such as blosum45 or blosum80, to optimize Identity, similarity or homology score. Preferably, homologous polynucleotides are those that hybridize under stringent conditions as defined herein and have at least 70%, preferably at least 80%, more preferably at least 90%, more preferably 95%, more preferably Polynucleotides with 97%, more preferably 98% and even more preferably 99% sequence identity. Homologous polypeptides preferably have at least 80%, or at least 90%, or at least 95%, or at least 97%, or at least 98% sequence identity when optimally aligned for sequences of comparable length, or have at least 99% sequence identity.

With respect to the antigen binding units identified herein, "percent sequence identity (%)" is defined after aligning the sequences and introducing gaps, if necessary, to obtain the maximum percent sequence identity, and without considering any conservative substitutions as As part of sequence identity, the percentage of amino acid residues in a query sequence that are identical to those of a second, reference polypeptide sequence, or portion thereof. Alignment to determine percent amino acid sequence identities can be achieved in various ways that are within the skill in the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, NEEDLE or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. Percent identity may be measured over the length of the entire defined polypeptide sequence, or may be measured over shorter lengths, e.g., over the length of fragments taken from a larger, defined polypeptide sequence, such as A fragment of at least 5, at least 10, at least 15, at least 20, at least 50, at least 100 or at least 200 contiguous residues. These lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown in the Tables, Figures, or Sequence Listing herein can be used to describe the length over which percent identity can be measured.

An antigen binding unit described herein may have one or more modifications relative to a reference sequence. The modifications may be deletions, insertions or additions, or substitutions or replacements of amino acid residues. "Deletion" refers to a change in amino acid sequence due to the absence of one or more amino acid residues. "Insertion" or "addition" refers to an amino acid sequence change that results in the addition of one or more amino acid residues compared to a reference sequence. "Substitution" or "replacement" refers to the replacement of one or more amino acids with a different amino acid. Herein, mutations of an antigen binding unit relative to a reference sequence can be determined by comparing the antigen binding unit to the reference sequence. Optimal alignment of sequences for comparison can be performed according to any method known in the art.

As used herein, the terms "novel coronavirus", "SARS-CoV-2" and "2019-nCov" refer to a class of coronaviruses that were discovered due to cases of viral pneumonia in Wuhan in 2019, and they have the same Meaning, used interchangeably. As used herein, the terms "new coronavirus pneumonia" and "COVID-19" refer to pneumonia caused by a new coronavirus infection, both have the same meaning and can be used interchangeably.

As used herein, the term "antigen" refers to a substance recognized and specifically bound by an antigen-binding unit. Antigens can include peptides, proteins, glycoproteins, polysaccharides, and lipids; portions thereof, and combinations thereof. Non-limiting exemplary antigens include proteins from coronaviruses such as SARS-CoV-2, and their other homologues.

As used herein, the term "isolated" means separated from cellular and other components with which polynucleotides, peptides, polypeptides, proteins, antibodies, or fragments thereof are normally associated in nature. Associated. Those of skill in the art appreciate that non-naturally occurring polynucleotides, peptides, polypeptides, proteins, antibodies or fragments thereof do not need to be "isolated" to be distinguished from their naturally occurring counterparts. Additionally, a "concentrated", "isolated" or "diluted" polynucleotide, peptide, polypeptide, protein, antibody or fragment thereof is distinguishable from its naturally occurring counterpart by the concentration or number of molecules per unit volume Greater than ("enriched") or less than its naturally occurring counterpart ("isolated"). Enrichment can be measured on an absolute basis, such as weight per unit volume of solution, or it can be measured relative to a second, potentially interfering substance present in the source mixture.

The terms "polynucleotide", "nucleic acid", "nucleotide" and "oligonucleotide" are used interchangeably. They refer to polymeric forms of nucleotides of any length, whether deoxyribonucleotides or ribonucleotides, or analogs thereof. A polynucleotide can have any three-dimensional structure and can perform any known or unknown function. The following are non-limiting examples of polynucleotides: coding or non-coding regions of genes or gene fragments, loci determined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomes RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, primers, oligonucleotides, or synthetic DNA . A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. Modifications to the nucleotide structure, if present, can be imparted before or after polymer assembly. The sequence of nucleotides may be interrupted by non-nucleotide components. Polynucleotides may be further modified after polymerization, for example by conjugation with labeling components.

"Recombinant" when applied to a polynucleotide means that the polynucleotide is the result of various combinations of cloning, restriction digest, and/or ligation steps, and other procedures that result in a construct different from the polynucleotide found in nature product of.

The terms "gene" or "gene fragment" are used interchangeably herein. They refer to polynucleotides containing at least one open reading frame capable of encoding a specific protein after transcription and translation. A gene or gene fragment can be genomic, cDNA or synthetic, so long as the polynucleotide contains at least one open reading frame, which can cover the entire coding region or a segment thereof.

The terms "operably linked" or "operably linked" refer to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. For example, a promoter sequence is operably linked to a coding sequence if the promoter sequence facilitates the transcription of the coding sequence.

As used herein, "expression" refers to the process by which a polynucleotide is transcribed into mRNA, and/or the process by which the transcribed mRNA (also referred to as "transcript") is subsequently translated into a peptide, polypeptide or protein. Transcripts and encoded polypeptides are collectively referred to as gene products. If the polynucleotide is derived from genomic DNA, expression can include splicing of the mRNA in eukaryotic cells.

As used herein, the term "vector" refers to a nucleic acid delivery vehicle into which a polynucleotide can be inserted. When the vector is capable of achieving expression of the protein encoded by the inserted polynucleotide, the vector is called an expression vector. A vector can be introduced into a host cell by transformation, transduction or transfection, so that the genetic material elements it carries can be expressed in the host cell. Vectors are well known to those skilled in the art, including but not limited to: plasmids; phagemids; artificial chromosomes, such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC) or artificial chromosomes (PAC) derived from P1; bacteriophages such as λ Phage or M13 phage and animal viruses, etc. Animal viruses that can be used as vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpesviruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses , Papillary polyoma vacuolar virus (such as SV40). A vector can contain a variety of elements that control expression, including but not limited to, promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and reporter genes. In addition, the vector may also contain an origin of replication.

As used herein, the term "host cell" refers to cells that can be used to introduce vectors, including, but not limited to, prokaryotic cells such as Escherichia coli or Bacillus subtilis, fungal cells such as yeast cells or Aspergillus, etc. , insect cells such as S2 Drosophila cells or Sf9, or animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK293 cells or human cells.

As used herein, the term "biological sample" includes a variety of sample types obtained from an organism and may be used in diagnostic or monitoring assays. The term includes blood and other liquid samples of biological origin, solid tissue samples such as biopsy specimens or tissue cultures, or cells derived therefrom and their progeny. The term includes samples that have been manipulated in any way after acquisition, for example by treatment with reagents, solubilization, or enrichment for certain components. The term includes clinical samples, and also includes cells in cell cultures, cell supernatants, cell lysates, serum, plasma, biological fluids, and tissue samples.

As used herein, the terms "recipient," "individual," "subject," "host" and "patient" are used interchangeably herein and refer to a subject for whom diagnosis, treatment, or therapy is desired. Any mammalian subject, especially a human.

As used herein, the terms "treatment", "treatment" and the like are used herein to refer broadly to obtaining a desired pharmacological and/or physiological effect. The effect may be prophylactic in terms of completely or partially preventing the disease or its symptoms, and/or therapeutic in terms of partially or completely stabilizing or curing the disease and/or adverse effects attributable to the disease. "Treatment" as used herein encompasses any treatment of disease in mammals such as mice, rats, rabbits, pigs, primates, including humans and other apes, especially humans, and The term includes: (a) preventing the occurrence of a disease or condition in a subject who may be susceptible to the disease or condition but has not yet been diagnosed; (b) inhibiting the symptoms of the disease; (c) arresting the development of the disease; (d) ameliorating the disease symptoms; (e) causing disease or symptom regression; or any combination thereof. As used herein, the term "specific binding" refers to a non-random binding reaction between two molecules, such as the reaction between an antibody and the antigen it is directed against. In certain embodiments, an antibody that specifically binds to an antigen (or an antibody specific to an antigen) refers to an antibody that is less than about 10 ^-5 M, such as less than about 10 ^-6 M, 10 ^-7 M, Binds the antigen with an affinity (KD) of 10 ⁻⁸ M, 10 ⁻⁹ M or 10 ⁻¹⁰ M or less.

As used herein, the term "KD" refers to the dissociation equilibrium constant for a particular antibody-antigen interaction, which is used to describe the binding affinity between an antibody and an antigen. Herein, KD is defined as the ratio of two kinetic rate constants Ka/Kd, where "Ka" refers to the rate constant for antibody association with antigen and "Kd" refers to the rate constant for antibody dissociation from the antibody/antigen complex. The smaller the equilibrium dissociation constant KD, the tighter the antibody-antigen binding, and the higher the affinity between the antibody and the antigen. Typically, antibodies bind antigen with an equilibrium constant for dissociation (KD) of less than about 10 ^-5 M. The specific binding properties between two molecules can be determined using methods well known in the art, for example using surface plasmon resonance (SPR) in a BIACORE instrument.

As used herein, the term "neutralizing activity" means that the antibody or antibody fragment has the ability to bind to the antigenic protein on the virus, thereby preventing the virus from infecting the cells and/or the maturation of the virus progeny and/or the release of the virus progeny The functional activity of the antibody or antibody fragment with neutralizing activity can prevent the amplification of the virus, thereby inhibiting or eliminating the infection of the virus. In some embodiments, the neutralizing activity is expressed by the _IC50 of the antibody or antibody fragment for virus inhibition. "Half maximal inhibitory concentration" ( _IC50 ) is a measure of the ability of a drug, such as an antibody, to inhibit a biological or biochemical function, such as viral potency. The IC ₅₀ herein is based on the neutralization inhibitory rate of the antigen-binding fragment to virus (eg, pseudovirus or true virus) infected cells, and is calculated using the Reed-Muench method. This article provides an antigen-binding unit that can specifically recognize and target the S protein of the new coronavirus, especially the receptor-binding domain (RBD) of the S protein, and has shown an efficient ability to neutralize the virus. Therefore, the antigen-binding unit described herein is particularly suitable for the diagnosis, prevention and treatment of novel coronavirus infection or diseases associated with novel coronavirus infection (such as novel coronavirus pneumonia). antigen binding unit

In one aspect, an antigen binding unit described herein comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region comprising VH CDR1, VH CDR2 and VH CDR3, and the light chain variable region comprising The chain variable region comprises VL CDR1, VL CDR2 and VL CDR3.

The VH of the antigen binding unit described herein may comprise a sequence selected from SEQ ID NO.: 721-1080 and 3111-3145, comprising one or more than the sequence selected from SEQ ID NO: 721-1080 and 3111-3145 A sequence of amino acid additions, deletions, or substitutions, or at least 80%, 85%, 90%, 91%, 92%, 93%, 94% of the sequence selected from SEQ ID NO: 721-1080 and 3111-3145 , 95%, 96%, 97%, 98%, 99% or 99% identical sequences. When the VH of the antigen-binding unit described herein has amino acid additions, deletions or substitutions compared with the reference polypeptide sequence, the VH of the antigen-binding unit described herein may have 1, 2, 3, or 3 amino acids compared with the reference polypeptide sequence. 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 Add, delete or replace. When the VH of the antigen binding unit described herein has amino acid additions, deletions or substitutions compared to the reference polypeptide sequence, there may be more than 1, 2, 3 amino acid substitutions in the VH of the antigen binding unit described herein compared to the reference polypeptide sequence. , 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 additions, deletions or substitutions. When the VH of the antigen binding unit described herein has amino acid additions, deletions or substitutions compared to the reference polypeptide sequence, the VH of the antigen binding unit described herein may have less than 2, 3, 4 amino acids compared to the reference polypeptide. 1, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 add , delete or replace.

The VH CDR1 of the antigen binding unit described herein may comprise a sequence selected from SEQ ID NO.: 1461-1820 and 2901-2935, as compared to a sequence selected from SEQ ID NO: 1461-1820 and 2901-2935 comprising one or A sequence of multiple amino acid additions, deletions, or substitutions, or at least 80%, 85%, 90%, 91%, 92%, 93%, 94% of the sequence selected from SEQ ID NO: 1461-1820 and 2901-2935 %, 95%, 96%, 97%, 98%, 99%, or 99% identical sequences. When the VH CDR1 of the antigen-binding unit described herein has amino acid additions, deletions or substitutions compared with the reference polypeptide sequence, the VH CDR1 of the antigen-binding unit described herein may have 1, 2, or 3 amino acids compared with the reference polypeptide sequence. , 4, or 5 additions, deletions, or substitutions. When the VH CDR1 of the antigen-binding unit described herein has amino acid additions, deletions or substitutions compared with the reference polypeptide sequence, there may be more than 1 or 2 of the VH CDR1 of the antigen-binding unit described herein compared with the reference polypeptide , 3, 4, or 5 additions, deletions, or substitutions. When the VH CDR1 of the antigen-binding unit described herein has amino acid additions, deletions or substitutions compared with the reference polypeptide sequence, the VH CDR1 of the antigen-binding unit described herein may be less than 2 or 3 compared with the reference polypeptide , 4, or 5 additions, deletions, or substitutions.

The VH CDR2 of the antigen binding unit described herein may comprise a sequence selected from SEQ ID NO.: 1821-2180 and 2936-2970, as compared to a sequence selected from SEQ ID NO: 1821-2180 and 2936-2970 comprising one or A sequence of multiple amino acid additions, deletions, or substitutions, or at least 80%, 85%, 90%, 91%, 92%, 93%, 94% of the sequence selected from SEQ ID NO: 1821-2180 and 2936-2970 %, 95%, 96%, 97%, 98%, 99%, or 99% identical sequences. When there are amino acid additions, deletions or substitutions in the VH CDR2 of the antigen-binding unit described herein compared with the reference polypeptide sequence, there may be 1, 2, or 3 amino acid substitutions in the VH CDR2 of the antigen-binding unit described herein compared with the reference polypeptide sequence. , 4, or 5 additions, deletions, or substitutions. When the VH CDR2 of the antigen-binding unit described herein has amino acid additions, deletions or substitutions compared with the reference polypeptide sequence, there may be more than 1 or 2 of the VH CDR2 of the antigen-binding unit described herein compared with the reference polypeptide , 3, 4, or 5 additions, deletions, or substitutions. When the VH CDR2 of the antigen-binding unit described herein has amino acid additions, deletions or substitutions compared with the reference polypeptide sequence, the VH CDR2 of the antigen-binding unit described herein may be less than 2 or 3 compared with the reference polypeptide , 4, or 5 additions, deletions, or substitutions.

The VH CDR3 of the antigen binding unit described herein may comprise a sequence selected from SEQ ID NO.: 1-360 and 2971-3005, comprising one or A sequence of multiple amino acid additions, deletions, or substitutions, or at least 80%, 85%, 90%, 91%, 92%, 93%, 94% of the sequence selected from SEQ ID NO: 1-360 and 2971-3005 %, 95%, 96%, 97%, 98%, 99%, or 99% identical sequences. When the VH CDR3 of the antigen-binding unit described herein has amino acid additions, deletions or substitutions compared with the reference polypeptide sequence, the VH CDR3 of the antigen-binding unit described herein may have 1, 2, or 3 amino acids compared with the reference polypeptide sequence. , 4, or 5 additions, deletions, or substitutions. When the VH CDR3 of the antigen-binding unit described herein has amino acid additions, deletions or substitutions compared with the reference polypeptide sequence, there may be more than 1 or 2 of the VH CDR3 of the antigen-binding unit described herein compared with the reference polypeptide , 3, 4, or 5 additions, deletions, or substitutions. When the VH CDR2 of the antigen-binding unit described herein has amino acid additions, deletions or substitutions compared with the reference polypeptide sequence, the VH CDR3 of the antigen-binding unit described herein may be less than 2 or 3 compared with the reference polypeptide , 4, or 5 additions, deletions, or substitutions.

The VL of the antigen binding unit described herein may comprise a sequence selected from SEQ ID NO.: 1081-1440 and 3146-3180, comprising one or more than the sequence selected from SEQ ID NO: 1081-1440 and 3146-3180 A sequence of amino acid additions, deletions, or substitutions, or at least 80%, 85%, 90%, 91%, 92%, 93%, 94% of the sequence selected from SEQ ID NO: 1081-1440 and 3146-3180 , 95%, 96%, 97%, 98%, 99% or 99% identical sequences. When the VL of the antigen-binding unit described herein has amino acid additions, deletions or substitutions compared with the reference polypeptide sequence, the VL of the antigen-binding unit described herein may have 1, 2, 3, or 3 amino acids compared with the reference polypeptide sequence. 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 Add, delete or replace. When there are amino acid additions, deletions or substitutions in the VL of the antigen binding unit described herein compared to the reference polypeptide sequence, there may be more than 1, 2, 3 in the VL of the antigen binding unit described herein compared to the reference polypeptide sequence. , 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 additions, deletions or substitutions. When the VL of the antigen binding unit described herein has amino acid additions, deletions or substitutions compared to the reference polypeptide sequence, the VL of the antigen binding unit described herein may have less than 2, 3, 4 amino acids compared to the reference polypeptide. 1, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 add , delete or replace.

The VL CDR1 of the antigen binding unit described herein may comprise a sequence selected from the group consisting of SEQ ID NO.: 2181-2540 and 3006-3040, compared to a sequence selected from the group consisting of SEQ ID NO: 2181-2540 and 3006-3040. or a sequence of amino acid additions, deletions, or substitutions, or at least 80%, 85%, 90%, 91%, 92%, 93%, Sequences that are 94%, 95%, 96%, 97%, 98%, 99%, or 99% identical. When the VL CDR1 of the antigen-binding unit described herein has amino acid additions, deletions or substitutions compared with the reference polypeptide sequence, the VL CDR1 of the antigen-binding unit described herein may have 1, 2, or 3 amino acids compared with the reference polypeptide sequence. , 4, or 5 additions, deletions, or substitutions. When the VL CDR1 of the antigen-binding unit described herein has amino acid additions, deletions or substitutions compared with the reference polypeptide sequence, there may be more than 1 or 2 of the VL CDR1 of the antigen-binding unit described herein compared with the reference polypeptide , 3, 4, or 5 additions, deletions, or substitutions. When the VL CDR1 of the antigen-binding unit described herein has amino acid additions, deletions or substitutions compared with the reference polypeptide sequence, the VL CDR1 of the antigen-binding unit described herein may be less than 2 or 3 compared with the reference polypeptide , 4, or 5 additions, deletions, or substitutions.

The VL CDR2 of the antigen binding unit described herein may comprise a sequence selected from SEQ ID NO.: 2541-2900 and 3041-3075, as compared to a sequence selected from SEQ ID NO: 2541-2900 and 3041-3075 comprising one or A sequence of multiple amino acid additions, deletions, or substitutions, or at least 80%, 85%, 90%, 91%, 92%, 93%, 94% of the sequence selected from SEQ ID NO: 2541-2900 and 3041-3075 %, 95%, 96%, 97%, 98%, 99%, or 99% identical sequences. When the VL CDR2 of the antigen-binding unit described herein has amino acid additions, deletions or substitutions compared with the reference polypeptide sequence, the VL CDR2 of the antigen-binding unit described herein may have 1, 2, or 3 amino acids compared with the reference polypeptide sequence. , 4, or 5 additions, deletions, or substitutions. When the VL CDR2 of the antigen-binding unit described herein has amino acid additions, deletions or substitutions compared with the reference polypeptide sequence, there may be more than 1 or 2 of the VL CDR2 of the antigen-binding unit described herein compared with the reference polypeptide , 3, 4, or 5 additions, deletions, or substitutions. When the VL CDR2 of the antigen-binding unit described herein has amino acid additions, deletions or substitutions compared with the reference polypeptide sequence, the VL CDR2 of the antigen-binding unit described herein may be less than 2 or 3 compared with the reference polypeptide , 4, or 5 additions, deletions, or substitutions.

The VL CDR3 of the antigen binding unit described herein may comprise a sequence selected from SEQ ID NO.: 361-720 and 3076-3110, as compared to a sequence selected from SEQ ID NO: 361-720 and 3076-3110 comprising one or A sequence of multiple amino acid additions, deletions, or substitutions, or at least 80%, 85%, 90%, 91%, 92%, 93%, 94% of the sequence selected from SEQ ID NO: 361-720 and 3076-3110 %, 95%, 96%, 97%, 98%, 99%, or 99% identical sequences. When the VL CDR3 of the antigen-binding unit described herein has amino acid additions, deletions or substitutions compared with the reference polypeptide sequence, the VL CDR3 of the antigen-binding unit described herein may have 1, 2, or 3 amino acids compared with the reference polypeptide sequence. , 4, or 5 additions, deletions, or substitutions. When the VL CDR3 of the antigen-binding unit described herein has amino acid additions, deletions or substitutions compared with the reference polypeptide sequence, there may be more than 1 or 2 of the VL CDR3 of the antigen-binding unit described herein compared with the reference polypeptide , 3, 4, or 5 additions, deletions, or substitutions. When the VL CDR3 of the antigen-binding unit described herein has amino acid additions, deletions or substitutions compared with the reference polypeptide sequence, the VL CDR3 of the antigen-binding unit described herein may be less than 2 or 3 compared with the reference polypeptide , 4, or 5 additions, deletions, or substitutions.

The VH CDR1 of the antigen binding unit described herein may comprise a sequence selected from SEQ ID NO.: 1461-1820 and 2901-2935, as compared to a sequence selected from SEQ ID NO: 1461-1820 and 2901-2935 comprising one or A sequence of multiple amino acid additions, deletions, or substitutions, or at least 80%, 85%, 90%, 91%, 92%, 93%, 94% of the sequence selected from SEQ ID NO: 1461-1820 and 2901-2935 %, 95%, 96%, 97%, 98%, 99% or 99% identical sequence; and the VL CDR1 of the antigen binding unit described herein may comprise a sequence selected from SEQ ID NO.: 2181-2540 and 3006 - a sequence of 3040, a sequence comprising one or more amino acid additions, deletions, or substitutions compared to the sequence selected from SEQ ID NO: 2181-2540 and 3006-3040, or a sequence selected from the group consisting of SEQ ID NO: 2181-2540 and Sequences of 3006-3040 having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99% identity .

The VH CDR2 of the antigen binding unit described herein may comprise a sequence selected from SEQ ID NO.: 1821-2180 and 2936-2970, as compared to a sequence selected from SEQ ID NO: 1821-2180 and 2936-2970 comprising one or A sequence of multiple amino acid additions, deletions, or substitutions, or at least 80%, 85%, 90%, 91%, 92%, 93%, 94% of the sequence selected from SEQ ID NO: 1821-2180 and 2936-2970 %, 95%, 96%, 97%, 98%, 99% or 99% identical sequence; and the VL CDR2 of the antigen binding unit described herein may comprise a sequence selected from SEQ ID NO.: 2541-2900 and 3041 - a sequence of 3075 comprising one or more amino acid additions, deletions, or substitutions compared to the sequence selected from SEQ ID NO: 2541-2900 and 3041-3075, or a sequence selected from the group consisting of SEQ ID NO: 2541-2900 and Sequences of 3041-3075 having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99% identity .

The VH CDR3 of the antigen binding unit described herein may comprise a sequence selected from SEQ ID NO.: 1-360 and 2971-3005, comprising one or A sequence of multiple amino acid additions, deletions, or substitutions, or at least 80%, 85%, 90%, 91%, 92%, 93%, 94% of the sequence selected from SEQ ID NO: 1-360 and 2971-3005 %, 95%, 96%, 97%, 98%, 99% or 99% identical sequence; and the VL CDR3 of the antigen binding unit described herein may comprise a sequence selected from SEQ ID NO.: 361-720 and 3076 - a sequence of 3110, a sequence comprising one or more amino acid additions, deletions, or substitutions compared to the sequence selected from SEQ ID NO: 361-720 and 3076-3110, or a sequence selected from the group consisting of SEQ ID NO: 361-720 and Sequences of 3076-3110 having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99% identity .

The VH of the antigen binding unit described herein may comprise VH CDR1, VH CDR2 and VH CDR3, wherein said VH CDR1 is selected from the sequences of SEQ ID NO.: 1461-1820 and 2901-2935, and is selected from the sequence of SEQ ID NO: 1461 - a sequence comprising one or more amino acid additions, deletions, or substitutions compared to the sequence of 1820 and 2901-2935, or having at least 80%, 85%, or A sequence of 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99% identity; wherein the VH CDR2 is selected from SEQ ID NO.: The sequence of 1821-2180 and 2936-2970, compared with the sequence selected from SEQ ID NO: 1821-2180 and 2936-2970, comprises a sequence of one or more amino acid additions, deletions, or substitutions, or is selected from the sequence of SEQ ID NO : The sequences of 1821-2180 and 2936-2970 have at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99% and wherein said VH CDR3 is selected from the sequence of SEQ ID NO.: 1-360 and 2971-3005, compared with the sequence selected from SEQ ID NO: 1-360 and 2971-3005 comprising one or A sequence of multiple amino acid additions, deletions, or substitutions, or at least 80%, 85%, 90%, 91%, 92%, 93%, 94% of the sequence selected from SEQ ID NO: 1-360 and 2971-3005 %, 95%, 96%, 97%, 98%, 99%, or 99% identical sequences.

The VL of the antigen binding unit described herein may comprise VL CDR1, VL CDR2 and VL CDR3, wherein said VL CDR1 is selected from the sequence of SEQ ID NO.: 2181-2540 and 3006-3040, and is selected from the sequence of SEQ ID NO: 2181 - 2540 and 3006-3040 compared to the sequence comprising one or more amino acid additions, deletions, or substitutions, or at least 80%, 85%, 85%, or A sequence of 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99% identity; wherein the VL CDR2 is selected from SEQ ID NO.: The sequence of 2541-2900 and 3041-3075, compared with the sequence selected from SEQ ID NO: 2541-2900 and 3041-3075, comprises one or more amino acid additions, deletions, or substituted sequences, or is selected from the sequence of SEQ ID NO : The sequences of 2541-2900 and 3041-3075 have at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99% and wherein the VL CDR3 is selected from the sequence of SEQ ID NO.: 361-720 and 3076-3110, compared with the sequence selected from the sequence of SEQ ID NO: 361-720 and 3076-3110 comprising one or A sequence of multiple amino acid additions, deletions, or substitutions, or at least 80%, 85%, 90%, 91%, 92%, 93%, 94% of the sequence selected from SEQ ID NO: 361-720 and 3076-3110 %, 95%, 96%, 97%, 98%, 99%, or 99% identical sequences.

The VH of the antigen binding unit described herein may comprise a sequence selected from the combination of CDR1, CDR2, and CDR3 of Table A below, wherein the CDR1, CDR2, and CDR3 sequences of the VH follow the definition of the IMGT system. Table A. Combinations of CDR1, CDR2, and CDR3 comprised by the VH of the exemplary antigen-binding units of the present application HCDR1 HCDR2 HCDR3 HCDR1 HCDR2 HCDR3 HCDR1 HCDR2 HCDR3 1461 1821 1 1581 1941 121 1701 2061 241 1462 1822 2 1582 1942 122 1702 2062 242 1463 1823 3 1583 1943 123 1703 2063 243 1464 1824 4 1584 1944 124 1704 2064 244 1465 1825 5 1585 1945 125 1705 2065 245 1466 1826 6 1586 1946 126 1706 2066 246 1467 1827 7 1587 1947 127 1707 2067 247 1468 1828 8 1588 1948 128 1708 2068 248 1469 1829 9 1589 1949 129 1709 2069 249 1470 1830 10 1590 1950 130 1710 2070 250 1471 1831 11 1591 1951 131 1711 2071 251 1472 1832 12 1592 1952 132 1712 2072 252 1473 1833 13 1593 1953 133 1713 2073 253 1474 1834 14 1594 1954 134 1714 2074 254 1475 1835 15 1595 1955 135 1715 2075 255 1476 1836 16 1596 1956 136 1716 2076 256 1477 1837 17 1597 1957 137 1717 2077 257 1478 1838 18 1598 1958 138 1718 2078 258 1479 1839 19 1599 1959 139 1719 2079 259 1480 1840 20 1600 1960 140 1720 2080 260 1481 1841 twenty one 1601 1961 141 1721 2081 261 1482 1842 twenty two 1602 1962 142 1722 2082 262 1483 1843 twenty three 1603 1963 143 1723 2083 263 1484 1844 twenty four 1604 1964 144 1724 2084 264 1485 1845 25 1605 1965 145 1725 2085 265 1486 1846 26 1606 1966 146 1726 2086 266 1487 1847 27 1607 1967 147 1727 2087 267 1488 1848 28 1608 1968 148 1728 2088 268 1489 1849 29 1609 1969 149 1729 2089 269 1490 1850 30 1610 1970 150 1730 2090 270 1491 1851 31 1611 1971 151 1731 2091 271 1492 1852 32 1612 1972 152 1732 2092 272 1493 1853 33 1613 1973 153 1733 2093 273 1494 1854 34 1614 1974 154 1734 2094 274 1495 1855 35 1615 1975 155 1735 2095 275 1496 1856 36 1616 1976 156 1736 2096 276 1497 1857 37 1617 1977 157 1737 2097 277 1498 1858 38 1618 1978 158 1738 2098 278 1499 1859 39 1619 1979 159 1739 2099 279 1500 1860 40 1620 1980 160 1740 2100 280 1501 1861 41 1621 1981 161 1741 2101 281 1502 1862 42 1622 1982 162 1742 2102 282 1503 1863 43 1623 1983 163 1743 2103 283 1504 1864 44 1624 1984 164 1744 2104 284 1505 1865 45 1625 1985 165 1745 2105 285 1506 1866 46 1626 1986 166 1746 2106 286 1507 1867 47 1627 1987 167 1747 2107 287 1508 1868 48 1628 1988 168 1748 2108 288 1509 1869 49 1629 1989 169 1749 2109 289 1510 1870 50 1630 1990 170 1750 2110 290 1511 1871 51 1631 1991 171 1751 2111 291 1512 1872 52 1632 1992 172 1752 2112 292 1513 1873 53 1633 1993 173 1753 2113 293 1514 1874 54 1634 1994 174 1754 2114 294 1515 1875 55 1635 1995 175 1755 2115 295 1516 1876 56 1636 1996 176 1756 2116 296 1517 1877 57 1637 1997 177 1757 2117 297 1518 1878 58 1638 1998 178 1758 2118 298 1519 1879 59 1639 1999 179 1759 2119 299 1520 1880 60 1640 2000 180 1760 2120 300 1521 1881 61 1641 2001 181 1761 2121 301 1522 1882 62 1642 2002 182 1762 2122 302 1523 1883 63 1643 2003 183 1763 2123 303 1524 1884 64 1644 2004 184 1764 2124 304 1525 1885 65 1645 2005 185 1765 2125 305 1526 1886 66 1646 2006 186 1766 2126 306 1527 1887 67 1647 2007 187 1767 2127 307 1528 1888 68 1648 2008 188 1768 2128 308 1529 1889 69 1649 2009 189 1769 2129 309 1530 1890 70 1650 2010 190 1770 2130 310 1531 1891 71 1651 2011 191 1771 2131 311 1532 1892 72 1652 2012 192 1772 2132 312 1533 1893 73 1653 2013 193 1773 2133 313 1534 1894 74 1654 2014 194 1774 2134 314 1535 1895 75 1655 2015 195 1775 2135 315 1536 1896 76 1656 2016 196 1776 2136 316 1537 1897 77 1657 2017 197 1777 2137 317 1538 1898 78 1658 2018 198 1778 2138 318 1539 1899 79 1659 2019 199 1779 2139 319 1540 1900 80 1660 2020 200 1780 2140 320 1541 1901 81 1661 2021 201 1781 2141 321 1542 1902 82 1662 2022 202 1782 2142 322 1543 1903 83 1663 2023 203 1783 2143 323 1544 1904 84 1664 2024 204 1784 2144 324 1545 1905 85 1665 2025 205 1785 2145 325 1546 1906 86 1666 2026 206 1786 2146 326 1547 1907 87 1667 2027 207 1787 2147 327 1548 1908 88 1668 2028 208 1788 2148 328 1549 1909 89 1669 2029 209 1789 2149 329 1550 1910 90 1670 2030 210 1790 2150 330 1551 1911 91 1671 2031 211 1791 2151 331 1552 1912 92 1672 2032 212 1792 2152 332 1553 1913 93 1673 2033 213 1793 2153 333 1554 1914 94 1674 2034 214 1794 2154 334 1555 1915 95 1675 2035 215 1795 2155 335 1556 1916 96 1676 2036 216 1796 2156 336 1557 1917 97 1677 2037 217 1797 2157 337 1558 1918 98 1678 2038 218 1798 2158 338 1559 1919 99 1679 2039 219 1799 2159 339 1560 1920 100 1680 2040 220 1800 2160 340 1561 1921 101 1681 2041 221 1801 2161 341 1562 1922 102 1682 2042 222 1802 2162 342 1563 1923 103 1683 2043 223 1803 2163 343 1564 1924 104 1684 2044 224 1804 2164 344 1565 1925 105 1685 2045 225 1805 2165 345 1566 1926 106 1686 2046 226 1806 2166 346 1567 1927 107 1687 2047 227 1807 2167 347 1568 1928 108 1688 2048 228 1808 2168 348 1569 1929 109 1689 2049 229 1809 2169 349 1570 1930 110 1690 2050 230 1810 2170 350 1571 1931 111 1691 2051 231 1811 2171 351 1572 1932 112 1692 2052 232 1812 2172 352 1573 1933 113 1693 2053 233 1813 2173 353 1574 1934 114 1694 2054 234 1814 2174 354 1575 1935 115 1695 2055 235 1815 2175 355 1576 1936 116 1696 2056 236 1816 2176 356 1577 1937 117 1697 2057 237 1817 2177 357 1578 1938 118 1698 2058 238 1818 2178 358 1579 1939 119 1699 2059 239 1819 2179 359 1580 1940 120 1700 2060 240 1820 2180 360 2901 2936 2971 2913 2948 2983 2925 2960 2995 2902 2937 2972 2914 2949 2984 2926 2961 2996 2903 2938 2973 2915 2950 2985 2927 2962 2997 2904 2939 2974 2916 2951 2986 2928 2963 2998 2905 2940 2975 2917 2952 2987 2929 2964 2999 2906 2941 2976 2918 2953 2988 2930 2965 3000 2907 2942 2977 2919 2954 2989 2931 2966 3001 2908 2943 2978 2920 2955 2990 2932 2967 3002 2909 2944 2979 2921 2956 2991 2933 2968 3003 2910 2945 2980 2922 2957 2992 2934 2969 3004 2911 2946 2981 2923 2958 2993 2935 2970 3005 2912 2947 2982 2924 2959 2994

The VL of the antigen binding unit described herein may comprise a sequence selected from the combination of CDR1, CDR2, and CDR3 of Table B below, wherein the CDR1, CDR2, and CDR3 sequences of the VL follow the definition of the IMGT system. Table B. Combinations of CDR1, CDR2, and CDR3 comprised by the VL of the exemplary antigen-binding units of the present application LCDR1 LCDR2 LCDR3 LCDR1 LCDR2 LCDR3 LCDR1 LCDR2 LCDR3 2181 2541 361 2301 2661 481 2421 2781 601 2182 2542 362 2302 2662 482 2422 2782 602 2183 2543 363 2303 2663 483 2423 2783 603 2184 2544 364 2304 2664 484 2424 2784 604 2185 2545 365 2305 2665 485 2425 2785 605 2186 2546 366 2306 2666 486 2426 2786 606 2187 2547 367 2307 2667 487 2427 2787 607 2188 2548 368 2308 2668 488 2428 2788 608 2189 2549 369 2309 2669 489 2429 2789 609 2190 2550 370 2310 2670 490 2430 2790 610 2191 2551 371 2311 2671 491 2431 2791 611 2192 2552 372 2312 2672 492 2432 2792 612 2193 2553 373 2313 2673 493 2433 2793 613 2194 2554 374 2314 2674 494 2434 2794 614 2195 2555 375 2315 2675 495 2435 2795 615 2196 2556 376 2316 2676 496 2436 2796 616 2197 2557 377 2317 2677 497 2437 2797 617 2198 2558 378 2318 2678 498 2438 2798 618 2199 2559 379 2319 2679 499 2439 2799 619 2200 2560 380 2320 2680 500 2440 2800 620 2201 2561 381 2321 2681 501 2441 2801 621 2202 2562 382 2322 2682 502 2442 2802 622 2203 2563 383 2323 2683 503 2443 2803 623 2204 2564 384 2324 2684 504 2444 2804 624 2205 2565 385 2325 2685 505 2445 2805 625 2206 2566 386 2326 2686 506 2446 2806 626 2207 2567 387 2327 2687 507 2447 2807 627 2208 2568 388 2328 2688 508 2448 2808 628 2209 2569 389 2329 2689 509 2449 2809 629 2210 2570 390 2330 2690 510 2450 2810 630 2211 2571 391 2331 2691 511 2451 2811 631 2212 2572 392 2332 2692 512 2452 2812 632 2213 2573 393 2333 2693 513 2453 2813 633 2214 2574 394 2334 2694 514 2454 2814 634 2215 2575 395 2335 2695 515 2455 2815 635 2216 2576 396 2336 2696 516 2456 2816 636 2217 2577 397 2337 2697 517 2457 2817 637 2218 2578 398 2338 2698 518 2458 2818 638 2219 2579 399 2339 2699 519 2459 2819 639 2220 2580 400 2340 2700 520 2460 2820 640 2221 2581 401 2341 2701 521 2461 2821 641 2222 2582 402 2342 2702 522 2462 2822 642 2223 2583 403 2343 2703 523 2463 2823 643 2224 2584 404 2344 2704 524 2464 2824 644 2225 2585 405 2345 2705 525 2465 2825 645 2226 2586 406 2346 2706 526 2466 2826 646 2227 2587 407 2347 2707 527 2467 2827 647 2228 2588 408 2348 2708 528 2468 2828 648 2229 2589 409 2349 2709 529 2469 2829 649 2230 2590 410 2350 2710 530 2470 2830 650 2231 2591 411 2351 2711 531 2471 2831 651 2232 2592 412 2352 2712 532 2472 2832 652 2233 2593 413 2353 2713 533 2473 2833 653 2234 2594 414 2354 2714 534 2474 2834 654 2235 2595 415 2355 2715 535 2475 2835 655 2236 2596 416 2356 2716 536 2476 2836 656 2237 2597 417 2357 2717 537 2477 2837 657 2238 2598 418 2358 2718 538 2478 2838 658 2239 2599 419 2359 2719 539 2479 2839 659 2240 2600 420 2360 2720 540 2480 2840 660 2241 2601 421 2361 2721 541 2481 2841 661 2242 2602 422 2362 2722 542 2482 2842 662 2243 2603 423 2363 2723 543 2483 2843 663 2244 2604 424 2364 2724 544 2484 2844 664 2245 2605 425 2365 2725 545 2485 2845 665 2246 2606 426 2366 2726 546 2486 2846 666 2247 2607 427 2367 2727 547 2487 2847 667 2248 2608 428 2368 2728 548 2488 2848 668 2249 2609 429 2369 2729 549 2489 2849 669 2250 2610 430 2370 2730 550 2490 2850 670 2251 2611 431 2371 2731 551 2491 2851 671 2252 2612 432 2372 2732 552 2492 2852 672 2253 2613 433 2373 2733 553 2493 2853 673 2254 2614 434 2374 2734 554 2494 2854 674 2255 2615 435 2375 2735 555 2495 2855 675 2256 2616 436 2376 2736 556 2496 2856 676 2257 2617 437 2377 2737 557 2497 2857 677 2258 2618 438 2378 2738 558 2498 2858 678 2259 2619 439 2379 2739 559 2499 2859 679 2260 2620 440 2380 2740 560 2500 2860 680 2261 2621 441 2381 2741 561 2501 2861 681 2262 2622 442 2382 2742 562 2502 2862 682 2263 2623 443 2383 2743 563 2503 2863 683 2264 2624 444 2384 2744 564 2504 2864 684 2265 2625 445 2385 2745 565 2505 2865 685 2266 2626 446 2386 2746 566 2506 2866 686 2267 2627 447 2387 2747 567 2507 2867 687 2268 2628 448 2388 2748 568 2508 2868 688 2269 2629 449 2389 2749 569 2509 2869 689 2270 2630 450 2390 2750 570 2510 2870 690 2271 2631 451 2391 2751 571 2511 2871 691 2272 2632 452 2392 2752 572 2512 2872 692 2273 2633 453 2393 2753 573 2513 2873 693 2274 2634 454 2394 2754 574 2514 2874 694 2275 2635 455 2395 2755 575 2515 2875 695 2276 2636 456 2396 2756 576 2516 2876 696 2277 2637 457 2397 2757 577 2517 2877 697 2278 2638 458 2398 2758 578 2518 2878 698 2279 2639 459 2399 2759 579 2519 2879 699 2280 2640 460 2400 2760 580 2520 2880 700 2281 2641 461 2401 2761 581 2521 2881 701 2282 2642 462 2402 2762 582 2522 2882 702 2283 2643 463 2403 2763 583 2523 2883 703 2284 2644 464 2404 2764 584 2524 2884 704 2285 2645 465 2405 2765 585 2525 2885 705 2286 2646 466 2406 2766 586 2526 2886 706 2287 2647 467 2407 2767 587 2527 2887 707 2288 2648 468 2408 2768 588 2528 2888 708 2289 2649 469 2409 2769 589 2529 2889 709 2290 2650 470 2410 2770 590 2530 2890 710 2291 2651 471 2411 2771 591 2531 2891 711 2292 2652 472 2412 2772 592 2532 2892 712 2293 2653 473 2413 2773 593 2533 2893 713 2294 2654 474 2414 2774 594 2534 2894 714 2295 2655 475 2415 2775 595 2535 2895 715 2296 2656 476 2416 2776 596 2536 2896 716 2297 2657 477 2417 2777 597 2537 2897 717 2298 2658 478 2418 2778 598 2538 2898 718 2299 2659 479 2419 2779 599 2539 2899 719 2300 2660 480 2420 2780 600 2540 2900 720 3006 3041 3076 3018 3053 3088 3030 3065 3100 3007 3042 3077 3019 3054 3089 3031 3066 3101 3008 3043 3078 3020 3055 3090 3032 3067 3102 3009 3044 3079 3021 3056 3091 3033 3068 3103 3010 3045 3080 3022 3057 3092 3034 3069 3104 3011 3046 3081 3023 3058 3093 3035 3070 3105 3012 3047 3082 3024 3059 3094 3036 3071 3106 3013 3048 3083 3025 3060 3095 3037 3072 3107 3014 3049 3084 3026 3061 3096 3038 3073 3108 3015 3050 3085 3027 3062 3097 3039 3074 3109 3016 3051 3086 3028 3063 3098 3040 3075 3110 3017 3052 3087 3029 3064 3099

In the antigen binding unit described herein, the VH may comprise a sequence selected from a combination of CDR1, CDR2, and CDR3 of Table C below, and the VL may comprise a sequence of CDR1, CDR2, and CDR3 selected from Table D below The sequence of the combination, wherein the sequences of CDR1, CDR2, and CDR3 of VH and CDR1, CDR2, and CDR3 of VL described in Table C and Table D follow the definition of the IMGT system. Form C HCDR1 HCDR2 HCDR3 HCDR1 HCDR2 HCDR3 HCDR1 HCDR2 HCDR3 1461 1821 1 1581 1941 121 1701 2061 241 1462 1822 2 1582 1942 122 1702 2062 242 1463 1823 3 1583 1943 123 1703 2063 243 1464 1824 4 1584 1944 124 1704 2064 244 1465 1825 5 1585 1945 125 1705 2065 245 1466 1826 6 1586 1946 126 1706 2066 246 1467 1827 7 1587 1947 127 1707 2067 247 1468 1828 8 1588 1948 128 1708 2068 248 1469 1829 9 1589 1949 129 1709 2069 249 1470 1830 10 1590 1950 130 1710 2070 250 1471 1831 11 1591 1951 131 1711 2071 251 1472 1832 12 1592 1952 132 1712 2072 252 1473 1833 13 1593 1953 133 1713 2073 253 1474 1834 14 1594 1954 134 1714 2074 254 1475 1835 15 1595 1955 135 1715 2075 255 1476 1836 16 1596 1956 136 1716 2076 256 1477 1837 17 1597 1957 137 1717 2077 257 1478 1838 18 1598 1958 138 1718 2078 258 1479 1839 19 1599 1959 139 1719 2079 259 1480 1840 20 1600 1960 140 1720 2080 260 1481 1841 twenty one 1601 1961 141 1721 2081 261 1482 1842 twenty two 1602 1962 142 1722 2082 262 1483 1843 twenty three 1603 1963 143 1723 2083 263 1484 1844 twenty four 1604 1964 144 1724 2084 264 1485 1845 25 1605 1965 145 1725 2085 265 1486 1846 26 1606 1966 146 1726 2086 266 1487 1847 27 1607 1967 147 1727 2087 267 1488 1848 28 1608 1968 148 1728 2088 268 1489 1849 29 1609 1969 149 1729 2089 269 1490 1850 30 1610 1970 150 1730 2090 270 1491 1851 31 1611 1971 151 1731 2091 271 1492 1852 32 1612 1972 152 1732 2092 272 1493 1853 33 1613 1973 153 1733 2093 273 1494 1854 34 1614 1974 154 1734 2094 274 1495 1855 35 1615 1975 155 1735 2095 275 1496 1856 36 1616 1976 156 1736 2096 276 1497 1857 37 1617 1977 157 1737 2097 277 1498 1858 38 1618 1978 158 1738 2098 278 1499 1859 39 1619 1979 159 1739 2099 279 1500 1860 40 1620 1980 160 1740 2100 280 1501 1861 41 1621 1981 161 1741 2101 281 1502 1862 42 1622 1982 162 1742 2102 282 1503 1863 43 1623 1983 163 1743 2103 283 1504 1864 44 1624 1984 164 1744 2104 284 1505 1865 45 1625 1985 165 1745 2105 285 1506 1866 46 1626 1986 166 1746 2106 286 1507 1867 47 1627 1987 167 1747 2107 287 1508 1868 48 1628 1988 168 1748 2108 288 1509 1869 49 1629 1989 169 1749 2109 289 1510 1870 50 1630 1990 170 1750 2110 290 1511 1871 51 1631 1991 171 1751 2111 291 1512 1872 52 1632 1992 172 1752 2112 292 1513 1873 53 1633 1993 173 1753 2113 293 1514 1874 54 1634 1994 174 1754 2114 294 1515 1875 55 1635 1995 175 1755 2115 295 1516 1876 56 1636 1996 176 1756 2116 296 1517 1877 57 1637 1997 177 1757 2117 297 1518 1878 58 1638 1998 178 1758 2118 298 1519 1879 59 1639 1999 179 1759 2119 299 1520 1880 60 1640 2000 180 1760 2120 300 1521 1881 61 1641 2001 181 1761 2121 301 1522 1882 62 1642 2002 182 1762 2122 302 1523 1883 63 1643 2003 183 1763 2123 303 1524 1884 64 1644 2004 184 1764 2124 304 1525 1885 65 1645 2005 185 1765 2125 305 1526 1886 66 1646 2006 186 1766 2126 306 1527 1887 67 1647 2007 187 1767 2127 307 1528 1888 68 1648 2008 188 1768 2128 308 1529 1889 69 1649 2009 189 1769 2129 309 1530 1890 70 1650 2010 190 1770 2130 310 1531 1891 71 1651 2011 191 1771 2131 311 1532 1892 72 1652 2012 192 1772 2132 312 1533 1893 73 1653 2013 193 1773 2133 313 1534 1894 74 1654 2014 194 1774 2134 314 1535 1895 75 1655 2015 195 1775 2135 315 1536 1896 76 1656 2016 196 1776 2136 316 1537 1897 77 1657 2017 197 1777 2137 317 1538 1898 78 1658 2018 198 1778 2138 318 1539 1899 79 1659 2019 199 1779 2139 319 1540 1900 80 1660 2020 200 1780 2140 320 1541 1901 81 1661 2021 201 1781 2141 321 1542 1902 82 1662 2022 202 1782 2142 322 1543 1903 83 1663 2023 203 1783 2143 323 1544 1904 84 1664 2024 204 1784 2144 324 1545 1905 85 1665 2025 205 1785 2145 325 1546 1906 86 1666 2026 206 1786 2146 326 1547 1907 87 1667 2027 207 1787 2147 327 1548 1908 88 1668 2028 208 1788 2148 328 1549 1909 89 1669 2029 209 1789 2149 329 1550 1910 90 1670 2030 210 1790 2150 330 1551 1911 91 1671 2031 211 1791 2151 331 1552 1912 92 1672 2032 212 1792 2152 332 1553 1913 93 1673 2033 213 1793 2153 333 1554 1914 94 1674 2034 214 1794 2154 334 1555 1915 95 1675 2035 215 1795 2155 335 1556 1916 96 1676 2036 216 1796 2156 336 1557 1917 97 1677 2037 217 1797 2157 337 1558 1918 98 1678 2038 218 1798 2158 338 1559 1919 99 1679 2039 219 1799 2159 339 1560 1920 100 1680 2040 220 1800 2160 340 1561 1921 101 1681 2041 221 1801 2161 341 1562 1922 102 1682 2042 222 1802 2162 342 1563 1923 103 1683 2043 223 1803 2163 343 1564 1924 104 1684 2044 224 1804 2164 344 1565 1925 105 1685 2045 225 1805 2165 345 1566 1926 106 1686 2046 226 1806 2166 346 1567 1927 107 1687 2047 227 1807 2167 347 1568 1928 108 1688 2048 228 1808 2168 348 1569 1929 109 1689 2049 229 1809 2169 349 1570 1930 110 1690 2050 230 1810 2170 350 1571 1931 111 1691 2051 231 1811 2171 351 1572 1932 112 1692 2052 232 1812 2172 352 1573 1933 113 1693 2053 233 1813 2173 353 1574 1934 114 1694 2054 234 1814 2174 354 1575 1935 115 1695 2055 235 1815 2175 355 1576 1936 116 1696 2056 236 1816 2176 356 1577 1937 117 1697 2057 237 1817 2177 357 1578 1938 118 1698 2058 238 1818 2178 358 1579 1939 119 1699 2059 239 1819 2179 359 1580 1940 120 1700 2060 240 1820 2180 360 2901 2936 2971 2913 2948 2983 2925 2960 2995 2902 2937 2972 2914 2949 2984 2926 2961 2996 2903 2938 2973 2915 2950 2985 2927 2962 2997 2904 2939 2974 2916 2951 2986 2928 2963 2998 2905 2940 2975 2917 2952 2987 2929 2964 2999 2906 2941 2976 2918 2953 2988 2930 2965 3000 2907 2942 2977 2919 2954 2989 2931 2966 3001 2908 2943 2978 2920 2955 2990 2932 2967 3002 2909 2944 2979 2921 2956 2991 2933 2968 3003 2910 2945 2980 2922 2957 2992 2934 2969 3004 2911 2946 2981 2923 2958 2993 2935 2970 3005 2912 2947 2982 2924 2959 2994 Form D LCDR1 LCDR2 LCDR3 LCDR1 LCDR2 LCDR3 LCDR1 LCDR2 LCDR3 2181 2541 361 2301 2661 481 2421 2781 601 2182 2542 362 2302 2662 482 2422 2782 602 2183 2543 363 2303 2663 483 2423 2783 603 2184 2544 364 2304 2664 484 2424 2784 604 2185 2545 365 2305 2665 485 2425 2785 605 2186 2546 366 2306 2666 486 2426 2786 606 2187 2547 367 2307 2667 487 2427 2787 607 2188 2548 368 2308 2668 488 2428 2788 608 2189 2549 369 2309 2669 489 2429 2789 609 2190 2550 370 2310 2670 490 2430 2790 610 2191 2551 371 2311 2671 491 2431 2791 611 2192 2552 372 2312 2672 492 2432 2792 612 2193 2553 373 2313 2673 493 2433 2793 613 2194 2554 374 2314 2674 494 2434 2794 614 2195 2555 375 2315 2675 495 2435 2795 615 2196 2556 376 2316 2676 496 2436 2796 616 2197 2557 377 2317 2677 497 2437 2797 617 2198 2558 378 2318 2678 498 2438 2798 618 2199 2559 379 2319 2679 499 2439 2799 619 2200 2560 380 2320 2680 500 2440 2800 620 2201 2561 381 2321 2681 501 2441 2801 621 2202 2562 382 2322 2682 502 2442 2802 622 2203 2563 383 2323 2683 503 2443 2803 623 2204 2564 384 2324 2684 504 2444 2804 624 2205 2565 385 2325 2685 505 2445 2805 625 2206 2566 386 2326 2686 506 2446 2806 626 2207 2567 387 2327 2687 507 2447 2807 627 2208 2568 388 2328 2688 508 2448 2808 628 2209 2569 389 2329 2689 509 2449 2809 629 2210 2570 390 2330 2690 510 2450 2810 630 2211 2571 391 2331 2691 511 2451 2811 631 2212 2572 392 2332 2692 512 2452 2812 632 2213 2573 393 2333 2693 513 2453 2813 633 2214 2574 394 2334 2694 514 2454 2814 634 2215 2575 395 2335 2695 515 2455 2815 635 2216 2576 396 2336 2696 516 2456 2816 636 2217 2577 397 2337 2697 517 2457 2817 637 2218 2578 398 2338 2698 518 2458 2818 638 2219 2579 399 2339 2699 519 2459 2819 639 2220 2580 400 2340 2700 520 2460 2820 640 2221 2581 401 2341 2701 521 2461 2821 641 2222 2582 402 2342 2702 522 2462 2822 642 2223 2583 403 2343 2703 523 2463 2823 643 2224 2584 404 2344 2704 524 2464 2824 644 2225 2585 405 2345 2705 525 2465 2825 645 2226 2586 406 2346 2706 526 2466 2826 646 2227 2587 407 2347 2707 527 2467 2827 647 2228 2588 408 2348 2708 528 2468 2828 648 2229 2589 409 2349 2709 529 2469 2829 649 2230 2590 410 2350 2710 530 2470 2830 650 2231 2591 411 2351 2711 531 2471 2831 651 2232 2592 412 2352 2712 532 2472 2832 652 2233 2593 413 2353 2713 533 2473 2833 653 2234 2594 414 2354 2714 534 2474 2834 654 2235 2595 415 2355 2715 535 2475 2835 655 2236 2596 416 2356 2716 536 2476 2836 656 2237 2597 417 2357 2717 537 2477 2837 657 2238 2598 418 2358 2718 538 2478 2838 658 2239 2599 419 2359 2719 539 2479 2839 659 2240 2600 420 2360 2720 540 2480 2840 660 2241 2601 421 2361 2721 541 2481 2841 661 2242 2602 422 2362 2722 542 2482 2842 662 2243 2603 423 2363 2723 543 2483 2843 663 2244 2604 424 2364 2724 544 2484 2844 664 2245 2605 425 2365 2725 545 2485 2845 665 2246 2606 426 2366 2726 546 2486 2846 666 2247 2607 427 2367 2727 547 2487 2847 667 2248 2608 428 2368 2728 548 2488 2848 668 2249 2609 429 2369 2729 549 2489 2849 669 2250 2610 430 2370 2730 550 2490 2850 670 2251 2611 431 2371 2731 551 2491 2851 671 2252 2612 432 2372 2732 552 2492 2852 672 2253 2613 433 2373 2733 553 2493 2853 673 2254 2614 434 2374 2734 554 2494 2854 674 2255 2615 435 2375 2735 555 2495 2855 675 2256 2616 436 2376 2736 556 2496 2856 676 2257 2617 437 2377 2737 557 2497 2857 677 2258 2618 438 2378 2738 558 2498 2858 678 2259 2619 439 2379 2739 559 2499 2859 679 2260 2620 440 2380 2740 560 2500 2860 680 2261 2621 441 2381 2741 561 2501 2861 681 2262 2622 442 2382 2742 562 2502 2862 682 2263 2623 443 2383 2743 563 2503 2863 683 2264 2624 444 2384 2744 564 2504 2864 684 2265 2625 445 2385 2745 565 2505 2865 685 2266 2626 446 2386 2746 566 2506 2866 686 2267 2627 447 2387 2747 567 2507 2867 687 2268 2628 448 2388 2748 568 2508 2868 688 2269 2629 449 2389 2749 569 2509 2869 689 2270 2630 450 2390 2750 570 2510 2870 690 2271 2631 451 2391 2751 571 2511 2871 691 2272 2632 452 2392 2752 572 2512 2872 692 2273 2633 453 2393 2753 573 2513 2873 693 2274 2634 454 2394 2754 574 2514 2874 694 2275 2635 455 2395 2755 575 2515 2875 695 2276 2636 456 2396 2756 576 2516 2876 696 2277 2637 457 2397 2757 577 2517 2877 697 2278 2638 458 2398 2758 578 2518 2878 698 2279 2639 459 2399 2759 579 2519 2879 699 2280 2640 460 2400 2760 580 2520 2880 700 2281 2641 461 2401 2761 581 2521 2881 701 2282 2642 462 2402 2762 582 2522 2882 702 2283 2643 463 2403 2763 583 2523 2883 703 2284 2644 464 2404 2764 584 2524 2884 704 2285 2645 465 2405 2765 585 2525 2885 705 2286 2646 466 2406 2766 586 2526 2886 706 2287 2647 467 2407 2767 587 2527 2887 707 2288 2648 468 2408 2768 588 2528 2888 708 2289 2649 469 2409 2769 589 2529 2889 709 2290 2650 470 2410 2770 590 2530 2890 710 2291 2651 471 2411 2771 591 2531 2891 711 2292 2652 472 2412 2772 592 2532 2892 712 2293 2653 473 2413 2773 593 2533 2893 713 2294 2654 474 2414 2774 594 2534 2894 714 2295 2655 475 2415 2775 595 2535 2895 715 2296 2656 476 2416 2776 596 2536 2896 716 2297 2657 477 2417 2777 597 2537 2897 717 2298 2658 478 2418 2778 598 2538 2898 718 2299 2659 479 2419 2779 599 2539 2899 719 2300 2660 480 2420 2780 600 2540 2900 720 3006 3041 3076 3018 3053 3088 3030 3065 3100 3007 3042 3077 3019 3054 3089 3031 3066 3101 3008 3043 3078 3020 3055 3090 3032 3067 3102 3009 3044 3079 3021 3056 3091 3033 3068 3103 3010 3045 3080 3022 3057 3092 3034 3069 3104 3011 3046 3081 3023 3058 3093 3035 3070 3105 3012 3047 3082 3024 3059 3094 3036 3071 3106 3013 3048 3083 3025 3060 3095 3037 3072 3107 3014 3049 3084 3026 3061 3096 3038 3073 3108 3015 3050 3085 3027 3062 3097 3039 3074 3109 3016 3051 3086 3028 3063 3098 3040 3075 3110 3017 3052 3087 3029 3064 3099

In addition, it should be understood that, in addition to the exemplary CDR sequences listed in Table A-Table D above, based on the VH and VL sequences in the antigen-binding unit of the present application, other numbering systems known in the art such as Kabat, Chothia, AbM or The CDR region determined by Contact is also included in the scope of this application.

The VH CDR1 of the antigen-binding unit described herein may comprise the same sequence as the CDR1 contained in SEQ ID NO: 721-1080 and 3111-3145; the VH CDR2 of the antigen-binding unit described herein may Comprising the same sequence as the CDR2 contained in SEQ ID NO: 721-1080 and 3111-3145; said VH CDR3 of the antigen binding unit described herein may comprise the same sequence as that contained in SEQ ID NO: 721-1080 and 3111-3145 The same sequence of the CDR3 comprised; the VL CDR1 of the antigen binding unit may comprise the same sequence as the CDR1 comprised in SEQ ID NO: 1081-1440 and 3146-3180; the VL of the antigen binding unit CDR2 may comprise the same sequence as the CDR2 comprised in SEQ ID NO: 1081-1440 and 3146-3180; and/or said VL CDR3 of said antigen binding unit may comprise the same sequence as SEQ ID NO: 1081-1440 and 3146- The same sequence as the CDR3 contained in 3180.

In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 regions are determined by the IMGT system based on the VH and VL sequences in the antigen binding unit of the present application. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 regions are determined by the Kabat system based on the VH and VL sequences in the antigen-binding unit of the present application. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 regions are determined by the Chothia system based on the VH and VL sequences in the antigen-binding unit of the present application. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 regions are determined by the AbM system based on the VH and VL sequences in the antigen-binding unit of the present application. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 regions are determined by the Contact system based on the VH and VL sequences in the antigen-binding unit of the present application.

The antigen binding unit described herein can bind to the novel coronavirus (SARS-CoV-2) S protein. The antigen binding unit described herein can be combined with the receptor binding domain (RBD) of the novel coronavirus (SARS-CoV-2) S protein. Binding of an antigen binding unit to an RBD can be characterized or expressed by any method known in the art. For example, binding can be characterized by binding affinity, which can be the strength of the interaction between the antigen-binding unit and the antigen. Binding affinity can be determined by any method known in the art, such as in vitro binding assays. The binding affinity of the antigen binding unit herein can be expressed in terms of KD, KD is defined as the ratio of two kinetic rate constants Ka/Kd, wherein "Ka" refers to the rate constant of antibody binding to antigen, and "Kd" refers to the rate constant of antibody binding to antibody/Kd Rate constant for dissociation in antigen complexes. The antigen binding unit as disclosed herein specifically binds the receptor binding domain (RBD) of the novel coronavirus (SARS-CoV-2) S protein with a KD ranging from about 10 μM to about 1 fM. For example, the antigen binding unit can be present at less than about 10 µM, 1 µM, 0.1 µM, 50 nM, 20 nM, 15 nM, 10 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 0.5 nM, 0.1 nM , 50 pM, 10 pM, 1 pM, 0.1 pM, 10 fM, 1 fM, 0.1 fM or less than 0.1 fM KD specifically binds to the receptor binding domain (RBD) of the novel coronavirus (SARS-CoV-2) S protein ). The antigen binding units disclosed herein may be present at less than 100 nM, less than 50 nM, less than 20 nM, less than 15 nM, less than 10 nM, less than 5 nM, less than 4 nM, less than 3 nM, less than 2 nM, less than 1 nM, less than 0.5 nM, less than 0.1 nM, less than 0.05 nM , or an equilibrium dissociation constant (K _D ) less than 0.01 nM binds to the receptor-binding domain (RBD) of the novel coronavirus (SARS-CoV-2) S protein.

The antigen-binding units described herein have neutralizing activity against the novel coronavirus (SARS-CoV-2). The neutralizing activity of the antigen-binding units described herein against the novel coronavirus (SARS-CoV-2) can be assayed by pseudoviruses. Pseudoviruses have cell infection characteristics similar to herpesviruses, can be compared to the early process of true virus infection of cells, and can be detected and analyzed safely and quickly. The neutralizing activity of the antigen-binding units described herein to the novel coronavirus (SARS-CoV-2) can be detected by methods known in the art, such as the use of microwell cell neutralization assays, referring to Temperton N J et al., Emerg Infect Dis , 2005, 11(3), 411-416 as described.

The neutralizing activity of the antigen-binding unit described herein to the novel coronavirus (SARS-CoV-2) can be tested using experimental cells such as Huh-7 cells and pseudovirus SARS-CoV-2 virus. The antigen binding unit described herein can be for example less than 100 µg/ml, less than 50 µg/ml, less than 20 µg/ml, less than 10 µg/ml, less than 9 µg/ml, less than 8 µg/ml, less than 7 µg/ml ml, less than 6 µg/ml, less than 5 µg/ml, less than 4 µg/ml, less than 3 µg/ml, less than 2 µg/ml, less than 1 µg/ml, less than 0.5 µg/ml, less than 0.25 µg/ml, Less than 0.2 µg/ml, less than 0.1 µg/ml, less than 0.05 µg/ml, less than 1 ng/ml, less than 0.5 ng/ml, less than 0.25 ng/ml, less than 0.2 ng/ml, less than 0.1 ng/ml, less than 50 IC50 neutralizing novel coronavirus (SARS- CoV-2) pseudovirus.

The neutralizing activity of the antigen-binding unit described herein to the novel coronavirus (SARS-CoV-2) can be tested by using the true virus of SARS-CoV-2 through the plaque reduction neutralization test (Plaque Reduction Neutralization Test, PRNT). The reduction in plaque after incubation was used to calculate the IC50 for the neutralization of SARS-CoV-2 euvirus by the antigen binding units described herein. The antigen binding unit described herein can be for example less than 100 µg/ml, less than 50 µg/ml, less than 20 µg/ml, less than 10 µg/ml, less than 9 µg/ml, less than 8 µg/ml, less than 7 µg/ml ml, less than 6 µg/ml, less than 5 µg/ml, less than 4 µg/ml, less than 3 µg/ml, less than 2 µg/ml, less than 1 µg/ml, less than 0.5 µg/ml, less than 0.25 µg/ml, Less than 0.2 µg/ml, less than 0.1 µg/ml, less than 0.05 µg/ml, less than 1 ng/ml, less than 0.5 ng/ml, less than 0.25 ng/ml, less than 0.2 ng/ml, less than 0.1 ng/ml, less than 50 IC50 neutralizing novel coronavirus (SARS- CoV-2) true virus. Preparation of Antigen Binding Units

Provided herein is a method of producing any of the antigen binding units disclosed herein, wherein the method comprises culturing a host cell expressing the antigen binding unit under conditions suitable for expression of the antigen binding unit, and isolating the antigen binding unit expressed by the host cell.

The expressed antigen binding unit can be isolated using a variety of protein purification techniques known in the art. Typically, antigen-binding units are isolated from the culture medium as secreted polypeptides, although they can also be recovered from host cell lysates or bacterial periplasm when produced directly in the absence of signal peptides. If the antigen-binding units are membrane-bound, they can be solubilized by solutions of appropriate detergents commonly used by those skilled in the art. Recovered antigen-binding units can be obtained by salt precipitation (e.g., with ammonium sulfate), ion exchange chromatography (e.g., run on a cation or anion exchange column at neutral pH and eluted with a gradient of increasing ionic strength steps), gel filtration Chromatography (including gel filtration HPLC) and tagged affinity column chromatography, or affinity resins such as protein A, protein G, hydroxyapatite and anti-immunoglobulin for further purification.

Derivatized immunoglobulins to which the following moieties have been added can be used in the methods and compositions described herein: chemical linkers, detectable moieties such as fluorescent dyes, enzymes, substrates, chemiluminescent moieties, specific binding moieties such as streptavidin Avidin, avidin or biotin, or a drug conjugate.

Also provided herein are antigen binding units conjugated to chemically functional moieties. Typically, the moiety is a label capable of producing a detectable signal. These conjugated antigen binding units can be used, for example, in detection systems such as severity of viral infection, imaging of foci of infection, and the like. Such labels are known in the art and include, but are not limited to, radioisotopes, enzymes, fluorescent compounds, chemiluminescent compounds, bioluminescent compound substrate cofactors, and inhibitors. See US Patent Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241 for examples of patents teaching the use of such tags. This moiety can be covalently linked to the antigen binding unit, recombinantly linked or conjugated to the antigen binding unit via a second reagent such as a second antibody, protein A or a biotin-avidin complex.

Other functional moieties include signal peptides, agents that enhance immunoreactivity, agents that facilitate conjugation to solid supports, vaccine vectors, biological response modifiers, paramagnetic labels, and drugs. Signal peptides are short amino acid sequences that direct newly synthesized proteins through the cell membrane (usually the endoplasmic reticulum in eukaryotic cells) and the inner membrane or both inner and outer membranes of bacteria. The signal peptide can be located at the N-terminal portion of the polypeptide or at the C-terminal portion of the polypeptide, and the signal peptide can be enzymatically removed from the cell between biosynthesis and secretion of the polypeptide. Such peptides can be incorporated into the antigen binding unit to allow secretion of the synthetic molecule.

Agents that enhance immunoreactivity include, but are not limited to, bacterial superantigens. Reagents that facilitate conjugation to solid supports include, but are not limited to, biotin or avidin. Immunogen carriers include, but are not limited to, any physiologically acceptable buffer. Biological response modifiers include cytokines, particularly tumor necrosis factor (TNF), interleukin-2, interleukin-4, granulocyte-macrophage colony-stimulating factor, and gamma-interferon.

The chemically functional portion can be produced recombinantly, for example by generating a fusion gene encoding the antigen binding unit and the functional portion. Alternatively, the antigen binding unit can be chemically bonded to the moiety by any of a variety of well-known chemical schemes. For example, when the moiety is a protein, attachment can be through a heterobifunctional crosslinker, eg, SPDP, carbodiimide glutaraldehyde, and the like. The moiety can be covalently linked or conjugated by a second reagent, such as a second antibody, protein A, or a biotin-avidin complex. Paramagnetic moieties and their conjugation to antibodies are well known in the art. See, eg, Miltenyi et al. (1990) Cytometry 11:231-238. nucleic acid

In one aspect, provided herein is an isolated polynucleotide encoding an antigen binding unit described herein. Nucleotide sequences corresponding to various regions of the L or H chain of existing antibodies can be readily obtained and sequenced using conventional techniques including, but not limited to, hybridization, PCR, and DNA sequencing. Hybridoma cells producing monoclonal antibodies are used as a preferred source of antibody nucleotide sequences. Large numbers of hybridoma cells producing a panel of monoclonal antibodies are available from public or private repositories. The largest repository is the American Type Culture Collection, which offers a wide variety of well-characterized hybridoma cell lines. Alternatively, antibody nucleotides can be obtained from immunized or unimmunized rodents or humans, and from organs such as spleen and peripheral blood lymphocytes. Specific techniques suitable for the extraction and synthesis of antibody nucleotides are described in Orlandi et al. (1989) Proc. Natl. Acad. Sci. U.S.A 86: 3833-3837; Larrick et al. 1989) biochem. Biophys. Res. Commun. 160: 1250-1255; Sastry et al. (1989) Proc. Natl. Acad. Sci., U.S.A. 86: 5728-5732; and U.S. Patent No. 5,969,108.

Antibody nucleotide sequences may also be modified, for example, by substituting coding sequences for human heavy and light chain constant regions in place of the cognate non-human sequences. In this way, chimeric antibodies are produced, which retain the binding specificity of the original antibody.

In addition, polynucleotides encoding the heavy and/or light chains of the antigen-binding units can be codon-optimized to achieve optimal expression of the subject's antigen-binding units in desired host cells. For example, in one codon optimization approach, native codons are replaced with the most common codons from a reference genome, where the codons for each amino acid are engineered to have a higher translation rate. Additional exemplary methods for generating codon-optimized polynucleotides for expression of desired proteins are described in Kanaya et al., Gene, 238:143-155 (1999), Wang et al., Mol. Biol. Evol. , 18(5):792-800 (2001), US Patent No. 5,795,737, US Publication No. 2008/0076161 and WO 2008/000632, the methods can be applied to the heavy and/or light chain of the antigen binding unit.

The polynucleotides disclosed herein include polynucleotides encoding functional equivalents of the exemplary polypeptides and fragments thereof.

Due to the degeneracy of the genetic code, the nucleotides of the L and H sequences and heterodimerization sequences suitable for construction of the polynucleotides and vectors described herein can vary considerably. These variations are included in the content of this article. treatment method

Provided herein are methods of using an antigen binding unit described herein to prevent or treat a novel coronavirus (SARS-CoV-2) infection in a subject, comprising administering to the subject an antigen binding unit described herein.

Provided herein are methods of treating a disease, condition or disorder in a mammal using an antigen binding unit described herein in combination with a second agent. The second agent can be administered with, before or after the antibody. The second agent may be an antiviral agent. Antiviral agents include, but are not limited to, telaprevir, boceprevir, semiprevir, sofosbuvir, daclastavir, anaprivir Asunaprevir, lamivudine, adefovir, entecavir, tenofovir, telbivudine, interferon alfa, and pegylated interferon alpha. The second agent may be selected from hydroxychloroquine, chloroquine, favipiravir, gimsilumab (Gimsilumab), AdCOVID (University of Alabama at Birmingham), AT-100 (Airway Therapeutics), TZLS-501 (Tiziana Life Sciences) , OYA1 (OyaGen), BPI-002 (BeyondSpring), INO-4800 (Inovio Pharmaceutical), NP-120 (ifenprodil), Remdesivir (GS-5734), Actemra (Roche), Galidevir (BCX4430) , SNG001 (Synairgen Research), or a combination thereof.

The second medicament may be an medicament for alleviating symptoms of a concurrent inflammatory condition in the subject. Such anti-inflammatory agents include non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. NSAIDs include, but are not limited to, salicylates such as acetylsalicylic acid; diflunisal, salicylic acid, and salicylate; propionic acid derivatives such as ibuprofen; naproxen; Dexketoprofen, flurbiprofen, oxaprozine, fenoprofen, loxoprofen, and ketoprofen; acetic acid derivatives such as indomethacin, diclofenac, tolmetin, aceclofenac, sulindac, nabumetone, etodolac, and ketorolac; enolic acid derivatives such as piroxicam, lornoxicam, meloxicam, isoxicam, tenoxicam, benzo butazone and droxicam; anthranilic acid derivatives such as mefenamic acid, flufenamic acid, meclofenamic acid, and tolfenamic acid; selective COX-2 inhibitors such as celex Coxib, lumiracoxib, rofecoxib, etoricoxib, valdecoxib, firocoxib, and parecoxib; sulfonicillin, such as nimesulide; and other NSAIDs such as Nissin and Lycafelon. Corticosteroids include, but are not limited to, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisone, and prednisolone.

The second agent may be an immunosuppressant. Immunosuppressants that can be used in combination with an antigen-binding unit include, but are not limited to, hydroxychloroquine, sulfasalazine, leflunomide, etanercept, infliximab, adalimumab, D-penicillamine, oral Gold compound, injectable gold compound (intramuscular injection), minocycline, gold sodium thiomalate, auranofin, D-penicillamine, clobenzalide, busillamine, actarit, cyclo Phosphamide, azathioprine, methotrexate, mizoribine, cyclosporine, and tacrolimus.

The specific dosage will vary depending on the particular antigen-binding unit chosen, the dosing regimen to be followed, whether it is administered in combination with other agents, the time of administration, the tissue to which it is administered, and the physical delivery system carrying the particular antigen-binding unit. In some embodiments, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, Antigen binding units in the range of 66, 67, 68, 69 or 70 mg. For example, about 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, or Antigen-binding units in the range of 55 mg. In some embodiments, the antigen is administered to the subject weekly in the range of about 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, or 55 mg combined unit.

May be administered at an average daily dose of greater than 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10 mg over the course of a treatment cycle An amount of the antigen binding unit is administered to the subject. For example, an antigen-binding agent is administered to a subject in an average daily amount of about 6 to 10 mg, about 6.5 to 9.5 mg, about 6.5 to 8.5 mg, about 6.5 to 8 mg, or about 7 to 9 mg over the course of a treatment cycle. unit.

The dosage of the antigen binding unit may be about, at least about or at most about 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, 1000 mg or mg/kg , or any range derivable therein. A dose in mg/kg is intended to refer to the mg amount of antigen binding unit per kilogram of total subject body weight. It is contemplated that when multiple doses are administered to a patient, the doses may vary in amount or they may be the same. pharmaceutical composition

Provided herein are pharmaceutical compositions comprising a subject antibody or functional fragment thereof and a pharmaceutically acceptable carrier, excipient or stabilizer, including but not limited to inert solid diluents and fillers, diluents, sterile aqueous solutions And various organic solvents, penetration enhancers, solubilizers and adjuvants. (Remington's Pharmaceutical Sciences 16th ed., edited by Osol, A. (1980)).

The pharmaceutical compositions may be in unit dosage form suitable for single administration of precise dosages. The pharmaceutical composition may further comprise an antigen-binding unit as an active ingredient, and may include conventional pharmaceutical carriers or excipients. Furthermore, it may include other drugs or agents, carriers, adjuvants and the like. Exemplary parenteral administration forms include solutions or suspensions of active polypeptides and/or PEG-modified polypeptides in sterile aqueous solutions, such as aqueous propylene glycol or dextrose solutions. Such dosage forms may be suitably buffered with salts such as histidine and/or phosphate, if desired.

The composition may further include one or more pharmaceutically acceptable additives and excipients. These additives and excipients include, but are not limited to, anti-adherents, antifoaming agents, buffers, polymers, antioxidants, preservatives, chelating agents, viscomodulators (viscomodulators), tonicity regulators, flavoring agents, coloring agents, Flavor enhancers, opacifiers, suspending agents, binders, fillers, plasticizers, lubricants and mixtures thereof. Reagent test kit

The kits described herein comprise an antigen binding unit as described herein or a conjugate thereof as described herein. Also provided is the use of the antigen-binding unit described herein in the preparation of a kit for detecting the presence or level of the novel coronavirus or its S protein or the RBD of the S protein in a sample, or for diagnosis Whether the subject is infected with the new coronavirus.

In some embodiments, the sample includes, but is not limited to, excreta, oral or nasal secretions, alveolar lavage fluid, and the like from a subject (eg, a mammal, preferably a human).

General methods for using antibodies or antigen-binding fragments thereof to detect the presence or level of a target virus or antigen (eg, novel coronavirus or its S protein or RBD of S protein) in a sample are well known to those skilled in the art. In some embodiments, the detection method may use enzyme-linked immunosorbent assay (ELISA), enzyme immunoassay, chemiluminescent immunoassay, radioimmunoassay, fluorescent immunoassay, immunochromatography, competition, and the like. [ example ]

The invention will now be described with reference to the following examples, which are intended to illustrate the invention, but not to limit it.

Unless otherwise specified, the molecular biology experimental methods and immunoassay methods used in this article basically refer to J. Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press, 1989, and FM Ausubel et al., Molecular Biology Laboratory Guide, 3rd Edition, John Wiley & Sons, Inc., 1995 described method; restriction enzymes used in accordance with the conditions recommended by the product manufacturer. Those who do not indicate the specific conditions in the examples are carried out according to the conventional conditions or the conditions suggested by the manufacturer. The reagents or instruments used were not indicated by the manufacturer, and they were all commercially available conventional products. Those skilled in the art understand that the examples describe the present invention by way of example and are not intended to limit the scope of the claimed invention. Example 1 : Isolation of memory B cells

Blood samples from patients infected with SARS-CoV-2 who were cured and discharged from the hospital (provided by Beijing You'an Hospital) were collected and performed in a P2+ biosafety laboratory using STEMCELL SepMate™-15 (Stemcell Technologies, catalog number: 86415). Extraction of PBMCs. Subsequently, the extracted PBMCs were enriched for memory B cells using the STEMCELL EasySep Human Memory B Cell Isolation Kit (Stemcell Technologies, catalog number: 17864) according to the manufacturer's instructions. Embodiment 2 : Obtaining and identification of antigen binding unit sequence

According to the manufacturer's instructions, Chromium Single Cell V(D)J Reagent Kits (purchased from 10X genomics, catalog number: 100006) were used to perform single-cell transcriptome VDJ sequencing on the above-mentioned enriched memory B cells. The sequencing results were analyzed, and 360 strains of antigen-binding units were obtained, which were named ABU 1-395. The sequence information of the obtained antigen-binding unit is shown in Table 1 below. Table 1 Exemplary antigen-binding units obtained herein ABU No. VH SEQ ID No. VL SEQ ID NO. ABU-1 721 1081 ABU-2 722 1082 ABU-3 723 1083 ABU-4 724 1084 ABU-5 725 1085 ABU-6 726 1086 ABU-7 727 1087 ABU-8 728 1088 ABU-9 729 1089 ABU-10 730 1090 ABU-11 731 1091 ABU-12 732 1092 ABU-13 733 1093 ABU-14 734 1094 ABU-15 735 1095 ABU-16 736 1096 ABU-17 737 1097 ABU-18 738 1098 ABU-19 739 1099 ABU-20 740 1100 ABU-21 741 1101 ABU-22 742 1102 ABU-23 743 1103 ABU-24 744 1104 ABU-25 745 1105 ABU-26 746 1106 ABU-27 747 1107 ABU-28 748 1108 ABU-29 749 1109 ABU-30 750 1110 ABU-31 751 1111 ABU-32 752 1112 ABU-33 753 1113 ABU-34 754 1114 ABU-35 755 1115 ABU-36 756 1116 ABU-37 757 1117 ABU-38 758 1118 ABU-39 759 1119 ABU-40 760 1120 ABU-41 761 1121 ABU-42 762 1122 ABU-43 763 1123 ABU-44 764 1124 ABU-45 765 1125 ABU-46 766 1126 ABU-47 767 1127 ABU-48 768 1128 ABU-49 769 1129 ABU-50 770 1130 ABU-51 771 1131 ABU-52 772 1132 ABU-53 773 1133 ABU-54 774 1134 ABU-55 775 1135 ABU-56 776 1136 ABU-57 777 1137 ABU-58 778 1138 ABU-59 779 1139 ABU-60 780 1140 ABU-61 781 1141 ABU-62 782 1142 ABU-63 783 1143 ABU-64 784 1144 ABU-65 785 1145 ABU-66 786 1146 ABU-67 787 1147 ABU-68 788 1148 ABU-69 789 1149 ABU-70 790 1150 ABU-71 791 1151 ABU-72 792 1152 ABU-73 793 1153 ABU-74 794 1154 ABU-75 795 1155 ABU-76 796 1156 ABU-77 797 1157 ABU-78 798 1158 ABU-79 799 1159 ABU-80 800 1160 ABU-81 801 1161 ABU-82 802 1162 ABU-83 803 1163 ABU-84 804 1164 ABU-85 805 1165 ABU-86 806 1166 ABU-87 807 1167 ABU-88 808 1168 ABU-89 809 1169 ABU-90 810 1170 ABU-91 811 1171 ABU-92 812 1172 ABU-93 813 1173 ABU-94 814 1174 ABU-95 815 1175 ABU-96 816 1176 ABU-97 817 1177 ABU-98 818 1178 ABU-99 819 1179 ABU-100 820 1180 ABU-101 821 1181 ABU-102 822 1182 ABU-103 823 1183 ABU-104 824 1184 ABU-105 825 1185 ABU-106 826 1186 ABU-107 827 1187 ABU-108 828 1188 ABU-109 829 1189 ABU-110 830 1190 ABU-111 831 1191 ABU-112 832 1192 ABU-113 833 1193 ABU-114 834 1194 ABU-115 835 1195 ABU-116 836 1196 ABU-117 837 1197 ABU-118 838 1198 ABU-119 839 1199 ABU-120 840 1200 ABU-121 841 1201 ABU-122 842 1202 ABU-123 843 1203 ABU-124 844 1204 ABU-125 845 1205 ABU-126 846 1206 ABU-127 847 1207 ABU-128 848 1208 ABU-129 849 1209 ABU-130 850 1210 ABU-131 851 1211 ABU-132 852 1212 ABU-133 853 1213 ABU-134 854 1214 ABU-135 855 1215 ABU-136 856 1216 ABU-137 857 1217 ABU-138 858 1218 ABU-139 859 1219 ABU-140 860 1220 ABU-141 861 1221 ABU-142 862 1222 ABU-143 863 1223 ABU-144 864 1224 ABU-145 865 1225 ABU-146 866 1226 ABU-147 867 1227 ABU-148 868 1228 ABU-149 869 1229 ABU-150 870 1230 ABU-151 871 1231 ABU-152 872 1232 ABU-153 873 1233 ABU-154 874 1234 ABU-155 875 1235 ABU-156 876 1236 ABU-157 877 1237 ABU-158 878 1238 ABU-159 879 1239 ABU-160 880 1240 ABU-161 881 1241 ABU-162 882 1242 ABU-163 883 1243 ABU-164 884 1244 ABU-165 885 1245 ABU-166 886 1246 ABU-167 887 1247 ABU-168 888 1248 ABU-169 889 1249 ABU-170 890 1250 ABU-171 891 1251 ABU-172 892 1252 ABU-173 893 1253 ABU-174 894 1254 ABU-175 895 1255 ABU-176 896 1256 ABU-177 897 1257 ABU-178 898 1258 ABU-179 899 1259 ABU-180 900 1260 ABU-181 901 1261 ABU-182 902 1262 ABU-183 903 1263 ABU-184 904 1264 ABU-185 905 1265 ABU-186 906 1266 ABU-187 907 1267 ABU-188 908 1268 ABU-189 909 1269 ABU-190 910 1270 ABU-191 911 1271 ABU-192 912 1272 ABU-193 913 1273 ABU-194 914 1274 ABU-195 915 1275 ABU-196 916 1276 ABU-197 917 1277 ABU-198 918 1278 ABU-199 919 1279 ABU-200 920 1280 ABU-201 921 1281 ABU-202 922 1282 ABU-203 923 1283 ABU-204 924 1284 ABU-205 925 1285 ABU-206 926 1286 ABU-207 927 1287 ABU-208 928 1288 ABU-209 929 1289 ABU-210 930 1290 ABU-211 931 1291 ABU-212 932 1292 ABU-213 933 1293 ABU-214 934 1294 ABU-215 935 1295 ABU-216 936 1296 ABU-217 937 1297 ABU-218 938 1298 ABU-219 939 1299 ABU-220 940 1300 ABU-221 941 1301 ABU-222 942 1302 ABU-223 943 1303 ABU-224 944 1304 ABU-225 945 1305 ABU-226 946 1306 ABU-227 947 1307 ABU-228 948 1308 ABU-229 949 1309 ABU-230 950 1310 ABU-231 951 1311 ABU-232 952 1312 ABU-233 953 1313 ABU-234 954 1314 ABU-235 955 1315 ABU-236 956 1316 ABU-237 957 1317 ABU-238 958 1318 ABU-239 959 1319 ABU-240 960 1320 ABU-241 961 1321 ABU-242 962 1322 ABU-243 963 1323 ABU-244 964 1324 ABU-245 965 1325 ABU-246 966 1326 ABU-247 967 1327 ABU-248 968 1328 ABU-249 969 1329 ABU-250 970 1330 ABU-251 971 1331 ABU-252 972 1332 ABU-253 973 1333 ABU-254 974 1334 ABU-255 975 1335 ABU-256 976 1336 ABU-257 977 1337 ABU-258 978 1338 ABU-259 979 1339 ABU-260 980 1340 ABU-261 981 1341 ABU-262 982 1342 ABU-263 983 1343 ABU-264 984 1344 ABU-265 985 1345 ABU-266 986 1346 ABU-267 987 1347 ABU-268 988 1348 ABU-269 989 1349 ABU-270 990 1350 ABU-271 991 1351 ABU-272 992 1352 ABU-273 993 1353 ABU-274 994 1354 ABU-275 995 1355 ABU-276 996 1356 ABU-277 997 1357 ABU-278 998 1358 ABU-279 999 1359 ABU-280 1000 1360 ABU-281 1001 1361 ABU-282 1002 1362 ABU-283 1003 1363 ABU-284 1004 1364 ABU-285 1005 1365 ABU-286 1006 1366 ABU-287 1007 1367 ABU-288 1008 1368 ABU-289 1009 1369 ABU-290 1010 1370 ABU-291 1011 1371 ABU-292 1012 1372 ABU-293 1013 1373 ABU-294 1014 1374 ABU-295 1015 1375 ABU-296 1016 1376 ABU-297 1017 1377 ABU-298 1018 1378 ABU-299 1019 1379 ABU-300 1020 1380 ABU-301 1021 1381 ABU-302 1022 1382 ABU-303 1023 1383 ABU-304 1024 1384 ABU-305 1025 1385 ABU-306 1026 1386 ABU-307 1027 1387 ABU-308 1028 1388 ABU-309 1029 1389 ABU-310 1030 1390 ABU-311 1031 1391 ABU-312 1032 1392 ABU-313 1033 1393 ABU-314 1034 1394 ABU-315 1035 1395 ABU-316 1036 1396 ABU-317 1037 1397 ABU-318 1038 1398 ABU-319 1039 1399 ABU-320 1040 1400 ABU-321 1041 1401 ABU-322 1042 1402 ABU-323 1043 1403 ABU-324 1044 1404 ABU-325 1045 1405 ABU-326 1046 1406 ABU-327 1047 1407 ABU-328 1048 1408 ABU-329 1049 1409 ABU-330 1050 1410 ABU-331 1051 1411 ABU-332 1052 1412 ABU-333 1053 1413 ABU-334 1054 1414 ABU-335 1055 1415 ABU-336 1056 1416 ABU-337 1057 1417 ABU-338 1058 1418 ABU-339 1059 1419 ABU-340 1060 1420 ABU-341 1061 1421 ABU-342 1062 1422 ABU-343 1063 1423 ABU-344 1064 1424 ABU-345 1065 1425 ABU-346 1066 1426 ABU-347 1067 1427 ABU-348 1068 1428 ABU-349 1069 1429 ABU-350 1070 1430 ABU-351 1071 1431 ABU-352 1072 1432 ABU-353 1073 1433 ABU-354 1074 1434 ABU-355 1075 1435 ABU-356 1076 1436 ABU-357 1077 1437 ABU-358 1078 1438 ABU-359 1079 1439 ABU-360 1080 1440 ABU-361 3111 3146 ABU-362 3112 3147 ABU-363 3113 3148 ABU-364 3114 3149 ABU-365 3115 3150 ABU-366 3116 3151 ABU-367 3117 3152 ABU-368 3118 3153 ABU-369 3119 3154 ABU-370 3120 3155 ABU-371 3121 3156 ABU-372 3122 3157 ABU-373 3123 3158 ABU-374 3124 3159 ABU-375 3125 3160 ABU-376 3126 3161 ABU-377 3127 3162 ABU-378 3128 3163 ABU-379 3129 3164 ABU-380 3130 3165 ABU-381 3131 3166 ABU-382 3132 3167 ABU-383 3133 3168 ABU-384 3134 3169 ABU-385 3135 3170 ABU-386 3136 3171 ABU-387 3137 3172 ABU-388 3138 3173 ABU-389 3139 3174 ABU-390 3140 3175 ABU-391 3141 3176 ABU-392 3142 3177 ABU-393 3143 3178 ABU-394 3144 3179 ABU-395 3145 3180 Example 3 : Preparation and Purification of Antigen Binding Units Herein

According to the sequence information of the antigen-binding units obtained in Example 2, Beijing Sino Biological Co., Ltd. was commissioned to express and purify the obtained antigen-binding units, and their antigen reactivity was tested.

Briefly, nucleic acid molecules encoding antibody heavy and light chains were synthesized in vitro, and then cloned into expression vectors, respectively, to obtain recombinant expression vectors encoding antibody heavy and light chains, respectively. HEK293 cells were co-transfected with the above-mentioned recombinant expression vectors encoding antibody heavy chain and light chain respectively. After 4-6 hours of transfection, the cell culture medium was replaced with serum-free medium, and cultured at 37°C for 6 days. After the culture is over, the antibody protein expressed by the cells is purified from the culture through an affinity purification column. Subsequently, the purified target protein was detected by reducing and non-reducing SDS-PAGE. Among them, taking ABU-174, ABU-175 and ABU190 as examples, the electrophoresis results after preparation are shown in Figures 1A-1C respectively. The results showed that the purity of purified ABU-174, ABU-175 and ABU190 were 95.9%, 96.4%, 98.2%, respectively.

Subsequently, using the recombinantly expressed S protein RBD as the coating antigen, and using horseradish peroxidase (HRP)-labeled Goat anti-human IgG Fc as the secondary antibody, the antigenic response of the purified antibody to be tested was detected by ELISA experiment sex. In brief, 96-well plates were coated with recombinantly expressed S protein RBD (the amino acid sequence of which is shown in SEQ ID NO: 1459, and the concentration is 0.01 μg/ml or 1 μg/ml), and then the 96-well plates were blocked with blocking solution. closed. Then, monoclonal antibodies to be tested (control antibody, ABU-174, ABU-175, and ABU190; concentrations of 0.1 μg/ml respectively) were added and incubated. After washing with ELISA washing solution, horseradish peroxidase (HRP)-labeled Goat anti-human IgG Fc was added as a secondary antibody (diluted at 1:500), and the incubation was continued. Then, wash the microtiter plate with PBST, and add a chromogenic reagent to develop the color. Then read the absorbance at OD450 nm on a microplate reader. The results are shown in Table 2. It can be seen from Table 2 that ABU-174, ABU-175 and ABU190 can all specifically recognize and bind to S protein RBD. Table 2: Reactivity of ABU-174, ABU-175 and ABU190 Antigen Binding Units to the S protein RBD detected by ELISA (OD450 readout) Sample to be tested RBD protein concentration 0.01 μg /ml 1 μg /ml Unrelated antibody (1ug/ml) 0.006 0.025 ABU-174 (1ug/ml) 1.261 2.909 ABU-175(1ug/ml) 2.274 2.963 ABU190 (1ug/ml) 0.288 3.057 Embodiment 4 : the evaluation of the binding ability of the antigen binding unit herein and S protein

In this example, surface plasmon resonance (SPR) was used to detect the affinity of the antibody to the RBD region of the Spike protein. Using Biacore T200 for measurement, the biotin-labeled SARS-COV-2 RBD domain was first coupled to the SA chip (GE Company), and the RU value of the signal resonance unit increased by 100 units. The running buffer is PBS pH 7.4 plus 0.005% P20 to ensure that the buffer in the analyte (such as antibody) is consistent with the running buffer. The purified antibody was serially diluted 3 times to make the concentration between 50-0.78125 nM. The measurement results were analyzed using Biacore Evaluation software, and all curves were fitted with a 1:1 model to obtain the rate constant Ka of the binding of the antibody to the antigen and the rate constant Kd of the dissociation of the antibody from the antibody/antigen complex, and calculate the dissociation equilibrium constant KD, where KD=Kd/Ka, the results are shown in Table 3 below.

Table 3 lists the binding affinities of the exemplary antigen-binding units herein to the RBD region of the Spike protein, wherein the KD values of each antigen-binding unit are all less than 20 nM. Table 3. The KD value of the binding affinity of the exemplary antigen-binding units herein and the Spike protein RBD region AUB No. KD (Kd/Ka, nM) ABU-145 <10 ABU-149 <10 ABU-174 <1 ABU-175 <1 ABU-181 <10 ABU-190 <10 ABU-205 <10 ABU-207 <10 ABU-208 <1 ABU-210 <10 ABU-211 <20 ABU-254 <10 ABU-257 <10 ABU-258 <1 ABU-288 <1 ABU-289 <10 ABU-290 <1 ABU-291 <1 ABU-296 <1 ABU-297 <1 ABU-298 <20 ABU-305 <20 ABU-308 <10 ABU-312 <20 ABU-316 <10 ABU-317 <20 ABU-319 <10 ABU-320 <10 ABU-322 <1 ABU-323 <20 ABU-325 <10 ABU-327 <20 ABU-328 <10 ABU-329 <10 ABU-330 <10 ABU-337 <20 ABU-339 <20 ABU-340 <10 ABU-341 <10 ABU-343 <20 ABU-344 <1 ABU-346 <10 ABU-348 <10 ABU-349 <1 ABU-351 <10 ABU-352 <10 ABU-354 <1 ABU-355 <1 ABU-356 <10 ABU-357 <10 ABU-358 <10 ABU-359 <10 ABU-360 <1 ABU-361 <20 ABU-362 <20 ABU-365 <10 ABU-367 <1 ABU-368 <20 ABU-369 <10 ABU-371 <20 ABU-372 <20 ABU-373 <10 ABU-375 <10 ABU-376 <10 ABU-377 <10 ABU-379 <10 ABU-380 <1 ABU-381 <1 ABU-382 <10 ABU-383 <20 ABU-384 <20 ABU-385 <20 ABU-386 <10 ABU-390 <10 ABU-391 <20 ABU-392 <10 ABU-393 <20 ABU-394 <20 ABU-395 <10

Figures 2A-2C further exemplarily show the binding affinities of ABU-174, ABU-175 and ABU190 to the RBD region of Spike protein. It can be seen from Figures 2A-2C that the KD value of ABU-174 is 0.29nM, the KD value of ABU-175 is 0.039nM, and the KD value of ABU190 is 2.8nM. Figures 2A-2C show that ABU-174, ABU-175 and ABU190 all have good affinity to the novel coronavirus S protein. Example 5 : Evaluation of the ability of the antigen-binding unit herein to neutralize SARS-CoV-2 pseudoviruses

In this example, referring to the description of Temperton NJ et al., Emerg Infect Dis, 2005, 11(3), 411-416, using the micropore cell neutralization experiment method, the antigen binding unit herein was detected against SARS-CoV -2 Neutralizing activity of pseudoviruses. The SARS-CoV-2 pseudovirus used in this example is provided by the China Institute for Food and Drug Control, which has similar cell infection characteristics to the true virus, can be compared to the early process of true virus infection of cells, and carries the reporter gene luciferase, which can Fast and easy assay analysis. The safety of operating the pseudovirus is high, and the neutralization experiment can be completed in the P2 level laboratory to detect the neutralization activity of the antibody (Neutralization titer). The specific steps of the experimental method are as follows. 1. Equilibrium reagents Take out the reagents (0.25% trypsin-EDTA, complete DMEM medium) stored at 2-8°C, and equilibrate at room temperature for more than 30 minutes. 2. Experimental operation (1) Take a 96-well plate and set the arrangement of the samples as shown in Table 4; among them, the wells A2-H2 are set as cell control wells (CC), which only contain experimental cells; the wells A3-H3 Set up as virus control wells (VV) containing experimental cells and pseudoviruses; wells A4-A11, B4-B11, C4-C11, D4-D11, E4-E11, F4-F11, G4-G11, H4-H11 Set as experimental wells, which contain experimental cells, pseudoviruses, and different concentrations of antibodies to be tested; the rest of the wells are set as blank. The experimental cells and pseudoviruses used in this example were Huh-7 cells and SARS-CoV-2 virus (both provided by China National Institutes for Food and Drug Control). Table 4. Arrangement of samples in 96 -well plate 1 2 3 4 5-10 11 12 A - CC VV Dilution 1 Dilution 1 Dilution 1 - B - CC VV Dilution 2 Dilution 2 Dilution 2 - C - CC VV Dilution 3 Dilution 3 Dilution 3 - D. - CC VV Dilution 4 Dilution 4 Dilution 4 - E. - CC VV Dilution 5 Dilution 5 Dilution 5 - f - CC VV Dilution 6 Dilution 6 Dilution 6 - G - CC VV Dilution 7 Dilution 7 Dilution 7 - h - CC VV Dilution 8 Dilution 8 Dilution 8 - (2) Add 100 μl/well DMEM complete medium (containing 1% antibiotics, 25mM HEPES, 10% FBS) to the cell control well; add 100 μl/well DMEM complete medium to the virus control well; and, in the experimental well Add 50 μl/well of the specified concentration of the antibody to be tested diluted in DMEM complete medium. Antibody concentrations of dilutions 1-8 used in Table 4 are 1/30 μg/μl, 1/90 μg/μl, 1/270 μg/μl, 1/810 μg/μl, 1/2430 μg/μl , 1/7290 μg/μl, 1/21870 μg/μl, 1/65610 μg/μl. (3) Dilute the SARS-CoV-2 pseudovirus to about 1.3×10 ⁴ /ml (TCID50) with DMEM complete medium; then add 50 μl/well of the SARS-CoV-2 pseudovirus to the virus control well and the experimental well. (4) Place the 96-well plate in a cell culture incubator (37°C, 5% CO ₂ ) and incubate for 1 hour. (5) Dilute the pre-cultured Huh-7 cells to 2×10 ⁵ cells/ml with DMEM complete medium. After the incubation in the previous step, add 100 μl/well of cells to the cell control wells, virus control wells, and experimental wells. (6) Place the 96-well plate in a cell culture incubator (37°C, 5% CO ₂ ) for 20-28 hours. (7) Take out the 96-well plate from the cell culture incubator, discard 150 μl of supernatant from each well, then add 100 μl of luciferase detection reagent, and react at room temperature for 2 minutes in the dark. (8) After the reaction, use a pipette to repeatedly blow and suck the liquid in each well 6-8 times to fully lyse the cells. Then, 150 μl of liquid was aspirated from each well, transferred to a corresponding 96-well chemiluminescence detection plate, and the luminescence value was read with a chemiluminescence detector (Perkinelmer EnSight multifunctional microplate reader). (9) Calculate neutralization inhibition rate: Inhibition rate = [1-(average luminous intensity of experimental wells-average luminous intensity of CC wells)/(average luminous intensity of VV wells-average luminous intensity of CC wells)]×100% . (10) According to the results of the neutralization inhibition rate, use the Reed-Muench method to calculate the IC50 of the antibody to be tested.

Table 5 lists the IC ₅₀ of neutralizing SARS-CoV-2 pseudovirus in the exemplary antigen-binding units herein, wherein the IC50 values of each antigen-binding unit are less than 1 μg/ml. Table 5. IC50 of SARS-CoV-2 pseudoviruses in exemplary antigen-binding units herein ABU No. IC50 (µg/ml) ABU-174 <0.1 ABU-175 <0.1 ABU-190 <0.1 ABU-207 <0.5 ABU-208 <0.5 ABU-257 <0.5 ABU-290 <0.1 ABU-291 <0.5 ABU-296 <0.1 ABU-297 <0.1 ABU-308 <0.5 ABU-322 <0.1 ABU-340 <0.5 ABU-341 <0.1 ABU-344 <1 ABU-349 <0.1 ABU-351 <0.1 ABU-352 <0.1 ABU-354 <0.1 ABU-355 <0.1 ABU-356 <0.1 ABU-357 <1 ABU-358 <0.1 ABU-359 <0.1 ABU-360 <0.1 ABU-361 <0.5 ABU-362 <0.5 ABU-365 <0.1 ABU-367 <0.1 ABU-368 <0.5 ABU-369 <0.1 ABU-371 <1 ABU-372 <0.5 ABU-373 <0.5 ABU-375 <0.1 ABU-376 <0.1 ABU-377 <0.5 ABU-379 <0.5 ABU-380 <0.1 ABU-381 <0.1 ABU-382 <0.1 ABU-386 <0.1 ABU-391 <1 ABU-392 <0.1 ABU-395 <0.1

Figures 3A-3C further exemplarily show the neutralizing activity of ABU-174, ABU-175 and ABU190 against SARS-CoV-2 pseudoviruses. It can be seen from Figure 3A-3C that ABU-174, ABU-175 and ABU190 all have good neutralizing activity, and their IC50 are 0.026μg/ml (ABU-174), 0.0086μg/ml (ABU-175), 0.039μg /ml (ABU190). Example 6 : Evaluation of the ability of the antigen-binding units herein to neutralize true viruses of SARS-CoV-2

In this example, the neutralizing activity of the antibody to be tested was evaluated by cytopathic pathology (CPE) assay and plaque reduction neutralization test (PRNT), respectively. The SARS-CoV-2 virus used was provided by the Military Medical Research Institute, and its titer (TCID50) was 10 ⁵ /ml, and all experimental operations were completed in the BSL-3 laboratory. 6.1 Cytopathic pathology (CPE) assay (1) Add 100µl Vero E6 cells to each well of a 96-well culture plate at a concentration of 5×10 ⁴ /ml, and incubate at 37°C, 5% CO ₂ for 24 hours . (2) Dilute the antibody to be tested to 10 concentrations: 1/10 μg/μl, 1/30 μg/μl, 1/90 μg/μl, 1/270 μg/μl, 1/810 μg/μl, 1 /2430 μg/μl, 1/7290 μg/μl, 1/21870 μg/μl, 1/65610 μg/μl, 1/196830 μg/μl. Take 100 µl of the antibody to be tested at the specified concentration, add an equal volume of SARS-CoV-2 true virus (100 TCID50), and incubate at 37°C, 5% CO ₂ for 1 hour. (3) After the culture in step (1), the cell culture medium in the 96-well culture plate was discarded, and the mixture (200 µl) containing the antibody to be tested and true virus prepared in step (2) was added as the experimental group. After incubation for 1 h, the supernatant was aspirated from the wells, and 200 µl of DMEM medium (containing 2% antibiotics and 16 µg/ml trypsin) was added to each well.

During the experiment, a cell control group and a virus control group were set in parallel. In the cell control group (4 replicate wells), after discarding the cell culture medium in the wells, add 200 µl DMEM medium (containing 2% antibiotics and 16 µg/ml trypsin) to each well. In the virus control group (3 duplicate wells), after discarding the cell culture medium in the wells, add 100 TCID50 true virus (100µl) to each well, and incubate at 37°C for 1h; Add 200 µl DMEM medium (containing 2% antibiotics and 16 µg/ml trypsin) to each well. (4) Culture the cells for 4-5 days at 37°C and 5% CO ₂ . (5) Observe the cytopathic effect (CPE) under an optical microscope, and evaluate the inhibitory activity of different concentrations of monoclonal antibodies on CPE according to the cytopathic condition.

The detection results of the antigen-binding unit ABU-174 are shown in Table 6 below. The results show that the antigen-binding unit ABU-174 has an inhibitory effect on the virus on cells, and the neutralizing antibody titer is 1.6 ng/μl. Table 6. Neutralizing activity of the antigen-binding unit ABU-174 against SARS-CoV-2 Antibody to be tested Dilution Results ( 3 replicate wells) Antigen Binding Unit ABU-174 1:10 - - - 1:30 - - - 1:90 - - - 1:270 - - - 1:810 - + + 1:2430 + + + 1:7290 + + + 1:21870 + + + 1:65610 + + + 1:196830 + + + cell control 200µl DMEM - - - negative control 100TCID50 + + + "+" indicates that the cells have CPE changes, "-" indicates that the cells have no CPE changes or normal cell morphology

The detection results of the antigen-binding unit ABU-175 are shown in Table 7 and Figure 4 below. The results show that the antigen-binding unit ABU-175 has an inhibitory effect on the virus on cells, and the neutralizing antibody titer is 0.7 ng/μl. Table 7. Neutralizing activity effect of antigen binding unit ABU-175 on SARS-CoV-2 Antibody to be tested Dilution Results ( 3 replicate wells) Antigen Binding Unit ABU-175 1:10 - - - 1:30 - - - 1:90 - - - 1:270 - - - 1:810 - - - 1:2430 + + + 1:7290 + + + 1:21870 + + + 1:65610 + + + 1:196830 + + + cell control 200µl DMEM - - - negative control 100TCID50 + + + "+" indicates that the cells have CPE changes, " ^- " indicates that the cells have no CPE changes or normal cell morphology Add 100 μl Vero E6 cells to each well and incubate for 24 hours at 37°C, 5% CO ₂ . (2) Dilute the antibody to be tested to 5 concentrations: 50 μg/ml, 10 μg/ml, 2 μg/ml, 0.4 μg/ml, 0.08 μg/ml. (3) After the culture in step (1), the cell culture medium in the 96-well culture plate was discarded, and the mixture (200 µl) containing the antibody to be tested and true virus prepared in step (2) was added as the experimental group. After incubation for 1 h, the supernatant was aspirated from the wells, and 200 µl of DMEM medium (containing 2% antibiotics and 16 µg/ml trypsin) was added to each well.

During the experiment, a cell control group and a virus control group were set in parallel. In the cell control group, after discarding the cell culture medium in the wells, add 200 µl DMEM medium (containing 2% antibiotics and 16 µg/ml trypsin) to each well. In the virus control group (4 duplicate wells), after discarding the cell culture medium in the wells, add 100 TCID50 true virus (100µl) to each well, and incubate at 37°C for 1h; Add 200 µl DMEM medium (containing 2% antibiotics and 16 µg/ml trypsin) to each well. (4) Culture the cells for 4 days at 37°C, 5% CO ₂ . (5) After the cells were fixed in formaldehyde, they were labeled with rabbit anti-SARS-COV serum (sino biology) and peroxidase-labeled goat anti-rabbit IgG (Dako). The plaques were observed after color development with TMB (True Blue, KPL), the inhibition rate was calculated and the dose-response curve was drawn.

Figure 5 shows dose-response curves for the exemplary antigen binding units ABU-174, ABU-175 and ABU190 herein. It can be seen from Figure 5 that the antigen-binding units ABU-174, ABU-175 and ABU190 all have good neutralizing activity against SARS-CoV-2 true virus, and can effectively inhibit virus infection and cell invasion, with IC50 of 0.5 μg/ml ( ABU-174), 0.3 μg/ml (ABU-175) and 0.8 μg/ml (ABU-190). Example 7 Efficacy of the antigen-binding unit of the present application in hACE2 transgenic mice

hACE2 transgenic mice were used as an animal model and treated with 2 different modes of pre-exposure prophylaxis or post-exposure prophylaxis. Specifically, hACE2 transgenic mice were intranasally infected with SARS-CoV-2 virus (2019-nCoV Beta CoV/Wuhan/AMMS01/2020) at a dose of 105 TCID50.

Antigen-binding units herein were injected intraperitoneally at a dose of 20 mg/kg into hACE2 transgenic mice 24 hours before viral infection in a PrEP treatment model and tested as PrEP The efficacy of the intervention.

In the post-exposure prophylaxis model, 20 mg/kg doses of antigen-binding units were injected into mice 2 hours after viral infection. HG1K (IgG1 antibody against H7N9 virus) was used as a negative control and injected at 20 mg/kg 2 hours after virus infection. Body weights reflecting the health status of infected mice were recorded daily for 5 consecutive days. Example 8. Efficacy of the antigen-binding unit of the present application in hamsters

Hamsters (Mesocricetus auratus) were used as an animal model and treated with 2 different modes of pre-exposure prophylaxis or post-exposure prophylaxis. Specifically, similar to hACE2 transgenic mice, hamsters were infected intranasally with the SARS-CoV-2 provirus (SARS-COV-2/WH-09/human/020/CHN) at a dose of 105 TCID50.

In the hamster pre-exposure prophylaxis model, a dose of 20 mg/kg of the antigen binding unit herein was injected into hamsters 1 day before virus infection. In the control group, animals were injected with PBS 2 hours after infection.

In the hamster post-exposure prophylaxis mode, 2 hours after infection, the antigen-binding units herein were injected intraperitoneally into hamsters at different doses (including 20, 10, 5 and 2 mg/kg) according to body weight. Meanwhile, hamsters injected with phosphate-buffered saline (PBS) were used as controls. Body weights of infected hamsters were recorded daily for 7 consecutive days. Hamsters were sacrificed 7 days after infection and lungs were collected for viral load analysis. [ Sequence Information ]

The information of the partial sequences involved in this article is shown in Table 8 below. Table 8. Sequence Listing SEQ ID sequence 1 ARDVTLVRGTASPRFDY 2 ARDVTLVRGTASPRFDY 3 ARSTRRWLQFVFPFDY 4 ARSTRRWLQFVFPFDY 5 ARSTRRWLQFVFPFDY 6 ARSTRRWLQFVFPFDY 7 ARSTRRWLQFVFPFDY 8 ARQAPGGGLLGYYHGLDV 9 ARQAPGGGLLGYYHGLDV 10 ARDRYCGGDCSGPHYYYYGMDV 11 ARWDCSGGSCNYYYYYNMDV 12 ARWDCSGGSCNYYYYYNMDV 13 AREDILLVPAASNFYYFGMDV 14 ARGDYYDPDDRYNAYYSLGA 15 TKGSMLLEVY 16 ARAPSDSSGINGAFDI 17 ARPKAPGYSYLSLDY 18 CGFGVVTTDAYGMDV 19 VKDKACTTTSCYEGTFFDY 20 VRGDDSILTPTFDH twenty one ARAGKGFMVITHFDY twenty two ARPHTNSWDQFDY twenty three ARPQGGSSWYRDYYYGMDV twenty four ATSTAVLRYFAPTGGWFDP 25 AKDNGHSYGYSWFDP 26 ATDGATIPINYYGMDV 27 ARSPITMIVVVNAFDI 28 ARARITMIVVVNHFDY 29 ARVQSTGYKYWYFDI 30 ARGFDY 31 ARARDYGSGSPMDV 32 ARDGVYYGSVIYHHYDLHV 33 ARGGGELLRYPFDY 34 AKAGLGLETSGGNYFES 35 AKDRVTMNYFDY 36 ARVREGYTSGWYADY 37 ARDRSYYHSSGYHYYFDY 38 VRDRIVGGYSYGGDY 39 AKGRLSPRL 40 ARVKVDNVVFDL 41 ARDRGLAARPAGWVDL 42 ARENFHFSGTPPLY 43 ARKYTYDTSGFFLSSSRNAFDV 44 ARLGSNGYGL 45 ARTYSYDSSGFFLTSSREAFDI 46 VRKYSFDVSGFFLSSSRHAFDV 47 ARKYSYDTSGFFLTSSRDAFDV 48 VRKFSYDISGFFLTSSRDAFDV 49 ATEGV 50 LLIEGMGATSGD 51 ATTNDGYYYGMDV 52 ATNPHNTAMVLDYYGMDV 53 AGAYIAAAGWGWELFQYYFDY 54 AHQAPFEWFGVDY 55 TTDGLYCSGGSCYYHSYYYYYGMDV 56 ARDGLGNYDILTGYTERAFDI 57 ARVKPILRVVVVAATPCDY 58 ARHARGYQLLSPRLGELSLYRSFDY 59 ARATTTKMIVVVINAFDI 60 ARHWITMIVVVIKGGWFDP 61 ARIRGQWLVGKYYYGMDV 62 AHRGWGFSSSSFFDY 63 ARMSSSLQHYYGMDV 64 ARMSSSLQHYYGMDV 65 ARDVTLVRGTASPRFDY 66 ARDVTLVRGTASPRFDY 67 AQEGRNYDRNWFDP 68 ARLIPIDGRDV 69 TTYWDQYTSTWT 70 ASIVKYDSSGYNFDY 71 TRDPWHESEHRFDP 72 AKDNKVSSWYSFDI 73 ARGLGYYVAL 74 VRGGQEVSLRRLDWFVGY 75 AKERGGSGKMYDY 76 ARRGAAVAGTTGGSAFDI 77 TKTSDLLYYGSGSYLPY 78 TRDGGAWD 79 ARGIPREYTTRWENAFDI 80 ARDRGADKDSNSGDVFDI 81 VGPQGAY 82 ARDPRGSSTSCSYDY 83 TGQERITIFGVVIISSDY 84 ARRLNDGANHS 85 SWDATVYYDMAV 86 ARPSSGSYADPFDI 87 VASRSSSLDY 88 ARSRGYGGLAGVDY 89 ARAYFDDSSGGFDY 90 AGSTYGDYVPHFYF 91 ARGLSSFTTIVVVFVGASFYFDS 92 ARGTTTSTTMIVIVITAVSTWFDP 93 ARHPLKVDTIFGVVIIDPAPFDY 94 ARIASYYYDSSGYYQTRPIGHAFDI 95 AKDRAQLLWFGQSRGMDV 96 TSTSDW 97 TRLRSGLVGFDWLPLYGMDV 98 ARRGVGILKDLPVYAMDV 99 AREARQIFITMMTTKTSWFDP 100 ARVSSTAVVTGLDYYYGMDV 101 TTISVGLLWFGLAVRDHYYFDY 102 ARSYYDSSTGYYPDALDL 103 AKSGSVWGSYHKTYYFDY 104 AKEILKGYSSGWKYYYYGMDV 105 ARATTTMVRGVIYHYYYYGMDV 106 ARERLGRMVRGVNWFDP 107 ASWTMVRGVIRWFDP 108 ARQFHYVGIVVVVAPHYYYGMDV 109 ASPRGYSYGPFDY 110 ARVLYYDILTGYWWYYYGMDV 111 ARGAPITIFGVVISTWFDP 112 ARAHTDSLELGI 113 VRKYTYDTSGFFLTSTRSAFDV 114 ARKHVYDTSGFFFLSSSRNAFDV 115 ARKYSFDISGFFLSSSRYALDV 116 ARDEGVTFHDHWANEIRYGMDV 117 ARARTTMIVVVSQFDY 118 ARDRGGWLLGSYYYYGMDV 119 ARGQISHYGFGESH 120 AHSGIAVVGNQLFHYYAMDV 121 AKERSSGSQWGWTYYYYGMDV 122 ARDPYGGNRRFHGWVYYYYGMDV 123 ARESTPDVRGVMNY 124 AKDAVASAGSPDY 125 ARDKLLWFGEPVVGYYYYYYMDV 126 ARDGGGDYAQIYFDY 127 ARDRLMTTYNYYSSMDV 128 AREPGDCSGGSCYYYGMDV 129 ARATRGYSYDDAFDI 130 ASPSYTDLLTGYYVPVDY 131 AKDPRVNELLWFGSLTQFYFDD 132 AKSGGPFHLSLYYYMDV 133 ARAFYGHAFDF 134 AKGLTIPFDK 135 AKGLTIPFDK 136 ARRGKYCSGGRCYSWWFDP 137 ARVASLIGDDY 138 ARVASLIGDDY 139 AHKPSGWSLRFDS 140 ARESLFNWFDS 141 AKGLTIPFDN 142 ARVDYDSSRNY 143 ARVERWLVLGYYYYGMDV 144 GSIDY 145 AKMYSDYDDNYYGLDV 146 ARDRYCSSTSCGGYYYYMDV 147 ARAPNDFWSGYPYYFDY 148 TRDGSTAAIFGNIDY 149 ARGVVRNDYGDPGFDY 150 ATAPAYCSGGSCPENNWFDP 151 AILWFGEFYFYDLFYNAVDV 152 AILWFGEFYFYDLFYNAVDV 153 ASRREQWLGDLGYYYYGMDV 154 ARGGAHSEDY 155 ARHQDPLDIVATVDWGGLDY 156 ARVASLIGDDY 157 ATTGTDNYYYYMDV 158 ARKNCSGGICYFHDY 159 AHKPSGWSLRFDS 160 AKGQTIQLWLFGAL 161 ALTVSSWYPGIFEN 162 AKAFSGSYWDAFDI 163 AKA AS GARGYYGMDV 164 ARSSSGHYVSDLGY 165 ARALNGYRYNDY 166 AREEGGGSSTHFDC 167 ARTREGSYYYGMDV 168 VRGGLQFVVAVGPYGVDV 169 VRGGLQFVVAVGPYGVDV 170 ARDIGGGAPDY 171 AIKPSIPGYFDP 172 ARVGGWQRSPRPN 173 ARVGGWQRSPRPN 174 ARGQGYGRVLLWFGE 175 ARGQGYGRVLLWFGE 176 ARPSSGSRFDY 177 ARGFDY 178 AKARGVVLFDY 179 ARHSYGSGTYLDPFDY 180 ARQPHLAYYYDSSGYNDAFDI 181 ARGAVVTPFGLDS 182 ASEDYYDSSGYYWY 183 ARLSAIAVVGYYYYAMDV 184 ARDFIAASPFYYYYYMDV 185 ATSPGGYGVRRTVLEDFRH 186 WTMEYDDYSFVYDY 187 ARGGKQQLVRNYYLDS 188 ATGFGGVIVRGFDY 189 ARVYGDYSYYMDV 190 ARDLGEAGGMDV 191 VREIESGVDFWSGHYY 192 ARDSAYYDTIGYYSGDY 193 GRSFRGSCFDYL 194 ALGTGSYYGVNY 195 AKDMGGRYSSGLYYYYYGMDV 196 ARELRGYFDY 197 ARDPNDFWSGFPRGAFDI 198 ASHARYEEETFDY 199 VRDSYTSAWTPAGYFDL 200 AKDHYGSIDY 201 ARPYTSRWFWSN 202 ALLPPNAYDYGDGLLDH 203 ARHRAAGGNYYYGMDV 204 ARERVGPAAGYMDV 205 ARAAYYYDSSGYGWFDP 206 ARGDYTEYSYYYMDV 207 ALPTGASS SYSGPNY 208 ARDEVIAVATGEGMDV 209 AKDMGYDILTGSGLGDY 210 AKEPLFGETYGMDV 211 ARDKGSGSYYSGAYYYYMDV 212 ATFNSGNDNAYEY 213 AREYPDFWSGHYYYYMDV 214 ARLPYGMDV 215 ARGLYDKSGYRSDGFDS 216 ARGFEGYCSGGRCYSYFDY 217 ARVKNWDYGLY 218 ARDGQSDWHFDL 219 ARVYGDYLDH 220 AHRSFLYNIFNGYSYAPFDY 221 AKDLFSGDRDF 222 AKDSGAVLLWFGADF 223 AREGAYDIWRGSYMRAYDH 224 ARYIEMFDP 225 ARQAYGDYGWDYYYGMDV 226 LKDWDWEYEDSRPTLRGSVY 227 ARGSVFWFGEGKNWFDP 228 ARGSVFWFGEGKNWFDP 229 AREDSSGWSRGDY 230 ARRFVVREVEYNWFDP 231 ARDGYCNSMRCYRYYHGMDV 232 ATGPTAKPNKQWGYWFDP 233 ASPVSVEQDFDI 234 TTPVGDF 235 STSHPPFFDY 236 ARGLWQLVSPVFDY 237 AKVTNRGVRGLYFDY 238 ASPVSVEQDFDI 239 AINTLLVTA 240 VHRSFLYDIFSGYSYAPFDY 241 AHRSFLYNIFDGYSYAPFDY 242 AGGADCRRTSCHYLVSNREEYMGV 243 ARGLVLSGTRYSYFYGMDV 244 VKDWDWEYEDNRPTLRGSVY 245 VKDWDWEYEESRPTLRGSVY 246 AKGGPIFWLGEGKNWFDA 247 ARDKGGILMLRGADF 248 ARTLIAAAGSAFDI 249 ARGPTSITMIVVVDDAFDI 250 ARVMNSSWYTRYYYNYMDV 251 ARRGGGCSEGVCYNFDR 252 ARGDPRDY 253 ARGSYYYDSSGYYLDY 254 ARAAYYYDSSGYGWFDP 255 TTDLGATGIYYYYYMDV 256 ARFPRDYYDSSGYLIQEGNFDY 257 ARVTRAGAAGDGGAFDI 258 ARSVVPVAGTDY 259 ARDQHPGYPALVYYYYYMDV 260 ARDNIQTFDY 261 ATSSPVAGYNSWFDP 262 ATGPAVIPLRWFDP 263 ATAPAAAGPTDWFDP 264 AISPSVHSLWWFDP 265 ARDEIHYDILTGYYNRFWFHP 266 ARDAETGYYDSSGYPINWFDP 267 ARHYYDTGAYYVPFDH 268 AHFQGFGESEYFQH 269 AHRHPLTGFDS 270 ATPRGYSYGPLDY 271 ASPRGYSYGPFDY 272 ARDRVDKGYDFWSSWYFDL 273 ASGGGSYFDAFDI 274 ARDRSGSYYGGFDY 275 AKAVYGGNSVYFDY 276 ARIYGGNYENYFDY 277 ARESEAGTTPSFDY 278 ARSLVRGVITYFDY 279 ARGLSMEV 280 ARGGYSSSWYGTKYYFDY 281 ARGPTVTTFFRRNAWFDP 282 ARGRYSSGWYGSRNWFDP 283 ARLSMGAARQSGFDP 284 ARDGGRDGYNELGARVYYYYGMDV 285 ARIGSYGI 286 AKLGCSGGSCYYYYGMDV 287 ARGDHYYDRSGPHKFDY 288 ARDSPLKFDSFGYPLYGMDV 289 ARGIVGATPGYFDY 290 AKAVSGWPIYFDA 291 AKAVSGWPIYFDA 292 AHTIHSGYDRTFDS 293 AREESYSSSSPLDY 294 AAGSDFWSGYYVNYYMDV 295 ARLTAAGVYFDY 296 AKTRGRGLYDYVWGSKDY 297 AKTRGRGLYDYVWGSKDY 298 ARDESGSYYGDQAFDI 299 ARDRRARAYEIPFGSDHYYFGMDV 300 ARDYYGSGSYPIGYMDV 301 TTSYCSTKVCFDYWFDP 302 ASNLYATSPYGGVKN 303 AKDIGSGSPDAFDI 304 VKDLEFRGGTGGFDL 305 ARDGHSAWGAFDI 306 ARDHPTLRRAFDY 307 ARDRGSSSWWGWLDP 308 ATRRGYSGYGAAYYFDY 309 AREVYVGGEDDYSYYYGLDV 310 TTDLGAGPTEWLRSSLFDY 311 TTSYCNPKVCFDYWFDP 312 AKEYYYDSSGYYYREDAFDI 313 AKDGGLTAYLEY 314 ATEKWEVVDVCFDY 315 AKDIGWDVVVVAATHGVFDY 316 AKDPYYYGSGSSNFFDY 317 ARGPDYYDTGGYFDL 318 ARDGYKQIYWYLDL 319 AKGEGVYGSGSRYFLDY 320 AREWSRGAVAGTGYFDY 321 AKVAKLPGDYYGMDV 322 ARELRGAFDI 323 ARDWGEYYFDY 324 ARDYGDLYFDY 325 ARDRRVGSPYYYYYMDV 326 ARDLGDNAFDI 327 ARDRYSGYDF 328 ARLSGTGYGGDGGWFDP 329 AGKKIYYGSSFDP 330 ARGGSGSGWYGGRFDY 331 ARVWRETYYYDSSGDSFDY 332 ARGR SIT GIR DVDF 333 ARGRGNYMFRWFDP 334 ARGGLWYDSINYYGMDV 335 ARLILRWPTTWDYFDY 336 ARVDGPFDY 337 ARCPFWNYGHCYLDN 338 ARPSVRWYYHAMDV 339 AKERRPVLRYFDWLPIEAPDY 340 ARGQYDILTGYQYGAFDI 341 AAHYYSRTDAFHI 342 ARDSVSGSGSGSYYKGLWFDP 343 VVGIGYSSSPSCPPLRWFDY 344 ARERGYSGSGSLYYFDY 345 AHYSSSRPPLFDY 346 AKGHWST 347 ANGAYYYGSGSYYNGAAY 348 AKGGYYDILTGYFPFDY 349 ARDLVVYGMDV 350 ARDPIRNGMDV 351 ARDLVVYGMDV 352 ARDAMSYGMDV 353 ARDRVVYGMDV 354 ARDAAVYGIDV 355 ARDLISRGMDV 356 ARDRVVYGMDV 357 ARDLVSYGMDV 358 ARDLVVYGMDV 359 ARDAQNYGMDV 360 ARDRGL VSDY 361 QQTYIIPYS 362 QQYYSYPYT 363 SSYAGSNNLV 364 QRYDSYRT 365 QQSYSTPYT 366 QQYDNLPLT 367 QQYATSPWT 368 AAWDDSLSSWG 369 QTWGTGTVV 370 QSADSSGTWV 371 QQRSDWTPT 372 QQFNSYPRT 373 CSYAGNTTF 374 STWDASLKEVL 375 MQGTHWPLT 376 QQYDSYPWT 377 QQLTTYPRT 378 QSADSSGTWV 379 QQFYSTPVT 380 QSYDGSNVV 381 QQYYSTPLT 382 QQYYDTPMYT 383 QQYNSYPYT 384 SSYTSSSTFV 385 QSADSSGTYSNWV 386 SSYTSSSTVV 387 QQYGSSPLT 388 QQYGSSPLT 389 QQYGA 390 QQYGSSPWT 391 AVWDDSLNGVV 392 SSFAGSNNPYV 393 QQYYSTPYT 394 HQYDSWPPT 395 QNRDDWPPLFT 396 QQYYSTPRT 397 QQAHSFLSLT 398 QSADTSGTYLWV 399 QQYDSLPIT 400 QQYYGIPT 401 QKCDNFPWT 402 AAWDDSLSVVV 403 QQSYSSPPT 404 QSYDDTLTI 405 QQSYGAPPT 406 QQSYSTPPT 407 QQSFSTPPT 408 QQSYSSPPT 409 YSTDSSGNHWV 410 LLSYSGVRI 411 QSYDSSLSKV 412 QAWDSSTFYV 413 GTWDSSSAVV 414 QQYNNWPWT 415 LLSYSGARPV 416 QQSYSTPPYT 417 SSYTSSSTRVV 418 QQYYSTPIT 419 QQYGSSPLT 420 GTWDSSLVVV 421 SSYTSSSTFAV 422 MQALQTPLT 423 MQALQTVFT 424 MQALQTVFT 425 QQTYIIPYS 426 QQYYSYPYT 427 QVWDSSSDHVV 428 QAWDSSTSYVV 429 GTWDSSLVGV 430 NSYTSSNSTAV 431 QQSYNWPRT 432 LQHNSYPYT 433 QQYNGYPHT 434 QQYSYYSA 435 QQYGT 436 SAWDSSSAWV 437 QQYYSTPIT 438 QSFDDNDQV 439 LLYVGGGIWV 440 QQYNIWLT 441 MQGTLLLT 442 ETWDSSLDAVI 443 AAWDDSLSGRV 444 MQGTHWPHPT 445 MQGTPWPT 446 QQSGSSYT 447 MQSLPSGFT 448 MQSLDLPPT 449 QQGSSFPLT 450 QQYDSSPIT 451 NSRDSSGQLHVVV 452 NSRDNNDDLPL 453 SSYAGSNNLGV 454 QSYDSLSGVV 455 QQYYSTPFT 456 MQGTHWPIT 457 SSYTSSSTLVV 458 QQSYSTPYT 459 CSYAGSYVV 460 QQSYSTLHT 461 NSRDSSGNHLV 462 QAWDTITHEEV 463 QQYNYYPVA 464 TQATQFPLT 465 QQSYSTPPYT 466 QSYDSSSSPVV 467 AAWDDSLSGPV 468 NSRDSSGNHLV 469 QQYDNLPYT 470 GTWDSSSAGV 471 QQYNNWPPWT 472 QAWDSSTYVV 473 QQSYSSPPT 474 QQSYSSPPT 475 QQSYSSPPT 476 HHYGTSPPFT 477 QQYGSSPLT 478 QSADSSGTYYV 479 QQSYSTPRT 480 QAWDSSTVV 481 MQSIQLPLT 482 MQSIQLPFT 483 MQALQTYT 484 YSTDSSGNHRRV 485 SSYTSSSTLV 486 YSTDSSGNHRGV 487 QQYNSFPYT 488 QQRSNWPVT 489 LQHNSYPLT 490 LQHNSYPFT 491 QQYGTSAGT 492 QQYGNLPPFT 493 QQYYSTPLT 494 MQNRHLYT 495 MQNRHLYT 496 MQTLQTSIT 497 QQYGSSQYS 498 QQYGSSQYT 499 QHYDTLLT 500 QQYFDTPWT 501 MQNRQLYT 502 QQFDNLPPFT 503 QQSYSARMST 504 MQGTQWPWT 505 QQFDNSPPWT 506 QSADSSGTYVV 507 CSYAGSYTLV 508 QQSYSTPFT 509 MQGTHSYT 510 QAWDSSTASYV 511 SSYTSASTVV 512 SSYTSASTVV 513 MQGTHSPWT 514 GTWDSSSAWV 515 QSADGRGDWV 516 QQYGSSQYS 517 QQYDSYSGT 518 ETWDSPYVV 519 QHYDSLLT 520 SSYTSSSTVV 521 MQALQTLT 522 QQYNSYPLFT 523 MQGTHWPMT 524 QQYGSSPMYT 525 QQANSFPA 526 QAWDSHTVV 527 QQYNSYSWT 528 QQYTSWPLT 529 QQYTSWPLT 530 YSPKV 531 QQYNILPHT 532 QQYYNAPLS 533 QQYYNAPLS 534 QQRSNWIT 535 QQRSNWIT 536 AAWDDSLNGPV 537 QQYGSSPQT 538 QQYNNWPPLT 539 QQYYSYSLT 540 CSYAGSSTFYV 541 QSADSSGTWV 542 QQYGSSPEMYT 543 HQYGSGLGT 544 MQSIQLRT 545 QQCSSWPLSLT 546 QQYNNWPPIT 547 QQSNSFPPT 548 QSYDISLSAYV 549 QQYNTYSLT 550 QQLNSYPPA 551 QQYYRTPLT 552 LQHHTYPLT 553 MQSIQLWS 554 LLSYSGPWV 555 SSYAGSNNYV 556 QQYDNLPSFT 557 CSYAGSYTLV 558 CSYAGSSTVV 559 QQSYNVPPWT 560 MQGTHWPWT 561 QSYDINLSAV 562 HQYHNSPWT 563 MQALQTPYT 564 QVWDSSSDHYV 565 QQYGSSPRT 566 QQYDNWLPYT 567 LLSYSGAYVL 568 QQYSNWPLYT 569 AAWDDSLNGPYV 570 SSYTSISTVL 571 QVWDGGSDDRGYV 572 SSFTSNGAWV 573 QQNYIRPYT 574 QQYDNLPIT 575 ATWDDSLNGV 576 QQYNNWPYT 577 GADHGSGSNFVYV 578 CSYAGSSTLV 579 QQHDSAPYT 580 QQYNSYVT 581 MQGKHLRWT 582 YSTDYSGNHGV 583 QQCSNWPNT 584 QSADSNDSWV 585 GTWDSSSAGV 586 QQGHNFPWT 587 QQYGSLPLT 588 QQYGSLPLT 589 QSYDSLSGWV 590 QQRRNWPLT 591 QHRSNWPYT 592 AAWDDSLNGVV 593 MQTTQFPRT 594 QSQDSSATYVV 595 QAWDSSIEV 596 QQYGSSPPWT 597 QSGDSSGTYVV 598 MQTTQFPRT 599 LQYNTYSYS 600 QQYNSYIT 601 QQYNSYVT 602 YSTDSSDNQRV 603 QHLKSYPLT 604 QQGHNFPWT 605 QQGHNFPWT 606 QQYHNFP 607 QSYDSSLVV 608 QAWDSNTGV 609 QSYDSLSGSV 610 QSVDNTGASPHVV 611 QQYHTYWT 612 QAWDSGT 613 QQYGSSPRT 614 QQYGSSPRT 615 QHYGTSPYT 616 QQYGSSTLVT 617 CSYAGSSLWV 618 QSYDSSFWV 619 GTWDSSSAVV 620 YSTDRSGNHRGV 621 NSRDSSGNHLYWV 622 QSYDSLSGHVV 623 GTWDSSSAGGV 624 CSYAGSSTFVV 625 GTWDSSSAVV 626 QQLNSYPPT 627 QQSYSTLWT 628 QQYGD SPET 629 QAWDSSTVV 630 QQYDNLPYT 631 QQYDNLPYT 632 QQRSNWPSIT 633 QQANSFPLA 634 QQSYSTPFG 635 LSYDSSSLSGSV 636 QQFNNYPLT 637 QQYDNLPFT 638 SSYTSSSAYV 639 NSRDSSGNHVV 640 CSYAGSYPVV 641 SSYAGSNKV 642 QQYGSSGGYT 643 QQSYSTPYT 644 QQYGSSSWT 645 QQSYSTPYT 646 QAWDSSTANWV 647 SSFTDSSTLVV 648 QQSYSVPHT 649 QQYNNWLT 650 QQYNNWPPIT 651 QQYNNWPPIT 652 SSYAGTNKIL 653 QQSYSTPLT 654 SSYTSSSTWV 655 QQSYSTPYT 656 MQALQTPGT 657 MQALQTPGT 658 QQYNSYSA 659 QAWDRTTAT 660 QSYDSLSGWV 661 SSYTSLNTLEVV 662 MQALQTPYS 663 QVWDSSSDRTVV 664 ASWDDKVRGWV 665 QQYGSSPWT 666 QQYNSYSRT 667 QQYNTSPLT 668 QSYDSLSGSL 669 QSADSSGTYRV 670 QQYGRT 671 SSYTNIDTLEIV 672 LQHNSYPRT 673 QVWHSSFDPWV 674 QQSYSTPPTT 675 QQYNSYFPT 676 QVWDSSSDHYWV 677 GTWDSSSAGV 678 QTWGTGPQVL 679 QQYDN LLT 680 QVWDSSGDHWV 681 QQRSNWLT 682 QQHDNLPSFT 683 QQYGSSPRT 684 QQYGSSPRT 685 LLYYGGAPV 686 QQLNSYPPA 687 QQYDNLPQT 688 CSYAGSSLWV 689 QSYDSSNQV 690 QQRSNWLFT 691 GTWDSSSAGV 692 MQASQFPLT 693 CSFAGSNRE 694 QQYGSSPWT 695 GTWDSSSAWV 696 QHYSSSAPIT 697 QQRNKWPGT 698 QQYGDSPYT 699 QQLNSYPLT 700 CTYAGSSTWV 701 QQSYSSPYT 702 QQANSFPRT 703 QQFNDYPLT 704 QSYDSLSGSV 705 QQYSTYYT 706 MQGSHWPWT 707 AAWDDSLNGPWV 708 CSYAGSYTWV 709 QQLNSYPFT 710 QQYDNLPRT 711 QQLNSYPLT 712 QQSYSTPPDT 713 QQYDNLPPT 714 QQSYTTPLFT 715 QQLNGYPHSA 716 HQYDNLPPT 717 QQLNSYPLT 718 QQLNSNPPIT 719 QQSYSTPPYT 720 HQYDNLPRT 721 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREGVDTAMVGFDYWGQGTLVTVSS 722 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREGVDTAMVGFDYWGQGTLVTVSS 723 EVQLVQSGAEVKKPGESLRISCKGSGYSFTSYWISWVRQMPGKGLEWMGRIDPSDSYTNYSPSFQGHVTISADKSISTAYLQWSSLKASDTAMYYCARSTRRWLQFVFPFDYWGQGTLVTVSS 724 EVQLVQSGAEVKKPGESLRISCKGSGYSFTSYWISWVRQMPGKGLEWMGRIDPSDSYTNYSPSFQGHVTISADKSISTAYLQWSSLKASDTAMYYCARSTRRWLQFVFPFDYWGQGTLVTVSS 725 EVQLVQSGAEVKKPGESLRISCKGSGYSFTSYWISWVRQMPGKGLEWMGRIDPSDSYTNYSPSFQGHVTISADKSISTAYLQWSSLKASDTAMYYCARSTRRWLQFVFPFDYWGQGTLVTVSS 726 EVQLVQSGAEVKKPGESLRISCKGSGYSFTSYWISWVRQMPGKGLEWMGRIDPSDSYTNYSPSFQGHVTISADKSISTAYLQWSSLKASDTAMYYCARSTRRWLQFVFPFDYWGQGTLVTVSS 727 EVQLVQSGAEVKKPGESLRISCKGSGYSFTSYWISWVRQMPGKGLEWMGRIDPSDSYTNYSPSFQGHVTISADKSISTAYLQWSSLKASDTAMYYCARSTRRWLQFVFPFDYWGQGTLVTVSS 728 QMQLQESGPGLVEPSETLALTCTVSGGSINRNHFWAWLRRPPGKGLEWIGSASYTGTTHDNPSLRSRLTISVDTSKNQFSLKMTSVTVADTAVYFCARQAPGGGLLGYYHGLDVWGQGTTVTVSP 729 QMQLQESGPGLVEPSETLALTCTVSGGSINRNHFWAWLRRPPGKGLEWIGSASYTGTTHDNPSLRSRLTISVDTSKNQFSLKMTSVTVADTAVYFCARQAPGGGLLGYYHGLDVWGQGTTVTVSP 730 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTMTTDTSTSTAYMELRRSLRSDDTAVYYCARDRYCGGDCSGPHYYYYGMDVWGQGTTVTVSS 731 EVQLVESGGGLVQPGGSLRLSCAASGFTFSYFEMNWVRQAPGKGLEWISYISSSGTNIYYADSVKGRFTISRDNAENSLYLQMNSLRVEDTAVYYCARWDCSGGSCNYYYYYNMDVWGQGTRVTVSS 732 EVQLVESGGGLVQPGGSLRLSCAASGFTFSYFEMNWVRQAPGKGLEWISYISSSGTNIYYADSVKGRFTISRDNAENSLYLQMNSLRVEDTAVYYCARWDCSGGSCNYYYYYNMDVWGQGTRVTVSS 733 QVQLVQSGAEVKKPGASVKVSCKASGYKFSNYYIHWVRQAPGQGLEWMGWINPYSGETNYAQKFQGRVTMTRDTSTSTAYMELSRLRADDTAVFFCAREDILLVPAASNFYYFGMDVWGQGTTAVVSS 734 QVQLVQSGAEVRKPGASVKISCKSSGYIFTNFYVDWVRQAPGRGLEWMGRVNPNDGSSIYAQKFRDRFSLTSDTSTSTVFLNLRGLTSEDTALYFCARGDYYDPDDRYNAYYSLGAWGQGTTVIVSS 735 EVQLLESGGGLQQRGGSLRLSCAASGFNFSSYAMSWVRQAPGKGLEWVSSISATGGTTFYADSEKGRFTISRDNSKNILYLQMNSLRAEDTAVYYCTKGSMLLEVYWGQGTLVTVSS 736 EVQLVESGGGLVQPGGSLRLSCGVSGIIVSRNEMSWVRQAPGKGLEWVSYISSSGTGVHYADSVKGRFTSSRDSAKNSVYLQMHSLRAEDTAVYYCARAPSDSSGINGAFDIWGQGTMVTVSS 737 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSTYAISWVRQAPGQGLEWMGGIIPIFGTPTYAQRFQGRVTITADESTSTAYMELTSLRSDDTAVFYCARPKAPGYSYLSLDYWGQGTLVTVSS 738 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCCGFGVVTTDAYGMDVWGQGTTVTVSS 739 EVQLVESGGGLVQPGGSLRLSCSASGFTFNNYAMHWVRQAPGKGLEHVSVISSYGDNTFYADSVKGRFTISRDNSKNTLYLQMSSLRAEDTAVYYCVKDKACTTTSCYEGTFFDYWGQGTLVTVSS 740 EVQLVESGGGLVQPGGSLRLSCAASGFVFSNYWMTWVRQAPGKGLEWVANIKQDESEEYYRDSLKGRFTISRDNAKNSVFLQMDSLRVEDSAVYYCVRGDDSILTPTFDHWGQGTLVTVSS 741 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGYYWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARAGKGFMVITHFDYWGQGTLVTVSS 742 EVELVQSGAEMKEPGESLKISCKGFGYNFNNYWVAWVRQTPGKGLEWMGIIYGGDSDTRYNPSMQGQVTISADKSINTIYLEWDVLRASDSGIYYCARPHTNSWDQFDYWGQGTLVTVSS 743 QVQLVQSGSELKKPGASVKVSCKASGYTFTSYAMNWVRQAPGQGLEWMGWINTNTGNPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARPQGGSSWYRDYYYGMDVWGQGTTVTVSS 744 QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATSTAVLRYFAPTGGWFDPWGQGTLVTVSS 745 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDNGHSYGYSWFDPWGQGTLVTVSS 746 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYPMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATDGATIPINYYGMDVWGQGTTVTVSS 747 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGYYWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARSPITMIVVVNAFDIWGQGTMVTVSS 748 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGYYWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARARITMIVVVNHFDYWGQGTLVTVSS 749 EVQLVESGGRSVQPGGSLRLSCEASGFTVSSNYMNWVRQAPGKGLEWLSVLYSGGNEYYADSVRGRFTISRHSSKNTLFLQMNRLRPEDTAVYYCARVQSTGYKYWYFDIWGRGTLVIVSS 750 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGFDYWGQGTLVTVSS 751 QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYFIYWVRQAPGQGLEWMGRINPSSGVANYAQKFQGRVTMTRDTSITTAYMELSRLTSDDTVVYYCARARDYGSGSPMDVWGQGTTVTVSS 752 EVQLVESGGGLVQPGGSLRLSCVASGFTASSNYMNWVRQAPGKGLEWVSVIYAGGGTHYADSVKGRFTISRDNFKNTVYLQMNSLRSEDTAVYYCARDGVYYGSVIYHHYDLHVWGQGTTVTVSS 753 QVQLVQSGPEVKKPGSSVKVSCKVSGGTFSSYGISWVRLAPGRGLEWMGRILPVLDTTTYAPKFEGRVTITADESTTTAYMELTSLKSDDTAVYYCARGGGELLRYPFDYWGQGTPVTVSS 754 QVHLVQSGPEVKKPGSSVKVSCKASGGRFGSFAFSWLRQAPGQGLEWMGKVTPIVGVPVYAEKFQGTVTISADESTNTAYMEVSSLRSEDTALYYCAKAGLGLETSGGNYFESWGQGTLVTVSS 755 QVRLVESGGGLVQPGRSLRLSCAASGFTFTDYAIHWVRQAPGKGLEWMATISYDGNDKYFAASVRGRFSISRDNSNNTLFLQMNNLRAEDTAVYYCAKDRVTMNYFDYWGQGTLVSVSS 756 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARVREGYTSGWYADYWGQGTLVTVSS 757 QVQLVQSGAEVQKPGASVRVSCKASGYTFTDYYIHWVRQAPGQGLEWMGWVNPNRGGTNNAQKFQGRVTMTRDTSITTAYMELHSLRSDDTAVYYCARDRSYYHSSGYHYYFDYWGQGSLVTVSS 758 QVQLVQSGAEVKKPGASVKVSCKASGYSFTGHYIHWVRQAPGQGLEWMGWINPDSGGTNNAQKFQGRVTMARDTSISTAYMDLSTLTNDDTAVYYCVRDRIVGGYSYGGDYWGQGTLVTVSS 759 EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAPGKGLEWVSAITGSGGSTHYADSVKGRFTISRDNSNNTLSLQMNSLRAEDTAVYYCAKGRLSPRLGQGTLVTVSS 760 QLQLKESGSGLVKSSQTLSLTCAVSGGSISDVYSWSWIRQAPGKGLEYIGYVFHTGSAYYNPSLKSRVIISVDRSKNQVSLNVTSVTAADTAIYYCARVKVDNVVFDLWGQGTMVTVSS 761 QVQLVQSGTEVKKPGSSVKVSCKASGDTFNSYAISWVRQAPGQGLEWMGRIIPILRLATYAQEFQGRVTITADKSTTTTYMEVTSLKSEDTAIYYCARDRGLAARPAGWVDLWGQGTLVTVSS 762 QTQLVESGGGVVQPGRSLRLSCAASGFTFSHYGMHWVRQAPGKGLEWVALIWYDGSKKYYADSVKGRFTISRDISENTLYLQMNSLRAEDTAVYYCARENFHFSGTPPLYWGQGTLVTVSS 763 EVQLVQSAAEQKKPGESLKLSCKGSGYSFPAHWIDWVRQMPGGGLEWVGSIFPGDSDTKYSPSFEGQVNISADRSINTAYLQWSSLKASDTAIYYCARKYTYDTSGFLSSSRNAFDVWGQGSMVFVSS 764 EVQLVQSGAEVKKPGESLKISCKGSGYNFDTYWIAWVRQTPGKGLEWMGDIYPGDSDSRYSPSFQGRVTFSADKSISVAYLQWSTLKASDTAMYFCARLGSNGYGLWGQGTLITVSS 765 EVQLVQSGAEVKEPGESLKISCKGSGYSFSGYWIAWVRQRPGKGLEWMGTIFPDSDTRYSPSFEGQVTISTDKSISTAYLQWSSLKASDTAMYYCARTYSYDSSGFFFLTSSREAFDIWGQGTMVIVSS 766 EVQLVQSGAEVKKPGESLKISCKASGYYFAAHWIDWVRQMPGRGLEWMGSIFPSDSDTEYGPSFQGQVNISADKSITTAYLQLKNLKASDTALYYCVRKYSFDVSGFFLSSSRHAFDVWGQGTMVTVSS 767 EVHLVQSGPEQKKPGESLRISCKGSGYSFPAFWIVWVRQMPGEGLEWMGSVFPGDSDTEYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARKYSYDTSGFFLTSSRDAFDVWGQGTMIAVSS 768 DVQLVQSGAEEKKPGEFLKISCKGSGYSFPAYWIGWVRQMPGKGLEWMGSIFPGDSDTEYSPSFQGHVTISADKSISTAYLQWSSLKASDTAMYYCVRKFSYDISGFFLTSSRDAFDVWGQGTKVTISS 769 QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATEGVWGQGTTVTVSS 770 QVQLVQSGAEAKKPGASVKVSCKASGYTFTRYWMHWVRQGPGQGLEWMGLMKPGDGKTIYAQKFQYRVTLTRDTSTSTVYMELRSLTSADTAMYYCLLIEGMGATSGDWGQGTLVTVSS 771 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCATTNDGYYYGMDVWGQGTTVTVSS 772 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCATNPHNTAMVLDYYGMDVWGQGTTVTVSS 773 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAGAYIAAAGWGWELFQYYFDYWGQGTLVTVSS 774 QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDDDKRYSPSLKSRLTITKDTSKNQVVLTMTNMDPVDTATYYCAHQAPFEWFGVDYWGQGTLVTVSS 775 EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVGRIKSKTDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTDGLYCSGGSCYYHSYYYYYGMDVWGQGTTVTVSS 776 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYEMNWVRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDGLGNYDILTGYTERAFDIWGQGTMVTVSS 777 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYEMNWVRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVKPILRVVVVAATPCDYWGQGTLVTVSS 778 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARHARGYQLLSPRLGELSLYRSFDYWGQGTLVTVSS 779 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGYYWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARATTTKMIVVVINAFDIWGQGTMVTVSS 780 QLQLQESGPGLVKPSETLSLTCTVSGGSISRSYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARHWITMIVVVIKGGWFDPWGQGTLVTVSS 781 QVTLKESGPVLVKPTETLTLTCTVSGFSLSNARMGVSWIRQPPGKALEWLAHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARIRGQWLVGKYYYGMDVWGQGTTVTVSS 782 QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDDDKRYSPSLKSRLTITKDTSKNQVVLTMTNMDPVDTATYYCAHRGWGFSSSFFDYWGQGTLVTVSS 783 QVQLVESGGGVVQPGRSLRLSCAASGFTISPYGMHWVRQAPGKGLECVAIIWYDGSNKYYADSVKGRFTISRDSSKNTLYLQMDRLRAEDTAVYYCARMSSSLQHYYGMDVWGQGTTVTVSS 784 QVQLVESGGGVVQPGRSLRLSCAASGFTISPYGMHWVRQAPGKGLECVAIIWYDGSNKYYADSVKGRFTISRDSSKNTLYLQMDRLRAEDTAVYFCARMSSSLQHYYGMDVWGQGTTVTVSS 785 QVQVVQSEGEVKKPGASVKVSCMASGYTFGDYGISWVRQAPGQGLEWMGWISGYNGDPKYAQKFQGRITLTTDAATSSAYMELRRSLRSDDTAVYFCARDVTLVRGTASPRFDYWGQGTLITVSS 786 QVQVVQSEGEVKKPGASVKVSCMASGYTFGDYGISWVRQAPGQGLEWMGWISGYNGDPKYAQKFQGRITLTTDAATSSAYMELRRSLRSDDTAVYFCARDVTLVRGTASPRFDYWGQGTLITVSS 787 QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDDDKRYSPSLKSRLTITKDTSKNQVVLTMTNMDPVDTATYYCAQEGRNYDRNWFDPWGQGTLVTVSS 788 QVRLQESGPGLVKPSETLSLTCTVSGGSISTYRWSWIRQPPGKGLEWIGYIYYSGRTNYHPSLKSRVTMSVDTSKNQFSLKLTFVSAADTAVYYCARLIPIDGRDVWGRGTTVTVSS 789 EVQLVESGGGLVEPGGSLRLSCAASGFTFSNAWMCWVRQAPGKGLEWVGRIKRIIDGGTINYAAPVKGRFTISRDDSTNTVYLQMNSLRSEDTAVYYCTTYWDQYTSTWTWGQGTLVTVSS 790 QVQLVQSGSELKKPGASVKVSCKASGYIFTNYAINWVRQAPGQGLEWMGWTNTNTGNPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCASIVKYDSSGYNFDYWGQGTLVTVSS 791 QVQLVQSGAEVKKPGASVKLSCKTSGYAFTSYQVHWVRQAPGQGLEWMGMINPSGSATHYAQKWQGRVSMTADTSTTTVYMELSGLRSEDTAVYYCTRDPWHESEHRFDPWGQGTLVTVSS 792 EVQLVESGGGLVQPGRSLRLSCAASGFTFGDYAMHWVRQVPGKGLEWVSSITWNSGNIGYADSVKGRFTISRDNAKNSLYLQMNSLRIEDTALYYCAKDNKVSSWYSFDIWGQGTMVTVSS 793 QVQLQQWGAGLLKPSETLSLTCAVSGASFSSYYWTWIRQPPGKGLEWIGDISQSASTNYSPSLKSRVTISADASRTQFSLNLISVTAADTAVYYCARGLGYYVALGQGTLVTVSS 794 EVQLVQSGVEVKEPGESLKISCKSSGYSFTKYWIGWVRQMPGKGLEWLGIIYPDDSETRYSPSFRGQVTISADKSISTAYLAWDRLKASDTAIYYCVRGGQEVSLRRLDWFVGYWGQGTLVTVSS 795 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSSISGSGDKTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTALYYCAKERGGSGKMYDYWGQGNLVTVSS 796 QVQLQQSGPGLLKPSQTLSLTCAISGDSVSSNTAWWSWIRQSPSRGLEWLGRTYYRSNWYNDYAVSVKGRITLNSDTSKNQLSLQLNSVTPEDTAVYYCARRGAAVAGTTGGSAFDIWGQGTMVTVSS 797 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYGMNWVRQAPGKGLEWVSGISWNSNSVAYADSVNGRFTISRDNAKNSLYLQMNSLRIEDTAFYYCTKTSDLLYYGSGSYLPYWGQGTLVVVSS 798 AVQLVESGGGFVQPGRSLRLSCAGSGFAFDDFAMHWVRQAPGKGLEWVSGINWNSDNIAYAASVKGRFIVSRDNGKNSLYLQMNSLRPEDTALYYCTRDGGAWDWGRGTLVTVSS 799 EVQVVESGGGLVQPGGSLRLSCAASGFTVSSTFMSWVRQAPGKGLEWVSVIYTVGDTFYADSVKGRFTISRHTSNNALYFQMNSLRTEDTAVYYCARGIPREYTTRWENAFDIWGQGTMVTVSS 800 QVQLQESGSGLVKPSQTLSLTCSVSGGSIKRRGYYWSWIRQHPGKGLEWIGYIYYSGTTYYNPSLQSRVNISVDTSKNQFSLNLRSVTAADTAVYYCARDRGADKDSNSGDVFDIWGQGTMVTVSS 801 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSAYYWSWIRQPPGKGLEWIGEINRRGNTNYNPSLKGRVTISIHTSKNQFSLNLSSMTAADTAVYYCVGPQGAYWGQGTLVTVSS 802 QLQLQESGPGLVKPSETLSLTCVVSGGSISSSDYYWGWIRQPPGKGLEWIGTIYYSGNTFYNPSLKSRVTMSVDPSKNQFSLKLSSVTAADTAVYYCARDPRGSSTSCSYDYWGQGTLVTVSS 803 EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVGRIKSKTDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTGQERITIFGVVIISSDYWGQGTLVTVSS 804 QVHLVQSGAEVKKPGSSVKVSCKASGGTFSTYAISWVRQAPGQGLEYMGGIIPSLRTANYAQRFQDRVSITADESTTTAYMELSSLRSDDTAVYYCARRLNDGANHSWGQGTRVTVSS 805 EVQLVQSGGGLVKPGESLRLSCAVSGLRFTDAWLNWVRQAPGKGLEWVGRIKSRGSGGTIELAAPVKGRFTISRDDSKSTLFLQMNSLRTEDTAIYYCSWDATVYYDMAVWGQGTTVTVSS 806 QVQLVESGGGVVQPGGSLRLSCAASGFSFSSYALHWVRQAPGKGLEWVALISYDGRNKYYADSVKGRFTISRDNSKKTLYLQMSTLTAEDTAVFYCARPSSGSYADPFDIWGQGTMVTVSS 807 QTVVESGGAVVQPGKSLTLSCEASGFSFSDFAMHWVRQSPGKGLEWVAVVSYDSRQQYYADSVQGRFRISRDNSQYTVTLRMDTLSFEDTGIYFCVASRSSSLDYWGQGTRVTVSS 808 QIQLVESGGGVVQPGRSLRLSCAASGFTFTTYGFHWVRQAPGKGLEWVAVIWYDGSNEAYADSVKGRITISRDNSRNTVYLQMNSLRAEDTAIYHCARSRGYGGLAGVDYWGQGTLVTVSS 809 DVQLVESGGGLVQPGGSLRLSCLATGFTFRSYSMNWVRQAPGKGLEWISYLSNDDRTRKYADSVNGRFFTISRDNDGSSLFLQMDSLRDEDTAIYYCARAYFDDSSGGFDYWGQGALVIVSS 810 QVQLQESGPGLVKPAETLSLTCTVSGDSITSYYWSWIRQPAGKGLEWIGRIYSSGDTNYDPSLKSRVTMSVDTSKDQFSLRLSVTAADTAIYYCAGSTYGDYVPHFYFWGQGTLVTVSS 811 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGSYWSWIRQSPGKGLEWIGEINPSGGSNYNPSLKSRVIISLDTSKNQFSLKLNSVTAADTAVYYCARGLSSFTTIVVVFVGASFYFDSWGQGTLATVAS 812 QVQLQQWGAGLLKPSETLSLTCAVSGGSFTDHYWTWIRQPPGKGLEWIGEINHSGRTNYSPSLKSRVTMSLDTSKNQFSLKLRSVTAADTGIYYCARGTTTSTTMIVIVITAVSTWFDPWGQGTLVTVSS 813 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARHPLKVDTIFGVVIIDPAPFDYWGQGTLVTVSS 814 QVTLKESGPVLVKPTETLTLTCTVSGFSLSNARMGVSWIRQPPGKALEWLAHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARIASYYYDSSGYYQTRPIGHAFDIWGQGTMVTVSS 815 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDRAQLLWFGQSRGMDVWGQGTTVTVSS 816 EVQLVESGGGLVKPGRSLRLSCTASGFTFGDYAMSWFRQAPGKGLEWVGFIRSKAYGGTTEYAASVKGRFTISRDDSKSIAYLQMNSLKTEDTAVYYCTSTSDWWGQGTLVTVSS 817 EVQLVESGGGLVQPGGSLKLSCAASGFTFSGSAMHWVRQASGKGLEWVGRIRSKANSYATAYAASVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCTRLRSGLVGFDWLPLYGMDVWGQGTTVTVSS 818 EVQLVQSGAEVKKPGESLRISCKGSGYSFTSYWISWVRQMPGKGLEWMGRIDPSDSYTNYSPSFQGHVTISADKTISTAYLQWSSLKASDTAMYYCARRGVGILKDLPVYAMDVWGQGTTVTVSS 819 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAREARQIFITMMTTKTSWFDPWGQGTLVTVSS 820 QVRLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGRIIPIFHIANSAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARVSSSTAVVTGLDYYYGMDVWGQGTTVTVSS 821 EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVGRIKSKTDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTISVGLLWFGLAVRDHYYFDYWGQGTLVTVSS 822 EVQLVESGGGSVRSGGSLRLSCAASGFTFRSYWMHWVRQAPGKGLVWVSRIFSDWSTTTYADSVRGRFTISRDNAKNTLYLEMNRLKVEDTAVYYCARSYYDSSTGYYPDALDLWGQGTTVTVSS 823 EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMSWVRQAPGKGLEWVAAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSGSVWGSYHKTYYFDYWGQGTLVTVSS 824 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKNYADSVKGRFTISRENSKNTLYLQMNSLRAEDTAVYYCAKEILKGYSSGWKYYYYGMDVWGQGTTVTVSS 825 EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMNWVRQAPGKGLEWVSVIYSGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARATTTMVRGVIYHYYYYGMDVWGQGTTVTVSS 826 QVQLQESGPGLVKPSQTLSLTCTVSGGPISSGGYYWSWIRQHPGKGLEWLGCIYYSGSTYYNPSLKSRVSISVDTSKSQFSLKLSSVTAADTAVYYCARERLGRMVRGVNWFDPWGQGILVTVSS 827 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSYYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCASWTMVRGVIRWFDPWGQGTLVTVSS 828 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARQFHYVGIVVVVAPHYYYGMDVWGQGTTVTVSS 829 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASPRGYSYGPFDYWGQGTLVTVSS 830 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTMTTDTSTSTAYMELRRSLRSDDTAVYYCARVLYYDILTGYWWYYYGMDVWGQGTTVTVSS 831 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMHWVRQAPGKGLVWVSRINSDGSSTSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARGAPITIFGVVISTWFDPWGQGTLVTVSS 832 QLQLQESGSGLVKPSQTLSLTCAVSGGSISSGGYSWSWIRQPPGKGLEWIGYIYHSGSTYYNPSLKSRVTISVDRSKNQFSLKLSSVTAADTAVYYCARAHTDSLELGIWGQGTMVTVSS 833 EVQLLQSGGEVRRPGESLKISCKASGYSFPAHWIGWVRQMPGRGLEWMGSIFPSDSDTEYSPSFEGQVKISADKSITTAYLQWSSLKASDTAFYYCVRKYTYDTSGFFLTSTRSAFDVWGQGTMVTVSS 834 EVQLEQSGAEEKKPGESLKISCKGSGYSFPAFYIAWMRQMPGKGLEWMGSIFPGDSETEYNPSFQGQVTISADKSITTAYLQWDNLKASDTALYYCARKHVYDTSGFFFLSSSRNAFDVWGQGTKVTVFS 835 EVQLVQSGAEQRKPGESLRISCKGSGYSFPAHWIAWVRQMPGRGLEWMGSIFPGDSDTEYNPSFQGHVNISADRSINTAYLQWSSLKASDSAIYYCARKYSFDISGFFLSSSRYALDVWAQGTTVTVSS 836 DMQLVESGGGLVQPGGSLKLSCAASGFTFSASAIHWVRQASGKGLEWVGHIRRTRTNRYATAFSEVNGRFTISRDDSKSTAYLQMNSLKAEDTAVYYCARDEGVTFHDHWANEIRYGMDVWGRGTTVTVSS 837 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGYYWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARARTTMIVVVSQFDYWGQGTLVTVSS 838 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMHWVRQAPGKGLVWVSRINSDGSSTSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARDRGGWLLGSYYYYGMDVWGQGTTVTVSS 839 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTMTTDTSTSTAYMELRRSLRSDDTAVYYCARGQISHYGFGESHWGQGTLVTVSS 840 QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVSVGWIRQPPGKALEWLALIYWDDDKRYSPSLKSRLTITKDTSKKQVVLTLTNMDPVDTASYYCAHSGIAVVGNQLFHYYAMDVWGQGTTVTVSS 841 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKERSSGSQWGWTYYYYGMDVWGQGTTVTVSS 842 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPYGGNRRFHGWVYYYYGMDVWGQGTTVTVSS 843 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYEMNWVRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARESTPDVRGVMNYWGQGTLVTVSS 844 EVQLLESGGGLVLPGGSLRLSCAASGFTFSIYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDAVASAGSPDYWGQGTLVTVSS 845 QVQLVESGVGVVQPGKSLRLSCAASGFTFTSYGMHWVRQAPGKGLEWVAVISFDGSNIYYADSVKGRFTISRDNFKNTLYLQMNSLRAEDTAVYYCARDKLLWFGEPVVGYYYYYYMDVWGKGTTVTVSS 846 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGGGDYAQIYFDYWGQGTLVTVSS 847 QVQLVESGGGVVHPGRSLRLSCAASGFAFNKYGIHWVRQAPGKGLEWVALIWNDGNKQYYGDSVKGRFTVSRDNSKNTVSLQMDTLRDEDTAVYYCARDRLMTTYNYYSSMDVWGRGATVIVSS 848 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREPGDCSGGSCYYYGMDVWGQGTTVTVSS 849 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGSIFYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARATRGYSYDDAFDIWGQGTMVTVSS 850 QVQLQESGPGLVKPSGTLSLTCSVSGGAITTSSYFWGWIRQPPGRGLEWIGSISYSGDTFYNPSLNDRVTISVDSSKNQFFLKLRSVTAADSAVYYCASPSYTDLLTGYYVPVDYWGQGILVIVSS 851 QVHLVESGGGVVQPGKSLTLSCAASGFTFSAYGMHWVRQTPGKGLEWVALISFDGSNKYYRDSVKDRFTIARDNSKNTLSLQMNSLRPEDTAIYYCAKDPRVNELLWFGSLTQFYFDDWGQGTLVTVSS 852 QVQLVESGGGVVQPGRSLTLSCAASGFTFNNYGMHWVRQAPGKGLEWLALISYEGSIRYYGDSVKGRFTISRDSSKNTVYLQMISLRAEDTAVYYCAKSGGPFHLSLYYYMDVWGKGTTVTVSS 853 QVQLQESGPGLVKPSETLSLTCTVSGGSINSYYWSWIRQTAGQGLEWIGRIYSGGSTNYNPSLKSRVTMSVDTSQNQFSLNLNSVTAADTAVYYCARAFYGHAFDFWGLGVLVIVSS 854 QVQLVESGGGVVHPGRSLLRLSCAASGFTFSRFGMHWVRQAPGKGLEWVALISYEGSTEQYSDSVKGRFAISRDNSKNTLYLQMNSLRPEDTAVYYCAKGLTIPFDKWGHGTLVTVSS 855 QVQLVESGGGVVHPGRSLRLSCAASGFTFSRFGMHWVRQAPGKGLEWVALISYEGSTEQYSDSVKGRFAISRDNSKNTLYLQMNSLRAEDTAVYYCAKGLTIPFDKWGHGTLVTVSS 856 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFWMTWFRQTPGKGLEWVANIKEDGSEKQYVDSVKGRFNISRDNAHNSLYLEMNSLRSEDAAVYYCARRGKYCSGGRCYSWWFDPWGQGTQVTVSS 857 QVQLVQSGGEMRKPGSSVKVSCKASGGTFSSYTISWVRQAPGQGLEWMGRIIPMLNKTYYAQKFQGRVTFAADESTSTVYMELSSLRSEDTAMYYCARVASLIGDDYWGQGSLVTVSS 858 QVQLVQSGGEMRKPGSSVKVSCKASGGSFSSYTISWVRQAPGHGLEWMGRIIPMLNKTYYAQKFQGRVTVAADESTSTVYMELSSSLSEDTAIYYCARVASLIGDDYWGQGSLVTVSS 859 QITLKESGPTLVKPTQTLTLTCTFSEFSLDSRGVGVGWIRQPPGRALEWLALIYWNDNKRYNPSLRSRLTITKDTSKNQVVLTMSNMDPVDTATYYCAHKPSGWSLRFDSWGQGTLVTVSS 860 QVQLQEAGPGLVKPSETLSLTCSVFGGSISSYYWSWIRQPPGKGLEWIGYIYYRGSTNYNPSLKSRVTMSVDTSKNQFSLNLTSVTAADTAVYFCARESLFNWFDSWGHGTLVTVSS 861 QVQLVESGGGVVQPGRSLRLSCAASGFTFSRYGMHWVRQAPGKGLEWVALISYEGSTEQYSDSVKGRFAISRDNSKNTLYLQMNSLRHEDTAVYYCAKGLTIPFDNWGQGTLVTVSS 862 EVQLVESGGGLVQTGGSLRLSCAASGFPFSGYALNWVRQAPGKGLEWVSYISSSSSTVYYADSVKGRFTISRDNAKNSLYLQMNSLRRDEDTAVYYCARVDYDSSRNYWGQGTLVTVSS 863 EVQLVESGGGLVQPGGSLRLSCAASGFTFINYDMTWVRQAPGKGLEWISYISSSSSTTHYSDSVKGRFTISRDNARNNSLYLEMNSLRAEDTAVYYCARVERWLVLGYYYYGMDVWGQGTTVTVSS 864 EVQLVESGGGLVQPGESLRLSCVASGFAFDKFWMAWLRQAPGKGLEWVALLNKDESEKYYVDSVKGRFTISRDNAIDSVFLQMNSLRTEDTAVYYCGSIDYWGQGALVTVSS 865 QVQLQESGPGLVKPSQTLSVTCTVSGGSINRDGHYWIWIRQHPEKGLEWLGYIYSGRNTFYNPSLRSRLSISADTSKSQFSLNLHSVTAADTAVYYCAKMYSDYDDNYYGLDVWGRGTTVTVSS 866 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDRYCSSTSCGGYYYYMDVWGKGTTVTVSS 867 QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGSYFWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLRSVTAADTAVYYCARAPNDFWSGYPYYFDYWGQGTLVTVSS 868 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTMTTDTSTSTAYMELRRSLRSDDTAVYYCTRDGSTAAIFGNIDYWGQGTLVTVSS 869 QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGVVRNDYGDPGFDYWGQGTLVTVSS 870 QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATAPAYCSGGSCPENNWFDPWGQGTLVTVSS 871 QVLLVQSGAEVKKPGASVKVSCKASGYRFTSYGIHWVRQAPGQSLEWMGCINTDNEKTEYSQKFQGRVTITRDTSASTAYMELSTLRFEDTAVYYCAILWFGEFYFYDLFYNAVDVWGQGTTVTVSS 872 QVLLVQSEAEVKKPGASVKVSCKASGYRFTSYGIHWVRQAPGQGLEWMGSINTDNGKTEYSQKFQGRVTITRDTSAGTAYMELSTLRSEDTAVYYCAILWFGEFYFYDLFYNAVDVWGQGTTVTVSS 873 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYAMHWVRQAPGQRLEWMGWINAGNGNTRYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCASRREQWLGDLGYYYYGMDVWGQGTTVTVSS 874 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPEQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGGAHSEDYWGQGTLVTVSS 875 QVQMVQSGAEVKKPGASVKVSCKASGYTFTNYYVHWVRQAPGQGLEWMGRINPSDGSTSYTQKFQGRVTMTRDTSTSTVYMQLSSLRSEDTALYYCARHQDPLDIVATVDWGGLDYWGQATLVTVSS 876 QVQLVQSGGELRKPGSSVKVSCKASGGTFSSYTISWVRQAPGQGLEWMGRIIPMLNKTYYAQKFQGRVTFAADESTNTVYMELSSLRSEDTAMYYCARVASLIGDDYWGQGSLVTVSS 877 QVQLVQSGAEVKKPGSAVKVSCKASGGTFNSYAFNWVRQAPGQGLEWMGGIIPIFGPPNYAQNFQGRVTITADESTSTAYMELSSLTSEDTAVYYCATTGTDNYYYYMDVWGKGTTVTVSS 878 QVQLVQSGAEVKKPGASVKVSCKASGYTFSSDINWVRQATGQGLEWMGWMNPNTGTTGYAQKFQDRVTMTRDTSINTAYMELSSLRSEDTAVYYCARKNCSGGICYFHDYWGQGTRVTVSS 879 QITLKESGPTLVKPTQTLTLTCTFSEFSLDARGVGVGWIRQPPGRALEWLALIYWNDYKRYSPSLQSRLTITKDTSKNQVVLTMTNMDPVDTATYYCAHKPSGWSLRFDSWGQGTLVTVSS 880 EVQLLESGGGLVQPGGSLRLSCAASGFTFISYATSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGQTIQLWLFGALWGQGTLVTVSS 881 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGTTYYADSVKGRFTISRDNSKNTLYLQMDSLRGDDTAVYSCALTVSSWYPGIFENWGQGTLVTVSS 882 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKAFSGSYWDAFDIWGQGTMVTVSS 883 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSHGMHWVRQAPGKGLEWVAVISYDGINKYYADSVKGRFTISRDNSKNTLFLQLNSLRAEDTAVYYCAKAASGARGYYGMDVWGQGTTVTVSS 884 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSSSGHYVSDLGYWGQGTLVTVSS 885 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARALNGYRYNDYWGQGTLVTVSS 886 QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVMWFDGVDKYYADSVKGRFTISRDNSKNTLYLQMNSLRDEDTAVYYCAREEGGGSSTHFDCWGQGTLVTVSS 887 QVQLVESGGGVVQPGRSLRLSCAASGFTFSTFAMHWVRQAPGKGLEWVAIISYDEINKYYADSVKGRFTISRDNSKNMLYLQMNSLRAEDTAVYYCARTREGSYYYGMDVWGQGTTVTVSS 888 EVKLVESGGHLVQPGRSLRLSCTASGFIFGDYAMGWVRQAPGKGLEWVSFIRGRLVGATVEYAASVKGRFTMSRDDSERVAYLQMNSLKIEDTGVYYCVRGGLQFVVAVGPYGVDVWGQGTTVTVSS 889 EVKLVESGGHLVQPGGSLRLSCTASGFIFGDYAMGWVRQAPGKGLEWVSFIRGRLVGATVEYAASVKGRFTMSRDDSERVAYLQMSSLKIDDTGVYYCVRGGLQFVVAVGPYGVDVWGQGTTVTVSS 890 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCARDIGGGAPDYWGQGTLVTVSS 891 QVLLQESGPGLVRPSQTLSLTCSVSGASISSGDYYWTWVRQTPGKGLEWLGFIYYSGSTYYNPSLQRRVLISMDTAMNQFSLRLTSVTAADTAVYYCAIKPSIPGYFDPWGQGTLVTVSS 892 QVQLQQWGAGLLKPSETLSLTCALNGGVLSDYYWSWIRQPPGQGLEWIGAIHRSGSTSYTPSLKSRVTMSVDTSKNQFSLRLSVTAADTAVYYCARVGGWQRSPRPNWGQGTRVTVSS 893 QVQLQQWGAGLLKPSETLSLTCALNGGVLSDYYWSWIRQPPGQGLEWIGAIHRSGSTSYTPSLKGRVTMSVDTSKNQFSLRLSVTAADTAVYYCARVGGWQRSPRPNWGQGTRVTVSS 894 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSDYYWNWIRRPPGKGLEWIGEITHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGQGYGRVLLWFGEWGQGTLVTVSS 895 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSDYFWYWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVSISVDTSKNQFSLKLSSVTAADTAVYYCARGQGYGRVLLWFGEWGQGTLVTVSS 896 QVQLQESGPGLVKPSGTLSLTCDVSGDSISSNNWWTWVRQPPGKGLEWIGDIYHSGTTNYNPSLKSRLTMSVDKSKNHFSLKLTSVTAADTAVYYCARPSSGSRFDYWGQGTLVTVSS 897 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPAGKGLEWIGHIYTSGSTNYNPSLKSRVTMSVDTSKNQFSLKLSSVTAADTAVYYCARGFDYWGQGTLVTVSS 898 QVQLQESGPGLVKPSETLSLTCTVSGDSISSYYWSWIRQSPGKGLEWIGYIYHSGSADYNPSLKSRVSMSLDASKNQFSLKMSSVTAADTALYYCAKARGVVLFDYWGQGTLVTVSS 899 QVQLRESGPGLVKPSETLSLTCTVSGGSISGYYWSWIRQPPGKGLEWIGYLHYSGRSNSSPSLNSRVSISVDTSQNRFSLKVTSLTAADTAVYYCARHSYGSGTYLDPFDYWGQGTLVTVSS 900 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGSYYWSWIRQPAGKGLEWIGRIYTSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARQPHLAYYYDSSGYNDAFDIWGQGTMVTVSS 901 QVQLQESGPGLVKPSQTLSLICTVSDDSISSGSYYWSWIRQPAGKGLEWIGRIYAGESTNYNPSLKSRVIISVDTSKKQFSLRLSVTAADTAVYYCARGAVVTPFGLDSWGQGTLVTVSS 902 EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCASEDYYDSSGYYWYWGQGTLVTVSS 903 EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWGSLKASDTAMYYCARLSAIAVVGYYYYAMDVWGQGTTVTVSS 904 QVQLVQSGSELKKPGASVKVSCKASGYTFTSYAMNWVRQAPGQGLEWMGWINTNTGNPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARDFIAASPFYYYYYMDVWGKGTTVTVSS 905 EVQLVQSGAEVKKPGESLKIFCKGSGYTFSFYWIGWVRQTPGKGLEWMGIIYPGDFDTRYSPSFQGQVTISADKSINTAYLQWSSLKASDTAMYYCATSPGGYGVRRTVLEDFRHWGQGTLVTVAS 906 QLQLQESGPGLVKPSETLSLTCTVSGGAFSSGRHYWGWIRQPPGKGLEWIGSIYSGVITHYNAPLKSRVTIAVDTSKNQFSLKLSSVTAADTAVYYCWTMEYDDYSFVYDYWGQGTLVTVSS 907 QVHLQQWGAGLLKPSQTLSLTCAVYGGSFSSYYWSWIRQTPGKGLEWIGEVTHSGSTNYKPSLKSRVTMSVDTSRNQFSLNLTSVTAADTAVYYCARGGKQQLVRNYYLDSWGQGTLVTVSS 908 QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSMDWVRQAPGKGLEWMGGFDPEDGETIDAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGFGGVIVRGFDYWGQGTLVTVSS 909 QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVYGDYSYYMDVWGKGTTVTVSS 910 EVQLVESGGGLIQPGGSLRLSCAASGITVSSNYMSWVRQAPGKGLEWVSVIYSGGSTDYADSVKGRFTISRDKSKNTLYLQMNSLRAEDTAVYYCARDLGEAGGMDVWGQGTTVTVSS 911 EVQLVESGGGLVQPGGSLRLSCAASGFTFSRFWMTWVRQAPGKGLEWVANIKEDGSVMFYVDSVKGRFSISRDNSKNSLYLEMNSLRAEDTAVYFCVREIESGVDFWSGHYYWGQGTLVTVSS 912 EVQLVESGGGLVQPGGSQRLSCVASGFTFSNYWMSWVRQAPGKGLHWVANIKSDGSETYYVDSLRGRFTISRDNAKNSLYLQLTSLTVEDTAVYYCARDSAYYDTIGYYSGDYWGRGTLVTVSS 913 QVQLVESGGGAVQPGRSLRLSCEASAFSFHLHGMHWVRQAPGKGLEWVALIWFDGSKKFYADAVKGRFTISRDNSKNTLYLQMNSLRVEDTAIYYCGRSFRGSCFDYLGQGTLVTVSS 914 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISSSGGGTYYADSVKGRFTISRDNSKNTLYVQMNSLRAEDTAVYYCALGTGSYYGVNYWGQGTLVTVSS 915 EVQLVESGGGLVQPGRSLRLSCAAFGFIFDDYGMHWVRQVPGKGLEWVSGITWNSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYFCAKDMGGRYSSGLYYYYYGMDVWGQGTTVTVSS 916 EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRHNSKNTLYLQMNSLRAEDTAVYYCARELRGYFDYWGQGTLVTVSS 917 QMRLQESGPGLVKPSETLSLTCTVSGGSIGSSSYFWGWIRQPPGKGLEWIGNIYYGGSTYYKPSLKSRVTISLDTSKNQLTRLLSVTAADTAVYYCARDPNDFWSGFPRGAFDIWGQGTMVTVSS 918 QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCASHARYEEETFDYWGQGTLVTVSS 919 EVQLVESGGGLAQPGGSLRLSCAASGFTFSSYDMHWVRQAAGKGLEWVSTIGTAGDTYYPGSVKGRFTISRENDKNSLYLQMNSLRAGDTAVYYCVRDSYTSAWTPAGYFDLWGRGTLVTVSS 920 QVQLVESGGGVVQPGRSLRLSCAASGFFTSRSAMHWVRQGPGKGLEWVAMMSYDGSDIQYADSVKGRFTISRGNSKNTLFLQMNSLRLADTAMYYCAKDHYGSIDYWGQGTLVTVSS 921 QVQLVESGGGVVQPGRSLRLSCVASGFTFSSQSMHWVRQAPGKGLEWVSIISYDGNNKQYADSVKGRFTISRDNSKSTLFLQINSLRPQDTAVYYCARPYTSRWFWSNWGQGTLVTVSS 922 EVQLVESGGGLVQPGRSLRLSCAASGFTFEEYSIHWVRQAPGKGLEWVSGVSWNSGTIAYADSVRGRFTISRDNAKNSLYLQMSRLRADDTALYYCALLPPNAYDYGDGLLDHWGQGTLVTVSS 923 EVQVVQSGAEVKKPGESLKISCKGSGYTFGRYWIAWVRQMPGKGLEWMGIINPADSDTRYSPTFQGQVTISVDQAISTAYLQWSSLKASDTAMYHCARHRAAGGNYYYGMDVWGQGTTVTVSS 924 QVQLVQSGAEVKKPGASVKVSCKASGYTFSTYYMHWVRQAPGQGLEWMGIINPSGDSTRYAQKFQGRVTMTRDTSTSTVYMEVSSLRFEDTAVYYCARERVGPAAGYMDVWGKGTTVTVSS 925 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGRIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARAAYYYDSSGYGWFDPWGQGTLVTVSS 926 QVQLVQSGAEVKNPGSSVKVSCKTSGATFTTYAINWVRQAPGQGLEWIGGIFPIFTAAVYAQKFQGRVTITADESTTTAYLELSSLRSEDTAVYYCARGDYTEYSYYYMDVWGKGTTVTVSS 927 EVQLLESGGGLVQPGGSLRLSCAASGFTLSSYAMSWVRQAPGRGLEWVSAVSGSGGSTYYADSVKGRFTISRDNSKNMLYLQMNSLRAEDTAIYYCALPTGASSSYSGPNYWGQGTLVTVSS 928 QVQLVESGGGVVQPGRSLRLSCVASGFTFSNYDMHWVRQAPGKGLEWVTVISSDGNNRRRYADSVKGRFTISRDNSKNMLYLQMNSLKAEDTAVYYCARDEVIAVATGEGMDVWGQGTTVTVSP 929 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDMGYDILTGSGLGDYWGQGTLVTVSS 930 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGTIGYEDSVKGRFIISRDNAKNSLYLQMNSLRAEDTALYYCAKEPLFGETYGMDVWGQGTTVTVSS 931 EAQLVESGGGLVQPGRSLTVSCAVSGFTFDDYAMHWVRQAPGKGLEWVSSISWNSEKIAYADSVKGRFTVSRDNAKNSLYLQMTSLRPEDTALYYCARDKGSGSYYSGAYYYYMDVWGKGTTVTVSS 932 EVQLVESGGGLVPPGGSLRLSCAASGFTFSSYTINWVRQAPGKGLEWVSYINSGSSIIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCATFNSGNDNAYEYWGQGTLVTVSS 933 EVRLVESGGGWVQPGGSLRLSCEASTFIFSNSEMNWVRQAPGKGLEWVSYISSSDNSVHYADSVKGRFTISKDSAKKTLYLQMNSLRAEDTGVYYCAREYPDFWSGHYYYYMDVWGKGTTVTVSS 934 EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLPYGMDVWGQGTTVTVSS 935 QVKLQQWGAGLVKPSETLSRTCAVYGGSFSGYFWSWIRQSPGKGLEWIGEINHSGKTNYSPSLKSRVSISVDTSKNQFSLKLTSVTAADTAVYYCARGLYDKSGYRSDGFDSWGQGAVVTVYS 936 QVQLQQWGAGLLKPSETLSRTCAVYGGSFSGYYWTWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRITMSVDTSKNQFSLELRSVSAADTAVYYCARGFEGYCSGGRCYSYFDYWGQGTLVTVSS 937 QVQLQESGPGLVKPSETLSLTCTVSGGSLSSYYWNWIRQPPGKGLEWIGYMYNSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARVKNWDYGLYWGQGTLVIVSS 938 QVQLQESGPGLVKPSETLSLTCTVSGGSISTFYWNWVRQPPGKGLEWIGFIYYSGRTNYNPSLKSRVTISVDTSKNQFSLKVSSVTAADTAVYYCARDGQSDWHFDLWGRGTLVTVSS 939 QVQLQESGPGLVKPSETLSLTCTVSGGSVSSYFWSWLRQPPGKGLEWIAYIFYTGTSNYNPSLKSRVTISLDTSKNQMSLNLSSVTTADTAVYYCARVYGDYLDHWGQGTVVTVSS 940 QITLKESGPTLVKPTQTLTLTCTFSGFSFNTPGVGVGWIRQPPGKAPECLALIYWDDEKLYNPSLKTRLTITKDPSKNQVVLTMTTMDPVDTATYYCAHRSFLYNIFNGYSYAPFDYWGQGSMVTVSS 941 QVQLVESGGGVVQPGRSLRLSCAASGFFSNHGMHWVRQAPGKGLEWVAVIWYDGDNRFYADSVRGRFTISRDNSKNTLFLQMDSLRAEDTGIYYCAKDLFSGDRDFWGQGTLVTVSS 942 QVQLVESGGGVVQPGRSLRLSCVASGFTFSNSAMHWVRQAPGMGLEWVAVIYYDGSNEYYADSVKGRFTISRDNSKNTLYLQMNSLRADDTAVYYCAKDSGAVLLWFGADFWGQGTLVTVSS 943 DVQLVESGGSLVQPGGSLRLSCAASEFTFSSYEMNWVRQAPGKGLEWVSYIDSSSTTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGAYDIWRGSYMRAYDHWGQGTLVTVSS 944 QVQLVQSGSELKKPGASVKVSCKASGYTFTNFAINWVRQAPGQGLEWMGWINTKTGIPTYAQGFTGRFVFSLDTSVSTAYLQISGLKAEDTAVYYCARYIEMFDPWGQGTLVTVSS 945 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTMTTDTSTSTAYMELRRSLRSDDTAVYYCARQAYGDYGWDYYYGMDVWGQGTTVTVSS 946 QVQLAEAGGGVVQPGTSLRLSCVVSGFSFSRYGMHWVRQAPGKGLEWVAVISHDDSQKYYGDSVKGRFTISRDNSKDTLYLEMTSLRLEDTAVYYCLKDWDWEYEDSRPTLRGSVYWGQGTLVIVSA 947 QVQLVESGGGAVQPGRSLRLSVTSGFNFNSYTMHWIRQAPGKGLEWVAVISYEGSKKYYADSLKGRFTISKDNSKNTVYLEMNSLTTEDTAVYYCARGSVFWFGEGKNWFDPWGQGTLVTVSS 948 QVQLVESGGGAVQPGRSLRLSCVTSGFNFNSYTMHWIRQAPGKGLEWVAVISYEGSKKYYADSLKGRFTISKDNSKNTVYLEMNSLTTEDTAVYYCARGSVFWFGEGKNWFDPWGQGTLVIVSS 949 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYEMNWVRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREDSSGWSRGDYWGQGTLVTVSS 950 QVQLVQSGSELKKPGASVKVSCKASGYIFTSYGMNWVRQAPGQGLEWMGWINTNTGSPMYAQGFTGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARRFVVREVEYNWFDPWGQGTLVTVSS 951 QAQLVQSGSEVRKPGASVKVSCKASGYSFNDYGITWVRQAPGQGLEWMGWISAYNGETNYAQKFQDTVTMTTDTSTNTAYLELRRSLRFADTALYYCARDGYCNSMRCYRYYHGMDVWGQGTTVTVSS 952 QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGPTAKPNKQWGYWFDPWGQGTLVTVSS 953 QVQLVQSGAEVKKPGASVKVSCKASGNTFSTYYIHWVRQAPGQGLEWMGIISPSGDDANYTQKFQDRVTMTRDTPTNTVYLELSSLRSEDTAVYYCASPVSVEQDFDIWGQGTMVTVSA 954 EVQLVESGGGSVKPGGSLRLSCAASGFTFSDVWMSWVRQAPGKGLEWVGRIRSKSDGGTTDYAAPMKERFSISRDDAKNTMYLQMNSLKTEDTGVYYCTTPVGDFWGQGTMVTVSS 955 EVQLMESGGGLVKPGGSLRLSCAGSGLTFDNAWMSWVRQAPGKGLEWVGRVKSKTDGGTTDYAAPVKGRFTISRDDSKNTLFLQMNSLKTEDTAVYYCSTSHPPFFDYWGQGTLVTVSS 956 QVQLVESGGGVVQPGRSLRLSCAASRFTFSSYAMHWVRQAPGKGLEWVALISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMDSLRPEDTAVYYCARGLWQLVSPVFDYWGQGTLVTVSS 957 EVQLVESGGVVVQPGGSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSLISWDGGSTYYADSVEGRFTISRDNSKNSLYLQMNSLRAEDSALYYCAKVTNRGVRGLYFDYWGQGTLVTVSS 958 QVQLVQSGAEVKKPGASVKVSCKASGNTFTTYYIHWVRQAPGQGLEWMGIISPSGDDANYTQKFQDRVTMTRDTPTNTVYLELSSLRSEDTAVYYCASPVSVEQDFDIWGQGTMVTVSA 959 QVQLVQSGAEVKKPGSSVNVSCKASGGTFNSYTLSWVRQAPGQGLEWMGRIVPMLGITNYAQKFQDRVTITADESTATAYMDLSSLTSEDTAVYFCAINTLLVTAWGQGTLVTVSS 960 QITLKESGPTLVKPTQTVTLTCTFSGFSLNTPGAGVGWIRQPPGQALECLALIYWDDDKRYSPSLRSRLSIAKDTAKNQVVLTVTNLDPVDTATYYCVHRSFLYDIFSGYSYAPFDYWGQGMLVTVSS 961 QITLKESGPTLVKPTQTLTLTCTFSGFSFNTPGVGVGWIRQPPGKAPECLGLIYWDDEKRYSPSLKSRLTITKDPSKNQVVLTMTTMDPVDTATYYCAHRSFLYNIFDGYSYAPFDYWGQGSMVTVSS 962 QVQLVESGGGLVKPGGSLRLSCAASGFTTFSDYYMNWIRQAPGGGLEYIAYISSGGDAIYYADSVKGRFIISRDNSESSVSLQMTSLRADDTAVYYCAGGADCRRTSCHYLVSNREEYMGVWGKGTTVTVSS 963 EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMNWVRQAPGKGLEWVSSMSSDSDYIFYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGLVLSGTRYSYFYGMDVWGQGTTVTVSS 964 QVHLAEAGGGVVQPGRSLRLSCVVSGFSFSRYGMHWVRQAPGKGLEWVAVISHDESQKYYGESVKGRFTISRDNSKDTVYLQMDSLRVEDTAVYYCVKDWDWEYEDNRPTLRGSVYWGQGTLVIVSA 965 QVQLAEAGGGVVPPGRSLRLSCVVSGLSFSRYGMHWVRQAPGKGLEWVAVISHDESQKYYGESVKGRFTISRDNSKDTLYLQMDGLRVEDTAMYYCVKDWDWEYEESRPTLRGSVYWGQGALVIVSA 966 QVQLVESGGGVVQPGRSLRLSCATSGFSFNNFGMHWVRQAPGKGLEWLAVISYEGSKKYYADSLKGRFTISRDGSKDTLYLQLSSLGVEDTAVYHCAKGGPIFWLGEGKNWFDAWGPGTPVIVSS 967 QVQLVESGGGVVQPGRSLRLSCAASGFTLSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYRDSVKGRFTISRDNSKNTLYLQINSLRVDDTAVYYCARDKGGILMLRGADFWGQGTLATVSS 968 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYEMNWVRQAPGKGLEWVSYITSSGNTILYADSVKGRFTISRDNAKNSLYLRMNSLRAEDTALYYCARTLIAAAGSAFDIWGQGTMVTVSS 969 EVQLVESGGGLGLPGGSLRLSCAASGFTFSSYAMNWVRQAPGKGLEWISYISSSSGTIYYADSVKGRFTISRDNAKNSLFLQMNSLRRDEDTAVYYCARGPTSITMIVVVDDAFDIWGQGTMVTVSS 970 QVQLQESGPGLVKPSETLSLTCSVSGGSISPYSWSWIRQPPGKGLEWIGYIYYTGKTNYNSSLKTRVTISLDTSKNQFSLRLTSVTTADTAIYYCARVMNSSWYTRYYYNYMDVWGKGTSVTVSS 971 QLQLQESGPRLVKPSATLSLTCTVSGDSIRSSSSFYWGWIRQPPEKGLEWLGSVYNSGTAYYNPSLKSRVSVSVDTSKNQFSLKVNSVTAADTAVYYCARRGGGCSEGVCYNFDRWGQGTLVTVSS 972 QVQLVQSGSELKKPGASVKISCKAFGYSFTTYAMNWVRQAPGRGLEWMGWIDTNTGKPTYARGFTGRFVFSLDTSVRTSYMQINTLKAEDTAVYYCARGDPRDYWGQGTLVTVSS 973 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGRIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGSYYYDSSGYYLDYWGQGTLVTVSS 974 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGRIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARAAYYYDSSGYGWFDPWGQGTLVTVSS 975 EVQLVESGGGLVKPGGSLRLSCAASGFFTSLGATGIYYYYYMDVWGKGTTVTVSS 976 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYEMNWVRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARFPRDYYDSSGYLIQEGNFDYWGQGTLVTVSS 977 EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVTRAGAAGDGGAFDIWGQGTMVTVSS 978 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTKYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARSVVPVAGTDYWGQGTLVTVSS 979 QVQLVQSGAEVKKPGASVKVSCKASGYTFTTYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTMTTDTSTSTAYMELRRSLRSDDTAVYYCARDQHPGYPALVYYYYYMDVWGKGTTVTVSS 980 QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGITWVRQAPGQGLEWMGWISTYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRRSLRSDDTAVYYCARDNIQTFDYWGQGTLVTVSS 981 QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATSSPVAGYNSWFDPWGQGTLVTVSS 982 QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGPAVIPLRWFDPWGQGTLVTVSS 983 QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATAPAAAGPTDWFDPWGQGTLVTVSS 984 QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCAISPSVHSLWWFDPWGQGTLVTVSS 985 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYAMHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVTITRDTSASTSYMELSSLRSGDTAVYYCARDEIHYDILTGYYNRFWFHPWGQGTLVTVSS 986 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDAETGYYDSSGYPINWFDPWGQGTLVTVSS 987 QVTLKESGPVLVKPTETLTLTCTVSGFSLSNARMGVSWIRQPPGKALEWLAHIFSNDKKSYSTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARHYYDTGAYYVPFDHWGQGTLVTVSS 988 QITLKESGPTLVKPTQTLTLTCTFSGFSLSTTGVGLAWIRQPPGKALEWLAFIYWDDDKRYSPSLQTRLTITKDTSKNQVVLTLTNMDPMDTATYYCAHFQGFGESEYFQHWGQGTLVTVSS 989 QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIFWDDDKRYSPSLKSRLTITKDTSKNQVVLTMTNMDPVDTATYYCAHRHPLTGFDSWGQGTLVTVSS 990 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCATPRGYSYGPLDYWGQGTLVTVSS 991 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASPRGYSYGPFDYWGQGTLVTVSS 992 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRVDKGYDFWSSWYFDLWGRGTLVTVSS 993 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASGGGSYFDAFDIWGQGTMVTVSS 994 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRSGSYYGGFDYWGQGTLVTVSS 995 QVQLVESGGGVVQPGWSLRLSCAASGFTFGSYGMHWVRQAPGKGLEWVALIWNDGSNKYYADSVKGRFTISRDKSKNTLYLQMNSLRAEDTAVYYCAKAVYGGNSVYFDYWGQGTLVTVSS 996 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIYGGNYENYFDYWGQGTLVTVSS 997 QVQLVESGGGVVQPGRSLRLSCAASGFTFSIYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARESEAGTTPSFDYWGQGTLVTVSS 998 EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTNYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSLVRGVITYFDYWGQGTLVTVSS 999 EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMNWVRQAPGKGLEWVANIKEDGSETYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGLSMEVWGQGTTVTVSS 1000 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEIDHSGSTNDNPSLKSRVTISVDTSKNQFSLKLSSVTAADAAVYYCARGGYSSSWYGTKYYFDYWGQGTLVTVSS 1001 QVQLQQWGAGLLKPSETLSLTCAVYDGSFSGHYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGPTVTTFFRRNAWFDPWGQGTLLTVSS 1002 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGRYSSGWYGSRNWFDPWGQGTLVTVSS 1003 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARLSMGAARQSGFDPWGQGTLVTVSS 1004 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDGGRDGYNELGARVYYYYGMDVWGQGTTVTVSS 1005 EVQLVQSGAEVKKPGESLRISCKGSGYNFTSYWISWVRQMPGKGLEWMGTIDPSDSYTNYRPSFQGHVTISADKSINTAYLQWSSLKASDTAMYYCARIGSYGIWGQGTLVTVSS 1006 QVQLVQSGSELKKPGASVKVSCKASGYTFTSYAMNWVRQAPGQGLEWMGWINTNTGNPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCAKLGCSGGSCYYYYGMDVWGQGTTVTVSS 1007 EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYVSWVRQAPGTGLEWVSVVYSGGHAYYADSVKGRFTMSRDNSENAVYLQMNSLRAEDTAVYYCARGDHYYDRSGPHKFDYWGQGTLVTVSS 1008 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGLYHWSWIRQPAGKGLEWIGRIFSSGSTAYSPSLKSRVIISADTSKNQFSLKLSSVTAADTAVYYCARDSPLKFDSFGYPLYGMDVWGQGTTVTVSS 1009 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYTISWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGIVGATPGYFDYWGQGTLVTVSS 1010 QVQLVQSGAEVKKPGASVKVSCKASGFTFGRHGITWVRQAPGQGLEWMGWISTYSGNTNYAQNLQGRVTMTTDTSTNTAYMELRSLFFDDTAVYYCAKAVSGWPIYFDAWGQGTLVTVSS 1011 QIQLVQSGAEVKKPGASVRVSCKASGFTFGRYGITWVRQVPGQGLEWMGWISTYSGNTNYAQNLQGRVTMTTDTSTNTAYMELRSLFFDDTAMYYCAKAVSGWPIYFDAWGQGTLVTVSS 1012 QITLEESGPTLVKPTQTLTLTCTFSGFSLTTRGEGVAWIRQPPGKALEWLALIYWDDDQRYTPSLDSRLTITKDISKNHVVLTLTDVEPVDTATYFCAHTIHSGYDRTFDSWGQGTLVIVSS 1013 QVQLVQSGSELKKPGASVKVSCKASGYTFTFYTIYWVRQAPGQGLEWMGWINTNTGTPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAEDTAIYYCAREESYSSSSPLDYWGPGTLVAVSS 1014 QMQLVQSGPEVKKPGTSVKVSCKASGFFTSSAVQWVRQARGQRLEWIGWIVVGSGNTNYAQKFQERVTITRDMSTSTAYMELSSLRSEDTAVYYCAAGSDFWSGYYVNYYMDVWGKGTTVTVSS 1015 QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMCVSWIRQPPGKALEWLARIDWDDDKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARLTAAGVYFDYWGQGTLVTVSS 1016 EVQLLESGGGVVQPGGSLRLSCAASGFTFTTYAMNWVRQAPGRGLEWVSAISDSGGSAYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKTRGRGLYDYVWGSKDYWGQGTLVTVSS 1017 EVQLLESGGGVVQPGGSLRLSCAASGFAFTTYAMNWVRQAPGRGLEWVSAISDGGGSAYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKTRGRGLYDYVWGSKDYWGQGTLVTVSS 1018 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTMTTDTSTSTAYMELRRSLRSDDTAVYYCARDESGSYYGDQAFDIWGQGTMVTVSS 1019 QAQLVQSGPEVKKPGASVKVSCEASGYTFSRYGISWVRQAPGQGLEWMGWISGYNGNTTSEQKVQGRVTMTTDTSTNKVFLELRSLRSDDTAMYYCARDRRRARAYEIPFGSDHYYFGMDVWGQGTTVTVSS 1020 QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDYYGSGSYPIGYMDVWGKGTTVTVSS 1021 EVQLVESGGGLAKPGGSLRVSCVVSGSGFTFRNAWMSWVRQAPGKGLEWVGRIKSKNDGGTTDYAASVKGRFTISRDDSKNSLDLQMQSLKTEDTAVYYCTTSYCSTKVCFDYWFDPWGQGTLVTVSS 1022 QVQLVESGGDVVQPGNSLRLSCAASGFTFNFYGMHWVRQAPGKGLEWVAFISYDGNKRYYVDSVRGRFTASRDNSKNTLFLQMNGLRNDDSAVYYCASNLYATSPYGGVKNWGRGTLVAVAS 1023 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDIGSGSPDAFDIWGQGTMVTVSS 1024 GVQLVESGGGLVQPGRSLRLSCAASGFIFDDYTMHWVRQAPTKGLEWVSGITWNYATVGYADSVRGRFTISRDNVKNSLFLQIHSLRPDDTAFYYCVKDLEFRGGTGGFDLWGQGTLVTVSS 1025 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTMTTDTSTSTAYMELRRSLRSDDTAVYYCARDGHSAWGAFDIWGQGTMVTVSS 1026 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTMTTDTSTSTAYMELRRSLRSDDTAVYYCARDHPTLRRAFDYWGQGTLVTVSS 1027 QVELVQSGAQVRKPGASVKVSCKASGDTFNDYHMHWVRQAPGQGLEWMGWINPNSGETRYSQRFQGTVTMTRDTSISTVYMELRRSLPSDDTAVYFCARDRGSSSWWGWLDPWGQGTLVTVSS 1028 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAHKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCATRRGYSGYGAAYYFDYWGQGTLVTVSS 1029 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCAREVYVGGEDDYSYYYGLDVWGQGTTVTVSS 1030 EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVGRIKSKTDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTDLGEAGPTEWLRSSLFDYWGQGTLVTVSS 1031 DIHMAESGGGLVKPGGSLRLSCAVSGLTFTKAWMSWVRQAPGKGPEWVGRIKRSSDGGKIDYAAPVKGRFIISRDDSKNTLYLQMHSLKTEDTALYYCTTSYCNPKVCFDYWFDPWGQGTLVTVSS 1032 EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMSWVRQAPGKGLEWVSVISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEYYYDSSGYYYREDAFDIWGQGTMVTVSS 1033 EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMTWVRQAPGKGLEWVSGISANGRSPYYADSVKGRFTISRDNSKNTMYVQMNSLRVEDTAVYYCAKDGGLTAYLEYWGLGTLVTVSA 1034 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATEKWEVVDVCFDYWGQGTLVTVSS 1035 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDIGWDVVVVAATHGVFDYWGQGTLVTVSS 1036 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYVDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPYYYGSGSSNFFDYWGQGTLVTVSS 1037 QVQLVESGGGVVQPGWSLRLSCAASGFTFSSFAMYWVRQAPGKGLEWVAVISYDGANKYYADSVKGRFTISRDNSKNTLYLQVNSLRVEDTAVYYCARGPDYYDTGGYFDLWGRGTLVTVSS 1038 QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAVMWHDGSNKYHSDSVKGRFTISRDNSKNTLYLQMKTLRADDTAVYYCARDGYKQIYWYLDLWGRGTLVTVSS 1039 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGEGVYGSGSRYFLDYWGQGTLVTVSS 1040 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYATHWVRQAPGKGLEWVAVISYDGSNKYHADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREWSRGAVAGTGYFDYWGQGTLVTVSS 1041 EVQLVESGGGLVQPGRSLRLSCAASGFTFHDYAMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKVAKLPGDYYGMDVWGQGTTVTVSS 1042 EVQLVESGGGLIQPGGSLRLSCAASGVIVSRNYMNWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARELRGAFDIWGQGTMVTVSS 1043 EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGTTYYADSVKGRFTISRHNSKNTLYLQMNSLRAEDTAVYYCARDWGEYYFDYWGQGTLVTVSS 1044 EVQLVESGGGLIQPGGSLRLSCAASEFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDYGDLYFDYWGQGTLVTVSS 1045 EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRRVGSPYYYYYMDVWGKGTTVTVSS 1046 EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSILYSGGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLGDNAFDIWGQGTMVTVSS 1047 EVQLVESGGGLVQPGGSLRLSCAASGITVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRITISRDNSKNTLYLQMNSLRAEDTAVYYCARDRYSGYDFWGQGTLVTVSS 1048 EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLSGTGYGGDGGWFDPWGQGTLVTVSS 1049 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMHWVRQAPGKGLVWVSRIKSDGSSTSYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCAGKKIYYGSSFDPWGQGTLVTVSS 1050 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGYYWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGGSGSGWYGGRFDYWGQGTLVTVSS 1051 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGYYWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARVWRETYYYDSSGDSFDYWGQGTLVTVSS 1052 QVQLQQWGAGLLKPSETLSRTCAVYGGSFSGYYWTWIRQSPGKRLEWIGEISHGGKTNYNIFFEGRVTLSVDSSKSQFSLTLASVTAADTAIYYCARGRSITGIRDVDFWGQGALVTVSS 1053 QVQLHQWGAGLLKPSETLSLTCAVSGGSFSDDFWNWIRQPPGKGLEWIGEINHSGTTNYNPSLKSRITMSVDTSKSQFSLKLNSVTAADSAMYFCARGRGNYMFRWFDPWGQGTLVTVSS 1054 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGGLWYDSINYYGMDVWGQGTTVTVSS 1055 EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARLILRWPTTWDYFDYWGQGTLVTVSS 1056 QVQLVQSGTEVKEPGSSVKVSCKASGDTFSNYPIAWVREAPGQGLEWMGRIIPIVGFANYAQKFQGRVTITADKSTSTAYMELSSLRFEDTAVYYCARVDGPFDYWGQGTLVTVSS 1057 QVQLVESGGGVVQPGRSLRLSCAASGFTFSTSAMHWVRQAPGKGLEWVAGISYDGSNEHLDSVKGRFTISRDNSKNTLYLQMSSLRPEDTAVYYCARCPFWNYGHCYLDNWGQGTLVTVSS 1058 QVQLVESGGGVVQPGGSLRLSCAASGFTFSTYAMHWLRQAPGRGLEWVAVISYDGSNKYNADSVKGRFTISRDNSKNTLSLHMNSLRPEDTAVYYCARPSVRWYYHAMDVWGQGTTVTVTS 1059 EMQLLESGGGLVQPGGSLRLSCAASGFTFFSYALSWVRQAPGKGLEWVSGISGISDSGGNTYYADSVKGRFTISRDNSQNMLYLQMNSLRVEDTAVYYCAKERRPVLRYFDWLPIEAPDYWGPGTLVTVSS 1060 EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMNWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTLSRDNSKNTLYLQMNSLRAEDTAVYYCARGQYDILTGYQYGAFDIWGQGTMVTVSS 1061 QVQLQESGPGLVKPSQTLSLTCTVSAGSISSDTYYWSWIRQPAGKGLEWIGRIYTTGSTIYNPSLNSRVLISADTSNNQFSLKLTSVTASDTAVYYCAAHYYSRTDAFHIWGQGTMVTVSS 1062 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTMTTDTSTSTAYMELRRSLRSDDTAVYYCARDSVSGSGSYYKGLWFDPWGQGTLVTVSS 1063 QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWMRQAPGQGLEWMGIINPSGGSTSYAHQFQGRVTMTRDTSTSTVYMEMSSLRSEDTAVYFCVVGIGYSSSPSCPPLRWFDYWGQGTLVTVSS 1064 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYTISWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARERGYSGSGSLYYFDYWGQGTLVTVSS 1065 QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDDDKRYSPSLKSRLTITKDTSKNQVVLTMTNMDPVDTATYYCAHYSSSRPPLFDYWGQGTLVTVSS 1066 EAQLLESGGGLVQPGGSLRLSCAVSGFTVSSYDMSWVRQAPGKRLEWVSFISARGSVTYYADSVRGRFTISRDNFKNTLYVEMNNLRVEDTAVYYCAKGHWSTWGQGTLVTVSS 1067 QVQLVESGGGVVQPGRSLRLSCAASGFTFRNYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKSTLYLQMNSLRAEDTAVYYCANGAYYYGSGSYYNGAAYWGQGTLVTVSS 1068 QVQLVESGGGVVQPGKSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISNYGSNKYHADSVKGRITISRDNSKNTLYLQMNSLRAEDTAVYYCAKGGYYDILTGYFPFDYWGQGTLVTVSS 1069 EVQLVESGGGLIQPGGSLRLSCAASGFTVSRNYMSWVRQAPGKGLEWVSLIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNTLRSEDTAVYYCARDLVVYGMDVWGQGTTVTVSS 1070 EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPIRNNGMDVWGQGTTVTVSS 1071 EVQLVESGGGLVQPGGSLRLSCAASGFTVSRNYMSWVRQAPGKGLEWVSVIYSGGTTHYADSVKGRFTISRHNSKNTLYLQMNSLRAEDTAVYYCARDLVVYGMDVWGQGTTVTVSS 1072 EVQLVESGGGLIQPGGSLRLSCAASGLTVSSNYMTWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRHNSKNTLYLQMNSLRAEDTAVYYCARDAMSYGMDVWGQGTTVTVSS 1073 EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRVVYGMDVWGQGTTVTVSS 1074 EVQLVESGGGLIQPGGSLRLSCAASGLIVSSNYMSWVRQAPGKGLEWVSVLYAGGSTDYAGSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDAAVYGIDVWGQGTTVTVSS 1075 EVQLVESGGGLVQPGGSLRLSCAASGITVRSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLISRGMDVWGQGTTVTVSS 1076 EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMNWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRVVYGMDVWGQGTTVTVSS 1077 EVQLVESGGGLVQPGGSLRLSCAASGVTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTNYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLVSYGMDVWGQGTTVTVSS 1078 EVQLVESGGGLIQPGGSLRLSCAASGLTVSSNYMNWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNMVYLQMNSLRAEDTAVYYCARDLVVYGMDVWGQGTTVIVSS 1079 EVQLVESGGGLVQPGGSLRLSCAASGFIVSSNYMTWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRHNSKNTLFLQMNSLRAEDTAVYYCARDAQNYGMDVWGQGTTVTVSS 1080 EVQLVESGGGLVQPGGSLRLSCAASEFIVSRNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTGVYYCARDRGLVSDYWGQGTLVTVSS 1081 DIEMTQSPSSLSASVGDRVTITCRASQSIASYAYWYQQKPGKAPKLLISAASILQSGVPSRFSGSGSGGHFTLTINSLQPEDVATYYCQQTYIIPYSFGQGTKLEIK 1082 AIRMTQSPSSFSASTGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISCLQSEDFATYYCQQYYSYPYTFGQGTKLEIK 1083 QSALTQPPSASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYAGSNNLVFGGGTKLTVL 1084 GIQMTQSPSTLSASVGDRVTITCRASQSISDWLAWYQQKPGKIPKLLIYKASTLESGVPSRFSGSGSGTEFTLTISSLQPDDFGTYYCQRYDSYRTFGQGTKVEIK 1085 DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKSPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYTFGQGTKLEIK 1086 DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKVLIYDASNLKTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPLTFGQGTRLEIK 1087 EIVLTQSPGTLLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASHRASGIPDRFSGSGSGTDFLTISRLEPGDFAMYYCQQYATSPWTFGQGTTVEIK 1088 QSVLAQPPSASGTPGQSVTISCSGNNSNIGINNVYWYQQFPGTAPKLLIHRSNQRPSGVPDRFSGSRSGTSASLVISGLRSEDEAEYHCAAWDDSLSSWGFGGGTKLTVL 1089 QLVLTQSPSASASLGASVKLTCTLSSGHSSYAIAWHQQQPEKGPRYLMKLSSDGSHRKGDGIPDRFSGSSSGAERYLTISSLQSEDEADYYCQTWGTGTVVFGGGTKLTVL 1090 SYELTQPPSVSVSPGQTARITCSGDALPKQYAYWYQQKPGQAPVLVIYKDSERPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCQSADSSGTWVFGGGTKLTVL 1091 EIVLTQSPATLSSLSPGERATLSCRASQSISSYLAWYQQKPGQAPRLLIYEAANRATGIADRFSGSGSGTDFTLTISSLEPEDFAIYYCQQRSDWTPTFGQGTKVEIK 1092 AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPRTFGGGTKVEIK 1093 QSALTQPASVSGSPGQSITISCTATSSDFGTFHLVSWYQQHPGKAPQLMIYEVNKRPSGVSDRFSASKSGNTASLTISGLQPEDEADYYCCSYAGNTTFFGGGTKLTVL 1094 QAVLTQPPSVSAAPGQRVSISCSGSAFNIGTNFVSWYQHLPGAAPKLLIYGDQWRISGTPDRFSGSKSGTSATLAITGLQSGDEAHYYCSTWDASLKEVLFGGGTRLDVL 1095 DVVMTQSPLSLPVTLGQPASISCRSSQSLVYYDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGPGTKVDIK 1096 DIQMTQSPSTLSASVGDSVTITCRPSQSISRWLAWYQQKPGKAPKLLIYKASTLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYDSYPWTFGQGTKVEIK 1097 DIQLTQSPSFLPASVGDRVTITCRASQHISNYVAWYQQKPGKAPKLLIYAASTLESGVPSRFGGSGSGTEFTLTINSLQPEDFATYYCQQLTTYPRTFGQGTKLEIK 1098 SYELTQPPSVSVSPGQTARITCSGDALPKQYAYWYQQKPGQAPVLVIYKDSERPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCQSADSSGTWVFGGGTKLTVL 1099 DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYFCQQFYSTPVTFGPGTKVDIK 1100 NFMLTQPHSLSESPGKTVTISCTGSGASIASNYVQWYQQRPGSAPVTVIFEDTQRPSGVPDRFSGSIDRSSNSASLTISGLRTEDEADYYCQSYDGSNVVFGGGTKLTVL 1101 DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPLTFGGGTKVEIK 1102 DIVMIQSPDSLAVSLGERATINCKSSHSVFFSKVNKDYLAWYQQKPGLPPKLLIYWASTRQTGVPDRFSGSGSGTDFSLTISNLQAEDVAVYYCQQYYDTPMYTFGQGTKLEIK 1103 DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYPYTFGQGTKLEIK 1104 QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTFVFGTGTKVTVL 1105 SYELTQPPSVSVSPGQTARITCSGDALPKQYAYWYQQKPGQAPVLVIYKDSERPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCQSADSSGTYSNWVFGGGTKLTVL 1106 QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTVVFGGGTKLTVL 1107 EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIK 1108 EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIK 1109 DFQMTQSPSSLSASVGDRVTISCQASEDIDNHLNWYQQKPGKAPRLLIYDASNLETGVPSRFSGSGSGTDFFLFTITSLQPEDFATYYCQQYGAFGQGTKVEIK 1110 EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK 1111 QSVLTQPPSASGTPGQRVTISCSGSRSNIGSKNVHWYQQLPGTAPKFLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAVWDDSLNGVVFGGGTKLTVL 1112 QSALTQPPSASGSPGQSVTISCTGTSSDVGSYHYVSWYQQHPGKAPKLIIYEVSKRPSGVPDRFSGSKSGNTASLTVSGLQTDDEADYYCSSFAGSNNPYVFGTGTKVTVL 1113 DIVMTQSPDSLAVSLGERATINCRSSQSVLYSANNKYYLAWYQHKPGQPPKLLIHWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAIYYCQQYYSTPYTFGQGTKLEIK 1114 EIVMTQSPATLSVSPGERATLSCRASQSVKSYLAWYQQKAGQAPRLLIYGASSRATGIPARFSGSRSGTEFTLTISSLQSEDFAVYFCHQYDSWPPTFGGGTKVEIK 1115 DVVLTQSPATLSSLSPGERATLSCRASKDINSYLAWYQQKPGQAPRLLIYDASKRATGVPVRFSGSGSGTDFTLTISSLEPEDSAIYFCQNRDDWPPLFTFGPGTKVDFK 1116 DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPRTFGQGTKLEIK 1117 DMQMTQSPSSVSASVGDRVTITCRASQDISSSLAWYQQKPGKPPKLLIYAASSLQRGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAHSFLSLTFGGGTKVEIK 1118 SCELTQPPSVVSPGQTARITCSGDALSNQYTYWYQQRPGQAPLLVIYKGTKRPSAIPERFSGSRSGTTVTLTISGVQAEDEADYYCQSADTSGTYLWVFGGGTKLTVL 1119 DIQMTQSPSSLSASVGDRVTITCQASQDISNFLNWYQQKPGKAPELLIYDASNLETGVPSRISGSGSGTDFTFTISSLQPEDIATYYCQQYDSLPITFGQGTRLEIK 1120 DIQMTQSPSSLSAVLGDRVTITCRASQAISNSLAWYQQKPGKAPKLLLYAASRLESGVPSRFSGSGSGTDYTLTISSLRPEDFATYYCQQYYGIPTFGQGTRLENK 1121 DVQMTQSPSSLSASVGDRVTITCQASRDIHNLLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTITGLQPEDVATYYCQKCDNFPWTFGQGTKVEIK 1122 QSVLTQSPSASGTPGQRVTISCSGSNSNIGSNYVFWYHQLPGTTPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSVVVFGGGTKLTVL 1123 DIHMTQSPSSLSASEGDRVTISCRASQGISTNYLNWYQQKSGKAPRLLIYATSTLQSGVSSRFSGSGSGTDFLTLTINSVQPEDFATYYCQQSYSSPPTFGGGTKLDIK 1124 QSVLTQPPSVSGAPGQRVTISCTGIGARYNVHWYQQVPGTAPKLLIYRNTNRPSGVPDRFSGSKSDTSASLAITGLQAEDEADYYCQSYDDTLTIFGGGTKLTVL 1125 DIQMTQSPSSLSASVGDRVTITCRASQSISNHFNWYQHRPQKAPKLLIYSASNLQSGVPSRFSGSGSGRNFTLTISSLQPEDFATYYCQQSYGAPPTFGGGTKVEIK 1126 DIQMTQSPSSLSASEGDRVTITCRANQSISTNYLNWYQQQSGKAPKLLIYASSTLQSGVPTRFSGSGSGTDFALTINSLQPEDFAAYYCQQSYSTPPTFGGGTRVDLR 1127 DIQMTQSPSSLSASEGDRVTILCRASQSISTNYLNWYQQKSGKAPKLLIYSTSNLQSGVPSRFSGSGSGTDFTLTIDSLQGEDFATYYCQQSFSTPPTFGGGTKVDIK 1128 DIQMTQSPSSLSASEGDRVTITCRANQSISTNYLNWYQQKSGKAPNLLIYATSSLERGVPSRFSGSGSGTEFSLTINSLQPEDFVTYYCQQSYSSPPTFGGGTKVEIKRMEIK 1129 SYELTQPPSVSVSPGQTARITCSGDALPKKYAYWYQQKSGQAPVLVIYEDSKRPSGIPERFSGSSSGTMATLTISGAQVEDEADYYCYSTDSSGNHWVFGGGTKLTVL 1130 QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGHYPYWFQQKPGQGPRTLIYDINNKYSWTPARFSGSLLGGKAALTLFGAQPEDEADYYCLLSYSGVRIFGGGTKLTVL 1131 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSSSKVFGGGTKLTVL 1132 SYELTQPPSVVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDSKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTFYVFGTGTKVTVL 1133 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSSAVVFGGGTKLTVL 1134 EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPWTFGQGTKVEIK 1135 QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGHYPYWFQQKPGQAPRTLIYDTSNKHSWTPARFSGSLLGGKAALTLSGAQPEDEAEYYCLLSYSGARPVFGGGTKLTVL 1136 DIQMTQSPSSLSASSVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPYTFGQGTKLEIK 1137 QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVVFGGGTKLTVL 1138 DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPITFGQGTRLEIK 1139 EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIK 1140 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSSVVVFGGGTKLTVL 1141 QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTFAVFGGGTQLTVL 1142 DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPLTFGGGTKVEIK 1143 DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTVFTFGPGTKVDIK 1144 DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTVFTFGPGTKVDIK 1145 DIEMTQSPSSLSASVGDRVTITCRASQSIASYAYWYQQKPGKAPKLLISAASILQSGVPSRFSGSGSGGHFTLTINSLQPEDVATYYCQQTYIIPYSFGQGTKLEIK 1146 AIRMTQSPSSFSASTGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISCLQSEDFATYYCQQYYSYPYTFGQGTKLEIK 1147 SYVLTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL 1148 SYELTQPPPSVSVSPGQTASITCSRDKLGDEYACWYQQKPGQSPILVIYQNNKRPAGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTSYVVFGGGTKLTVL 1149 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRLSGIPDRFSGSKSGTSATLDITGLQTGDEADYYCGTWDSSSLSVGVFGGGTKLTVL 1150 QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCNSYTSNSTAVFGGGTKLTVL 1151 EVVLTQSPATLSASPGERATLSCRASLSINTDLAWYQQRPGQPPRLLIYGASTRATGIPARFSGSGSGTEFTLTVSSLQSEDFALYYCQQSYNWPRTFGQGTRVEIK 1152 DIQMTQSPSAMSASVGDRVTITCRASQGMSNYLAWFQQKPGKVPKRLIYAASSLASGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPYTFGQGTKLEIK 1153 DIQMTQSPSTLSAPVGDRVTITCRASQSINSWLAWYQQKPGKAPKLLIYKASNLESGVSSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNGYPHTFGQGTKLEIK 1154 DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASNLESGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQYSYYSAFGQGTQVEFK 1155 EIVLTQSPGTLSLPGERASLSCRASQTVSSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTITRLEPEDFAVYYCQQYGTFGQGTKLEIK 1156 QAGLTQPPSVSKGLRQTATLTCTGTSSNVGNQGAAWLQQHQGHPPKLLSYRNNDNRPSGISERLSASRSGNTASLTITGLQPEDEADYYCSAWDSSSAWVFGGGTKLTVL 1157 DIVMTQSPDSLAVSLGERATINCKSSQSVLYNSNNKDYLAWYQQKPGQPPKLLFSWASTRQSGVPARFSGGGSGTDFTLTISSLQAEDVAVYYCQQYYSTPITFGGGTKVEIK 1158 DFVLTQPHSVSESPGKTVTISCTRSSGSIASYFVHWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLIISGLKTEDEADYYCQSFDDNDQVFGGGTKLTVL 1159 QTVVTQEPSFSVSPGGTVTLTCGLTSGSVSTTYYPSWYQQTPGQPPRTLIYSTNIRSSGVPDRFSGSILGNKAALTITGAQADDESNYYCLLYVGGGIWVFGGGTKLTVL 1160 EIVMTQSPATLAVSPGERATLSCRASQSVSDNLAWYQQRPGQPPRLLIYAASTRATGIPPRFSGSGSGTEFTLTIASLQSEDFALYYCQQYNIWLTFGGGTKVEIK 1161 AVVMTQSPLSLPVTLGQPASISCRSSQSLVHSDGNTYLNWFQQRPGQSPRRLIYKVSDRDSGVPDRFSGSGSGTDFTLKINRVEAEDVGVYYCMQGTLLLTFGGGTKVEIK 1162 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGVPDRFSGSKSGTSATLGITGLQTGDEADYYCETWDSSLDAVIFGGGTKLTVL 1163 QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNYVYWYQQLPGTAPKVLIYRNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSGRVFGGGTKLTVL 1164 DVVVTQSPLSLSVTLGQPASISCRSSQSLVHSDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEADDVGVYYCMQGTHWPHPTFGQGTRVEIK 1165 AVVVTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLQISKVEAEDVGVYYCMQGTPWPTFGQGTKVEIK 1166 EIVLTQSPGTLSLPGERATLSCRASQSVRSNYLAWYQLKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQSGSSYTFGQGTKLEIK 1167 AIVMTQSPLSLPVTPGEPASISCRSSQSLRQSQRFSYLDWYVQKPGQSPQLLIYLNSRRAPGVPDRFSASGSGTDFTLKISRVEAEDVGVYYCMQSLPSGFTFGPGTNVHIK 1168 DIVMTQAPLSLSVTPGQPASISCKSSQSLLHSIGKTHLYWYLQKPGQPPQLLIYEVSNRFSGVPERVSGSGSGTDFLTISRVEAEDVGVYYCMQSLDLPPTFGQGTKVDIK 1169 DIQMTQSPSFVSASVGDRVTITCRASHDIRTWLSWYQQKPGKAPKLLIYTAFRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQGSSFPLTFGGGTTVDIR 1170 DIQMTQSPSSLSASVGDSVTVTCRASQDIGNWLAWYQLKPEKAPRSLIFAASILRSGVPSRFSGSGSGTEFTLTISSLQPEDFGVFYCQQYDSSPITFGQGTRLEIK 1171 SSQLTQDPAVSVALGQTVRITCQGDSLETYYATWYQQKPGQAPLLVIYGKNSRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDSSGQLHVVVFGGGTKLTVL 1172 SSELTQDPAVSVALGQTVRITCQGDSLRTSYASWYQQKPGQAPMLVIYEKNNRPSGVPDRFSGSTSFNTASLTITGAQAEDEAEYYCNSRDNNDDLPLFGGGTRLTVL 1173 QSALTQPPSASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYAGSNNLGVFGTGTKVTVL 1174 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSSLSGVVFGGGTKLTVL 1175 DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPFTFGPGTKVDIK 1176 DVVMTQSPLSLPVTLGQPASISCRSSQSLVHSDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPITFGQGTRLEIK 1177 QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLVVFGGGTKLTVL 1178 DIQMTQSPSSLSASSVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYTFGQGTKLEIK 1179 QSALTQPRSVSGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSYVVFGGGTKLTVL 1180 DIQMTQSPSSLSASSVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLHTFGQGTKVEIK 1181 SSELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDSSGNHLVFGGGTKLTVL 1182 SYELTQPPSVSVSPGQTATITCSGDELGDTDIAWYQQKPGQSPVLVILQDTKRPSGIPERFSGSNSGTTATLTIGGTQAMDEAEYYCQAWDTITHEEVFGGGTKLTVL 1183 DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNYYPVAFGQGTKVEIK 1184 DIVMTQTPLSSPVTLGQPASISCRSSQSLVHSDGNTYLSWLQQRPGQPPRLLIYKISNRFSGVPDRFSGSGAGTDFTLKISRVEAEDVGVYYCTQATQFPLTFGGGTKVEIK 1185 DIQMTQSPSSLSASSVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDLATYYCQQSYSTPPYTFGQGTKLEIK 1186 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGIAPKLLIYGNNNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSSSLSPVVFGGGTKLTVL 1187 QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYRNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLSGPVFGGGTKLTVL 1188 SSELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDSSGNHLVFGGGTKLTVL 1189 DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPYTFGQGTKLEIK 1190 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSSLAGVFGGGTKLTVL 1191 EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPWTFGQGTKVEIK 1192 SYELTQPPSVVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDSKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTYVVFGGGTKLTVL 1193 DIQMTQSPSSLSASEGDRVTITCRASQSISTNYLNWYQQKSGRAPTLLIYATSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSSPPTFGGGTTVDVK 1194 DIQMTQSPSSVYASEGDRVTITCRASHSISTNYLNWYQQNSGKAPKLLIYATSSLQSGVPFRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSSSPPTFGGGTKVEIK 1195 DIQMTQSPSSLSASEGDRVTISCRASQTISTNYLNWYQQKSGKAPRLLIYATSTLESGVPSRFSGSGSGTDFTLTINTLQPDDFATYYCQQSYSSPPTFGGGTKVDIK 1196 EIVLTQSPATLSSLSPGERAALSCRASQTINSGYLAWYQQKPGQAPRLLIYAASHRATGIPNRFSGSGSATDFLTITRLEPEDVAVYYCHHYGTSPPFTFGPGTKVDIK 1197 EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIK 1198 SYELTQPPPSVSVSPGQTARITCSGDALPKQYAYWYQQKPGQAPVLVIYKDSERPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCQSADSSGTYYVFGTGTKVTVL 1199 DIQMTQSPSSLSASSVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPRTFGQGTKVEIK 1200 SYELTQPPSVVSPGQTASISCSGDKLGDTYASWYQQKPGQSPVLVMYQDNKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTVVFGGGTKLTVL 1201 DIVMTQTPLSLSVTPGQPASISCKSSQSLLHSDGKTYLYWYLQKPGQSPQLLIYEVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQSIQLPLTFGGGTKVEIK 1202 DIVMTQTPLSLSVTPGQPASISCKSSQSLLHSDGKTYLYWYLQKPGQSPQLLIYEVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQSIQLPFTFGQGTRLEIK 1203 DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTYTFGQGTKLEIK 1204 SYELTQPPSVSVSPGQTARITCSGDALPKKYAYWYQQKSGQAPVLVIYEDSKRPSGIPERFSGSSSGTMATLTISGAQVEDEADYYCYSTDSSGNHRRVFGGGTKLTVL 1205 QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKWPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLVFGGGTKLTVL 1206 SYELTQPPSVSVSPGQTARITCSGDALPKKYAYWYQQKSGQAPVLVIYEDSKRPSGIPERFSGSSSGTMATLTISGAQVEDEADYYCYSTDSSGNHRGVFGGGTKLTVL 1207 DIQMTQSPDTLSASVGDRVTITCRASESISNWLAWYQKKVGQAPNLLIDKASNLHRGVPSRFSGSGSGTEFTLTITSLQPDDSASYYCQQYNSFPYTFGQGTTLEIK 1208 EIVLTQSPATLSSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPVTFGQGTKVEIK 1209 DIQMTQSPSSLSASSVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIK 1210 DIQMTQSPSSLSASVGDRVTITCRASQGIGNDLGWFQQKPGKAPKRLIYGASNLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPFTFGGGTKVEIK 1211 ETVLTQSPGTLLSPGERATLSCRASQSVSGSYLAWYQQKPGQAPRLLIYGASRRATGIADRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGTSAGTFGQGTKVEIK 1212 EIVLTQSPGTLSLPGERGTLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGNLPPFTFGPGTKVDIK 1213 DIVVTQSPDSLAVSLGERATINCKSSQSLLYNFNNENYLGWYQQKPGQPPKLLIYWASTRESGVPDRFNGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPLTFGGGTKVEIK 1214 GIVMTQSPLSLSVTPGQPASISCKSSQSLLDSDGKTYMCWYLQKPGQPPQLLIYEVSNRFSGVPERFSGSGSGTDFTLKISRVETEDVGVYYCMQNRHLYTFGQGTKLEIK 1215 GIVMTQSPLSLSVTPGQPASISCKSSQSLLDSDGKTYMCWYLQKPGQPPQLLIYEVSNRFSGVPERFSGSGSGTDFTLKISRVEAEDVGVYYCMQNRHLYTFGQGTKLEIK 1216 NIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQTLQTSITFGQGTRLEIK 1217 EIVLTQSPGTLSLPGERATLSCRASQSVSTYLAWYQQRPGQAPRLLIYGSSSRAAGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSQYSFGQGTKLEIK 1218 EIVLTQSPGTLSLPGERATLSCRASQSVSSYLAWYQQRPGQAPRLLIYGASSRAAGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSQYTFGQGTKLEIK 1219 DIQMTQSPSSLSASVGDRVTITCQASQDSSKYLNWYQQKPGKAPKLLIYDASTLETGVPSRFSGSGSGTDFTFTISGLQPEDVATYYCQHYDTLLTFGPGTKVEIK 1220 DIVMTQSPDSLAVSLGERATINCKSSQSVSFTSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVALYLCQQYFDTPWTFGQGTKVEIK 1221 GIVMTQSPLSLSVTPGQPASISCKSSQSLLDSDGKTYLCWYLQKPGQPPQLLIYEVSNRFSGVPERFSGSGSGTDFTLKISRVEAEDVGVYYCMQNRQLYTFGQGTKLEIK 1222 DIQMTQSPSSLSASVGDRVTITCQASQDISTYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQFDNLPPFTFGPGTRVHIT 1223 DIQMTQSPSSLSASVGDRVTITCRASQSISNYLNWYQQKPGRAPKVLIYGASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSARMSTFGQGTKLEIK 1224 DVVMTQSPLSLPVTLGQPASISCRSSQSVVHSDGKTYLNWYHQRPGQSPRRLIYEVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTQWPWTFGQGTKVEIK 1225 EIVLTQSPGTLSLPSPGERATLSCRASHTISSSYLAWYQQKAGQAPRLLIYAASSRATGIPARFSGSGSGTDFLTISRLEPEDFAVYYCQQFDNSPPWTFGRGTKVEMR 1226 SYELTQPPSVSVSPGQTARITCSGDALPKQYAYWYQQKPGQAPVLVIYKDSERPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCQSADSSGTYVVFGGGTKLTVL 1227 QSALTQPRSVSGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSYTLVFGGGTKLTVL 1228 DIQMTQSPSSLSASVGDRVTITCRASQSISNYLNWYQQKPGKAPKLLIYAASGLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPFTFGPGTKVDIK 1229 DVVMTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHSYTFGQGTKLEIK 1230 SYELTQPPSVVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDSKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTASYVFGTGTKVTVL 1231 QSALTQPASVSGSPGQAITISCTGTSSDVGGHDYVSWYQQHPGKVPKLVVYDVTNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSASTVVFGGGTKLTVL 1232 QSALTQPASVSGSPGQAITISCTGTSSDVGGHDYVSWYQQHPGKVPKLVVYDVTNRPSGISNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSASTVVFGGGTKLTVL 1233 DVVMTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHSPWTFGQGTKVEIK 1234 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYHCGTWDSSSLAWVFGGGTKLTVL 1235 SYELTQPPPSVSVSPGQTASITCSGDALPKQYGYWYQQKPGQAPVMVIYKDNERPSGIPERFSGSSSGTTVTLTISGAQAEDEADYYCQSADGRGDWVFGGGTKLTVL 1236 EIVLTQSPGTLSLPGERATLSCRASQSVSTYLAWYQQRPGQAPRLLIYGSSSRAAGIPDRFSGSGSGTDFLTISRLEPEDFAVYFCQQYGSSQYSFGQGTKLDIK 1237 DIQMTQSPSTLSASIGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYETSSLEPGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYDSYSGTFGQGTKVEIK 1238 QPVLTQSSSASASLGSSVKLTCTLSVGHDYFTIAWHQQQPGKAPRFLMKLEGSGSYYKGSGVPDRFSGSSSGADRYLIISNLQSEDEADYFCETWDSPYVVFGGGTKLTVL 1239 DIQMTQYPSLSASVGDTVTITCQASQDSNTYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISGLQPEDIATYYCQHYDSLLTFGPGTKVDIK 1240 QSALTQPASVSGSPGQSITISCNGTNSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDDADYYCSSYTSSSTVVFGGGTKLTVL 1241 DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTLTFGPGTKVDIK 1242 DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYPLFTFGPGTKVDIK 1243 DVVLTQSPLSLPVTLGQPASISCRSSQSLIYSDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCMQGTHWPMTFGQGTKVEIK 1244 EIVLTQSPGTLLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPMYTFGQGTKLEIK 1245 DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPAFGGGTKVEIK 1246 SYEVTQSPSVSVSPGQTASITCSGDKLGDKYACWYQQRPGQSPVLVIYQDSKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSHTVVFGGGTKLTVL 1247 DIQMTQSPSTLSASVGDRVTITCRASQSISTWLAWYQQRPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYSWTFGQGTKVEIK 1248 ETMMTQSPVALSVSPGDRATLSCEASQYVGDNLAWYQQKPGQAPRLLIYGAFTRATGVPARFSASGSGAGFTLTISSLQSEDFAVYYCQQYTSWPLTFGGGTKVEIK 1249 ETMMTQSPVALSVSPGDRATLSCKASQYIGDNLAWYQQKPGQTPRLLIYGASTRATGVPARFSASGSGAGFTLTISSLQSEDFAVYYCQQYTSWPLTFGGGTKVEIK 1250 SYELTQPPSVSVSPGQTARITCSGDALPKKYAYWYQQKSGQAPVLVIYEDSKRPSGIPERFSGSSSGTMATLTISGAQVEDEADYYCYSPKVFGGGTKLTVL 1251 DIQMTQSPSSLSASVGDRVTVACQASQDVSIYLNWYQQKPGRAPKLLIYDAYNLQTGVPSRFSGSGSGTHFTLTISSLQPEDVATYHCQQYNILPHTFGGGTKVELT 1252 DIVMTQSPDSLAVSLGERATIKCKSSQSVYDSSNSKNYLAWFQQKPGQPPQLLIFWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYNAPLSFGGGTKVEIK 1253 DIVMTQSPDSLPVSLGERATIKCKSSQSVYDTSNSKNYLAWFQQKPGQPPQLLIFWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYNAPLSFGGGTKVEIK 1254 EIVLTQSPATLSSLSPGERATLSCRASQSVSTYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWITFGQGTRLEIK 1255 EIVLTQSPATLSSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWITFGQGTRLEIK 1256 QSVLTQPPSASGTPGQGVTISCSGGSSNIGAYTVSWYQQLPGTAPKLLIYSTDQRPSGVPDRFSGSKSGTSASLAVTGLQSEDEADYYCAAWDDSLNGPVFGGGTKLTVL 1257 EIVLTQSPGTLSLPGERATLSCRASQSVSSIYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPQTFGQGTKLEIK 1258 EIVMTQSPATLSVSPGERATLSCRASQSVTSYLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPLTFGGGTKVEIK 1259 DIQMTQSPSTLSASVGDRVTITCRASQSITNWLAWYQQRPGKAPKLLLSKASSLESGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQYYSYSLTFGGGTKVESK 1260 QSALTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQHPGKAPKLMIYEVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSTFYVFGTGTKVTVL 1261 SYELTQPPSVSVSPGQTARITCSGDALPKQYAYWYQQKTGQAPVLVIYKDSERPSGIPERVSGSSSGTTVTLTISGVQAEDEADYYCQSADSSGTWVFGGGTKLTVL 1262 EIVLTQSPGTLSLPGERATLSCRASQSVSSRYLAWYQQKPGQAPRLLIYGASRRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPEMYTFGQGTKLEIK 1263 EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCHQYGSGLGTFGPGTKVDIK 1264 DIVMTQTPLSLSVTPGQPASISCKSSQSLLDSDGKTYLYWYLQKPGQTPQLLIYEVSDRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQSIQLRTFGQGTKVEIK 1265 EIVLTQSPATLSSLSPGERATLSCRASQRVGSSLAWYQQKPGQAPRLLIYGASNRATGIPARFSGSGSGTDFTLTITRLEPEDFAVYYCQQCSSWPLSLTFGGGTKVEIR 1266 EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPITFGQGTRLDIK 1267 DIQMTQSPSSVSASVGDRVTITCRASQGIRFWLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNSFPPTFGGGTKVEIK 1268 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNTNRPSGVPDRFSGSKSGTSPSLAITGLQAEDEAGYYCQSYDISLSAYVFGGGTKLTVL 1269 DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTEFTLTISLLPAFATYYCQQYNTYSLTFGQGTRLEIK 1270 AIQLTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLNSYPPAFGGGTKVEIK 1271 EIVMTQSPDSLAVSLGERATINCKSSQSVLYSASNKNYLAWYQQKQGQSPKLLIYWASTRESGVPDRFSGSGSGTDFLTLTINGLQAEDVAVYYCQQYYRTPLTFGGGTKVEIK 1272 DIQMTQSPSAMSASVGDRVTITCRASQDISNYLAWFQQRPGKVPKRLIYAASSLQSGVPSRFSGTGSGTEFTLTISSLQPEDFATYYCLQHHTYPLTFGGGTKVEIR 1273 EIVLTQTPLSLSVTPGQPASISCKSSHSLLHSDGKTYVYWYLQRPGQPPQLLIYELFNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGTYYCMQSIQLWSFGQGTKVEIK 1274 QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGHYPYWFQQKPGQAPRTLIYDTNNKHSWTPARFSGSLLGGKAALTLSGAQPEDEAEYYCLLSYSGPWVFGGGTKLTVL 1275 QSALTQPPSASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYAGSNNYVFGTGTKVTVL 1276 DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPSFTFGPGTKVDIK 1277 QSALTQPRSVSGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVNKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSYTLVFGGGTKLSVL 1278 QSALTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQHPGKAPKLMIYEVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSTVVFGGGTKLTVL 1279 DIQMTQSPSSLSASVGDRVTISCRASQSIGKYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFLTINNLQPEDFATYYCQQSYNVPPWTFGQGTKVEIK 1280 DVVMTQSPVSLTVTLGQPASISCRPSQSIEHSDGNIYLNWFQQRPGQSPRRLIYKISNRDSGVPDRISGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPWTFGQGTKVEIK 1281 QSVLTQPPSVSGAPGQRVIIPCTGSSSNTGAGYDVHWYQQLPGTAPKLVIYDNSHRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDINLSAVFGGGTKLTVL 1282 EIVLTQSPGTLSLSPGERATLSCRATQSLTSSSLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLKPEDFAVYYCHQYHNSPWTFGQGTKVEIK 1283 DFVMTQSPLSLPVTPGEPASISCRSSQSLLHGNGYTYLDWYLQKPGQSPQLLIYLGSTRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFGQGTKLEIK 1284 SYVLTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHYVFGTGTKVTVL 1285 EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPRTFGQGTKVEIK 1286 QIVMTQSPATLSVSPGGGATLSCRASQSVSSKVAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDSAVYYCQQYDNWLPYTFGQGTKLEIK 1287 QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGHYPYWFQQKPGQAPRTLIYDTSNKHSWTPARFSGSLLGGKAALTLSGAQPEDEAEYYCLLSYSGAYVLFGGGTKLTVL 1288 EIVMTQSPAILSVSPGERATLSCRASQSVTRNLAWYQQKPGQAPRLLIYGASTRATNIPARFSGSGFGTEFTLIISSLQSEDFAVYYCQQYSNWPLYTFGQGTKLEIK 1289 QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGPYVFGTGTKVTVL 1290 QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQHHPGKAPKLMIYEVSNRPSGVSNRFSGSKSANTASLTISGLQTEDEADYYCSSYTSISTVLFGGGTKLTVL 1291 SDALTQPPSVSVAPGKTAAITCGGDNIGSKNVHWYQQKPGQAPLLVVFDDGDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDGGSDDRGYVFGTGTKVTVL 1292 QSALTQPASVSGSPGQSITISCTGTSSDVGAYNYVSWYQQHPGKAPKLMIYDVTKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSFTSNGAWVFGGGTKVTVL 1293 DIQMTQSPSSLSASVGDRVTITCRASQSISNYLNWYQQKPGKAPKFLIYAASTLHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQNYIRPYTFGQGTKLEIK 1294 DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPITFGGGTKVEIK 1295 QSVLTQPPSTSGAPGQRVTISCSGSSSNVALNAVSWYQQLPRMAPKLLIYRDNQRPSGVPERFSGSRSGTSASLAITGLQSDDEADYYCATWDDSLNGVFGGGTKLTVL 1296 EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASSRATGIPARFSGSGSGTEFTLTISSLQSEDFGVYYCQQYNNWPYTFGQGTKLEIK 1297 QPVLTQPPSASASLGASVTLTCTLSSGYSNYKVDWYQQRPGKGPRFVMRVGTGGIVGSKGDGIPDRFSVLGSGLNRYLTIKNIQEEDESDYHCGADHGSGSNFVYVFGTGTKVTVL 1298 QSALTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQHPGKAPKLMIYEVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSTLVFGGGTKVTVL 1299 DIKMTQSPSTLSASVGDRVTITCRASQHINRWLAWYQQKPGKAPKLLIYEASSLKSGVPSRFSGSGSGTEFTLTITSLQLDDFATYSCQQHDSAPYTFGQGTKLEIK 1300 DIQMTQSPSTLSASLGDRVMITCRASQNISRWLAWYQQKPGKAPKFLIYKASALETGVPSRFSGSGSGTEFTLTITGLQPDDFATYYCQQYNSYVTFGGGTKVEMK 1301 DIVMTQTPLSLSVTPGQPASISCKSSQSLLHSDGKTYLYWFLLKPGQSPQFLIYEVSSRFSGVPDRFRGSGSGTDFTLKISRVEAEDVGVYYCMQGKHLRWTFGQGTKVEIK 1302 SYELAQPPSVSVSPGQTARITCSGDALPIKYAYWYQQKSGQAPVLVISEDSKRPSGIPERFSGSSSGTMATLTISGAQVEDEADYYCYSTDYSGNHGVFGGGTKLTVV 1303 EIVLTQSPATLSLSPGERATLSCRASQSVSTYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQCSNWPNTFGQGTKLEIK 1304 SYELTQPPSVVSPGQTARITCSGDELPKQYSYWFQQRPGQAPVLVIYKDRERPSGIPERFSGSHSGTTVTLTISGVQAEDEADYYCQSADSNDSWVFGGGTKLTVL 1305 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSSLAGVFGGGTKLTVL 1306 GIQLTQSPSSVSASLGDTVTITCRASQNINVFLAWYQQRPGSAPSLLIYAASNLQSGVPSRFVGSGSGTDFTLTISGLQPEDFATYYCQQGHNFPWTFGRGTKVEVK 1307 EIVLTQSPGTLSLSPGDRATLSCRASQSLNNNQLAWYQQKLGQAPRLLIYGASSRATGIPDKISGSGSGTVFTLTISRLEPEDFAVYYCQQYGSLPLTFGGGTKVEIK 1308 EIVLTQSPGTLSLSPGDRATLSCRASQSLNNNQLAWYQQKLGQAPRLLIYGASSRATGIPDKISGSGSGTVFTLTISRLEPEDFAVYYCQQYGSLPLTFGGGTKVEIK 1309 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSSLSGWVFGGGTKLTVL 1310 EIVLTQSPATLSSLSPGERATLSCRASQSISSHLGWYQQKPGQAPRLLIYDASNRAPGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRRNWPLTFGGGTKVEIK 1311 EIVLTQSPATLSSLSPGEGATLSCRASQSVASYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHRSNWPYTFGQGTKLEIK 1312 QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGVVFGGGTKLTVL 1313 DIVMTQTPLSSPVILGQSASISCRSSHSLLHNNGNTYLSWLHQRPGQPPRLLIYEISNRFSGVPDRFSGSGAGTDFTLKISRVEAEDVGIYYCMQTTQFPRTFGQGTKVEIR 1314 SYELTQPPPSVSVSPGQTAKITCSGDALPKEFAYWYQQKPGQAPVLIIYKDKERPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCQSQDSSATYVVFGGGTKLTVL 1315 SSDLTQPPSVSVPGQTASIACSGDKLGDKYVSWYQQKPRQSPVLVIYQDNKRPSGIPERFAGSNSGNTATLTISGTQTMDEADYYCQAWDSSIEVFGTGTKVTVL 1316 EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPPWTFGQGTKVEIK 1317 SYELTQPPPSVSVSPGQTARITCSADALSKQYAYWYQQKPGQAPVLVIYKDSERPSGIPERFSGSNSGTTVTLTISGVQAEDEAEYYCQSGDSSGTYVVFGGGTKLTVL 1318 DIVMTQTPLSSPVILGQSASISCRSSQSLLHNNNGNTYLSWLHQRPGQPPRLLIYEISNRFSGVPDRFSGSGAGTDFTLKISRVEAEDVGIYYCMQTTQFPRTFGQGTKVEIR 1319 DIQMTQSPSAMSASVGDRVTITCRASQGIRNSLAWFQQKPGKVPKRLIYDASNLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQYNTYSYSFGQGTKLEIK 1320 DIQMTQSPSILSASVGDRVTITCRASQNISRWLAWYQQKPGKAPKFLIYKASGLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYITFGGGTKIEIK 1321 DIQMTQSPSTLSASVGDRVIITCRASQNISRWLAWYQQKPGTAPKFLIYKASALESGVPSRFSGSGSGTEFTLTITSLQPDDFATYYCQQYNSYVTFGGGTKVEMK 1322 SYELTQPPSVSVSPGQTARITCSGDALPQRYAYWYQQKSGQAPVLVIYEDTKRPSGIPERFSGFSLGTLATLTISGAQVEDEADYYCYSTDSSDNQRVFGGGTKLTVL 1323 AIQLTQSPSSLSASVGDRVTITCRASQGVASYLAWYQQKPGKAPNLLIYAASTLQGGVPSRFSGSGSGTDFLTISNLQPEDFATYYCQHLKSYPLTFGGGTKVEIK 1324 DIQMTQSPPSVSASIGDTVTITCRATQNINVFLAWYQQKPGSAPTLLIYGASSLQSGVPSRFVGSGSGTDFTLTISGLQPEDFATYYCQQGHNFPWTFGRGTKVEVK 1325 DIQMTQSPSSVSASIGDTVTITCRATQNINVFLAWYQQKPGSAPTLLIYGASSLQSGVPSRFVGSGSGTDFTLTISGLQPEDFATYYCQQGHNFPWTFGRGTKVEVK 1326 EIVMTQSPATLSVSPGERATLSCRASQSLNSNLAWYQQKPGQAPRLVIYGASTRAAGFPARFSGSGSETEFTLTISSLQSEDFAIYFCQQYHNFPLTFGQGTEVEVR 1327 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQLLPGTAPKLLIYGNNNRPSGVPDRFSGSKSGTSASLAIIGLQAEDEATYYCQSYDSSSLSVVFGGGTKVTVL 1328 SYELTQPPSVSVSPGQTAIITCSGDKLGEKYASWYQQRPGQSPMLVIYQDTKRPSGIPERFSGSNSGNTATLTISGTQAVDEADYFCQAWDSNTGVFGTGTKVTVL 1329 QSVLTQPPSLSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGDSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSSLSGSVFGGGTKLTVL 1330 SYELTQPPSVSVSPGQTARISCSADALPKQNAYWYQCKPGQAPILLIYKDTERPSGIPERFSGSSSGTTVTLTISGVQPEDDADYYCQSVDNTGASPHVVFGGGTKLTVL 1331 DIQMTQSPSTLSASVGDSVTITCRANETIASWVAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSESGTEFTLTISSLQPDDFATYYCQQYHTYWTFGQGTKVEVK 1332 SYELTQPPSVVSPGQTASIACSGDKLGDKYTCWYQQKPGQSPVLVMYQDSKRPSGIPERFSGSNSGNTATLTISGTQVMDEADYYCQAWDSGTVVFGGGTKLTVL 1333 EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPRTFGQGTKVEIK 1334 EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPRTFGQGTKVEIK 1335 DIVLTQSPGTLSLPGERATLSCRASQSISSSYLAWYQQKPGQAPRLVIHGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQHYGTSPYTFGQGTKLEIK 1336 EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSTLVTFGQGTKVEIK 1337 QSALTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQHPGKAPKLMIYEVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSLWVFGGGTKLTVL 1338 NFMLTQPHSVSESPGKTVTISCTGSSGSIASNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSFWVFGGGTKLTVL 1339 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSSAVVFGGGTKLTVL 1340 SYELTQPPSVSVSPGQTARITCSGDALPEKYAYWFQQKSGQAPVLVIYEDNKRPSGIPERFSGSSSGTMATLTISGAQVEDEADYYCYSTDRSGNHRGVFGTGTKVTVL 1341 SSELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDSSGNHLYWVFGGGTKLTVL 1342 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSSLSGHVVFGGGTKLTVL 1343 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSSLAGGVFGTGTKVTVL 1344 QSALTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQHPGKAPKLMIYEGSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSTFVVFGGGTKLTVL 1345 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQFPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSSAVVFGGGTKLTVL 1346 AIQLTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLNSYPPTFGQGTKVEIK 1347 DIQMTQSPSSLSASSVGDRVTITCRASQSIRFYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLWTFGQGTKVEIK 1348 EIVLTQSPGTLSLPGERATLSCRASQSVSSTYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGGGSGTDFLTISRLEPEDFAVYYCQQYGDSPETFGQGTKVEIK 1349 SYELTQPPSVVSPGQTASITCSGDKLGDNYASWYQQKSGQSPVLVIYQDTKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTVVFGGGTKLTVL 1350 DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPYTFGQGTKLEIK 1351 DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPYTFGQGTKLEIK 1352 EIVLTQSPATLSSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPSITFGQGTRLEIK 1353 DIQMTQSPSSVSASVGDRVTITCRASQGISNWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPLAFGGGTKVEIK 1354 DIQMTQSPSSLSASSVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPFGFGPGTKVDIK 1355 QSVLTQPPSVSGAPGQRVTISCTGSRSNIGAGFDVHWYQQLPGTAPKLLIYGNNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEAVYYCLSYDSSSLSGSVFGGGTKLTVL 1356 AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKVLIYDASSLESGVPPRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNNYPLTFGGGTKVEIK 1357 DIQMTQSPSSLSASVGDRVTITCQASQDMSNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPFTFGPGTKVDIK 1358 QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSAYVFGTGTKVTVL 1359 SSELTQDPAVSVALGQTVRITCQGDSLRSYSASWYQQKPGQAPVLVIYVKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDSSGNHVVFGGGTRLTVL 1360 QSALTQPRSVSGSPGQSVTISCTGTSSDVGDYDYVSWYQHHPGKAPKLMIYDVSKRPSGVPDRFSGSKSGNTASLTISGLQAEDDADYYCCSYAGSYPVVFGGGTKLTVL 1361 QSALTQPPSASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYAGSNKVFGGGTKLTVL 1362 EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSGGYTFGQGTKLEIK 1363 DIQMTQSPSSLSASSVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYTFGQGTKLEIK 1364 EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSSWTFGQGTKVEIK 1365 DIQMTQSPSSLSASSVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYTFGQGTKLEIK 1366 SYELTQPPSVVSPGQTASITCSGDKLGNKYACWYQQKPGQSPVLVIYQDSKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTANWVFGGGTKLTVL 1367 QSALTQPASVSGSPGQSITISCTATSGDVGGYNYVSWYQQHPGKAPKLMIFDVYNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSFTDSSTLVVFGGGTKLTVL 1368 DIQMTQSPSSLSASVRDKVTITCRASQSISSCLNWYQQKPGKAPKVLIYAASSLQSGVPSRFSGSGSGTDFLTISSVQPEDFATYYCQQSYSVPHTFGQGTKVEIK 1369 EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWLTFGGGTKVEIK 1370 EIVMTQSPATLSVSPGERVTLSCRASQSINRNLAWYQQKPGQAPRLLVYDASTRAPGIPTRVSGSGSGTDFTLTISSLQSEDFAVYYCQQYNNWPPITFGQGTRLEIQ 1371 EIVMTQSPATLSVSPGERVTLSCRASQSVNRNLAWYQQKPGQAPRLLVYDASTRAPGIPTRVRGSGSGTDFTLTISSLQSEDFAVYYCQQYNNWPPITFGQGTRLEIQ 1372 QTALTQPPSASGSPGQSVTISCTGSSGDVGGYNYVSWYQQYPGKAPKLILSEVSQRPSGVPDRFFGSKSGNTASLTVFGLQAEDEADYYCSSYAGTNKILFGGGTKLTVL 1373 DIQMTQSPSSLSASVGDRVTITCRASQSISSFLNWFQQKPGKAPKLLIYAASSLQGGVPSRFSGSGSGTDFTLTINSLQPEDFATYYCQQSYSTPLTFGGGTKVEIK 1374 QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTWVFGGGTKLTVL 1375 DIQMTQSPSSLSASSVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYTFGQGTKLEIK 1376 DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPGTFGQGTRLEIK 1377 DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPGTFGQGTRLEIK 1378 DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYSAFGQGTKLEIK 1379 PYDLTQPPSVVSPGQTATITCSGDKLGKKYACWYQQKPGQSPVLLIYQDVKRPSGIPERFSGSNSGTTATTLTISETQTMDEADYYCQAWDRTTATFGGGTRLTVL 1380 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSSLSGWVFGGGTKLTVL 1381 QSALTQPASVSGSPGQSITISCTGTTFDVGVYDFVSWYQQLPGKAPKLIIHDDTHRPSGVSDRFSGSRSGTTASLTISGLQADDEADYYCSSYTSLNTLEVVFGGGTKLTVL 1382 DIVMTQSPLSLPVTPGEPASMSCKSTQSLLHSNGNYYVTWYLQKPGQSPHLLIYLASNRASGVPDRFSGSGSGTDFTLKISSVEEAEDVGVYYCMQALQTPYSFGQGTKLEIK 1383 SYVLTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDRTVVFGGGTKLTVL 1384 QSVLTQPPSASGTPGQRVTISCSGSSSNIGNNYVYWYQHLPGTAPKLLIYRNNQRPSGVPDRFSGSKSGTSASLAISGLRSENEADYYCASWDDKVRGWVFGGGTKLTVL 1385 EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK 1386 DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYSRTFGQGTKVEIK 1387 DIQMTQSPSTLSASVGDRVTITCRASQSISDWLAWYQQKPGKAPKLLIYKASTLEGGVPSRFSGSESGTEFTLTISSLQPDDFATYYCQQYNTSPLTFGGGTKVEIK 1388 QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSSLSGSLFGGGTKLTVL 1389 SYELTQPPSVSVSPGQTARITCSGDALPKQYAYWYQQKPGQAPVLVIYKDSERPSGIPERFSGSSSGTTVTLTISGVQAEDEADYYCQSADSSGTYRVFGGGTKLTVL 1390 EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGRTFGQGTKVEIK 1391 QSALTQPASVAGSPGQTITISCTGPNSDINSYDYVSWYQQRPGKAPKLIIHDDVDHRPSGVSDRFSGFMSDNTASLTISGLQAEDEAHYYCSSYTNIDTLEIVFGAGTKLTVL 1392 DIQMTQSPSAMSASVGDRVTITCRASQGISNYLAWFQQKPGKVPKRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPRTFGQGTKVEIK 1393 SYELTQPPSVSVAPGKAASITCGGINIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVESGDEADYYCQVWHSSFDPWVFGGGTKLTVL 1394 DIQMTQSPSSLSASSVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTTFGPGTKVDIK 1395 DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYFPTFGQGTKVEIK 1396 SYVLTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDNDRPSGIPDRFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHYWVFGGGTKLTVL 1397 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSSLAGVFGGGTKLTVL 1398 QLVVTQSPSASASLGASVKLTCTLSSGHSSYVIAWHQQQPEKGPRFLMKLNSDGSHNKGDGIPDRFSGSSSGAERYLTISNLQSEDEADYYCQTWGTGPQVLFGGGTKLTVL 1399 DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGRAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLLTFGGGTKVEIK 1400 SYVLTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSGDHWVFGGGTKLTVL 1401 EIVLTQSPATLSSLSPGERATLSCRASQSVSNYLAWYQQKPGQVPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWLTFGGGTKVEIK 1402 DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLISDASLLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQHDNLPSFTFGPGTKVDIK 1403 EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPRTFGQGTKVEIK 1404 EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQTPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPRTFGQGTKVEIK 1405 QTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGYYPNWFQQKPGQAPRALIYSTSNKHSWTPARFSGSLLGGKAALTLSGVQPEDEAEYYCLLYYGGAPVFGGGTKLTVL 1406 DIQLTQSPSSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPPAFGQGTKVEIK 1407 DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPQTFGPGTKVDIK 1408 QSALTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQHPGKAPKLMIYEVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSLWVFGGGTKLTVL 1409 NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGSIDSSSSNSASLTISGLKTEDEADYYCQSYDSSNQVFGGGTKLTVL 1410 EIVLTQSPATLSSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWLFTFGPGTKVDIK 1411 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSSLAGVFGGGTKLTVL 1412 VIVLTQTPLSSPVTLGQPASISCRSRRSLVHTNGNTYLSWLHQRPGQTPRLLIHNVSNRFSGVPDRFSGSGAGTDFTLNISRVEADDVGIYYCMQASQFPLTFGGGTKLEIK 1413 QSALTQPASVSGSPGQSITISCTGTFSDIGNYDLVSWYQQHPGKAPKVIIYEGYKRPSGVSDRFSGSKSGNTASLTISGLQAEDEADYFCCSFAGSNREFGGGTKLTVL 1414 EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK 1415 QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSSLAWVFGGGTKLTVL 1416 EIVLTQSPGTLSLPGERATLSCRASQSVSNYLAWYQHKPGQAPRLLIYGASNGATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQHYSSSAPITFGQGTRLEIK 1417 EIVLTQSPATLSSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIFDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRNKWPGTFGQGTKVEIK 1418 ETVLTQSPGTLSLPGERATLSCRASQSVNSNYLAWYQQKPGQAPRLLIYGASSRATGIPDNFSGSGSGTDFLTISRLEPEDFAVYYCQQYGDSPYTFGQGTNLEIK 1419 AIQLTQSPSSLSASVGDRVTITCRASQGISSSLAWYQQKPGKAPKLLIYSASTLQSGVPSRFSGSGSGTDFTLTITSLQPEDFATYYCQQLNSYPLTFGGGTKVEIK 1420 QSALTQPASVSGSPGQSITISCTGTSSDVGTYNLVSWYQQHPGKAPKLMIYEVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCTYAGSSTWVFGGGTKLTVL 1421 DIQMTQSPSSLSASVGDRVTITCRASQSIAKFLNWYQKKPGKAPNLLISTASSFQSGVPSRFSGSGSGTDYTLTISGLQPEDFATYYCQQSYSSPYTFGQGTNLEIK 1422 DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGIPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPRTFGQGTKVEIK 1423 AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKVLIYDASGLQSGVPSRFSGGGSGTDFTLTISSLQPEDFATYYCQQFNDYPLTFGGGTKVEIK 1424 QSVLTQPPSVSGAPGQRVTISCTGSNSNIGAGYDVHWYQQLPGTAPKLLIYVNTNRPSGVPDRFSGSKSGTSASLAITGLQAEDEAHYYCQSYDSSSLSGSVFGGGTKLTVL 1425 DIQMTQSPSTLSASVGDRVTITCRASQIISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYSTYYTFGQGTKLEIK 1426 DVVLTQSPLSLPVTLGQPASISCRSSHSLVYSDGYTHLHWIQERPGQSPRRLIYSVSHRDSGVPDRFSGSGSATDFTLQISRVEAEDVGVYYCMQGSHWPWTFGQGTKVEIK 1427 QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGPWVFGGGTKLTVL 1428 QSALTQPRSVSGSPGQSVTISCTGTSSDVGGYNYVSWYQQYPGKAPKLMIYEVSKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSYTWVFGTGTKVTVL 1429 DIQLTQSPSSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQVGVPSRFSGSGSGTEFTLTISSLQPEDFATYFCQQLNSYPFTFGPGTKVDIK 1430 DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPRTFGQGTKVEIK 1431 DIQLTQSPSSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSSFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPLTFGGGTKVEIK 1432 DIQMTQSPSSLSASSVGDRVTITCRASQSISNFLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTGFTLTISSLQPEDFATYYCQQSYSTPPDTFGQGTRLEIK 1433 DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPPTFGGGTKVEIK 1434 DIQMTQSPSSLSASSVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYTTPLFTFGPGTKVDIK 1435 DIQLTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLNGYPHSAFGPGTKVDIK 1436 DIQMTQSPSSLSASVGDRVTITCQASQDIINYLNWYQQKPGKAPKLLIYGASNLETGVPSRFSGGGSGTDFTFTISSLQPEDIATYYCHQYDNLPPTFGQGTRLEIK 1437 DIQLTQSPSSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPLTFGGGTKVEIK 1438 DIQLTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQQLNSNPPITFGPGTKVDIK 1439 DIQMTQSPSSLSASSVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIFAASSLQTGAPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPYTFGQGTKLEIK 1440 DIQMTQSPSSLSASVGDRVTITCQASQDINKYLNWYQQKPGKAPKLLIFDASHLETGVPSRFSASGSGTDFTFTISSLQPEDIATYYCHQYDNLPRTFGQGTRLEIK 1441 GGSFSDYY 1442 GGSFSDYF 1443 GITVSSNY 1444 GYTFTSYA 1445 ITHSGST 1446 INHSGST 1447 IYSGGST 1448 INTNTGNP 1449 QSVSTY 1450 QSVSSY 1451 QGISSY 1452 QSISSW 1453 DAS 1454 DAS 1455 AAS 1456 KAS 1457 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 1458 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 1459 RVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNF 1460 1461 GFTFSSYG 1462 GFTFSSYG 1463 GYSFTSYW 1464 GYSFTSYW 1465 GYSFTSYW 1466 GYSFTSYW 1467 GYSFTSYW 1468 GGSINRNHF 1469 GGSINRNHF 1470 GYTFTSYG 1471 GFTFSYFE 1472 GFTFSYFE 1473 GYKFSNYY 1474 GYIFTNFY 1475 GFNFSSYA 1476 GIIVSRNE 1477 GGTF STYA 1478 GFTFSSYG 1479 GFTFNNYA 1480 GFVFSNYW 1481 GGSISSGGYY 1482 GYNFNNYW 1483 GYTFTSYA 1484 GYTLELS 1485 GFTFSSYG 1486 GFTFSSYP 1487 GGSISSGGYY 1488 GGSISSGGYY 1489 GFTVSSNY 1490 GGSISSYY 1491 GYTFTGYF 1492 GFTASSNY 1493 GGTFSSYG 1494 GGRFGSFA 1495 GFTFTDYA 1496 GGSISSYY 1497 GYTFTDYY 1498 GYSFTGHY 1499 GFTFSNYG 1500 GGSIS SDVYS 1501 GDTFNSYA 1502 GFTFS HYG 1503 GYSFPAHW 1504 GYNFDTYW 1505 GYSFSGYW 1506 GYYFAAHW 1507 GYSFPAFW 1508 GYSFPAYW 1509 GYTLELS 1510 GYTFTRYW 1511 GFTFSSYS 1512 GFTFSSYS 1513 GGSISSSSSYY 1514 GFSLSTSGVG 1515 GFTFSNAW 1516 GFTFSSYE 1517 GFTFSSYE 1518 GGSISSSSSYY 1519 GGSISSGGYY 1520 GGSISRSRSYY 1521 GFSLSNARMG 1522 GFSLSTSGVG 1523 GFTISPYG 1524 GFTISPYG 1525 GYTFGDYG 1526 GYTFGDYG 1527 GFSLSTSGVG 1528 GGSISTYR 1529 GFTFSNAW 1530 GYIFTNYA 1531 GYAFTSYQ 1532 GFTFGDYA 1533 GASFSSYY 1534 GYSFTKYW 1535 GFTFSSYA 1536 GDSVSSNTVA 1537 GFTFDDYG 1538 GFAFDDFA 1539 GFTVSSTF 1540 GGSIKRRGYY 1541 GGSFSAYY 1542 GGSISSSDYY 1543 GFTFSNAW 1544 GGTF STYA 1545 GLRFTDAW 1546 GFSFSSYA 1547 GFSFSDFA 1548 GFTFTTYG 1549 GFTFRSYS 1550 GDSITSYY 1551 GGSFSGSY 1552 GGSFTDHY 1553 GGSISSSSSYY 1554 GFSLSNARMG 1555 GFTFSSYG 1556 GFTFGDYA 1557 GFTFSGSA 1558 GYSFTSYW 1559 GYTFTSYY 1560 GGTFSSYA 1561 GFTFSNAW 1562 GFTFRSYW 1563 GFTFSTYA 1564 GFTFSSYG 1565 GFTVSSNY 1566 GGPISSGGYY 1567 GGSISSSYYY 1568 GGSISSSSSYY 1569 GFTFSSYS 1570 GYTFTSYG 1571 GFTFSSYW 1572 GGSISSGGYS 1573 GYSFPAHW 1574 GYSFPAFY 1575 GYSFPAHW 1576 GFTFSASA 1577 GGSISSGGYY 1578 GFTFSSYW 1579 GYTFTSYG 1580 GFSLSTSGVS 1581 GFTFSSYG 1582 GFTFSSYA 1583 GFTFSSYE 1584 GFTFSIYA 1585 GFTTFTSYG 1586 GFTFSSYG 1587 GFAFNKYG 1588 GFTFSSYG 1589 GGSISSSSSYY 1590 GGAITTSSYF 1591 GFTFSAYG 1592 GFTFNNYG 1593 GGSINSYY 1594 GFTFSRFG 1595 GFTFSRFG 1596 GFTFSSFW 1597 GGTFSSYT 1598 GGSFSSYT 1599 EFSLDSRGVG 1600 GGSISSYY 1601 GFTFSRYG 1602 GFPFSGYA 1603 GFTFINYD 1604 GFAFDKFW 1605 GGSINRDGHY 1606 GGSISSYY 1607 GGSVSSGSYF 1608 GYTFTSYG 1609 GYTFTGYY 1610 GYTLELS 1611 GYRFTSYG 1612 GYRFTSYG 1613 GYTFTSYA 1614 GYTFTSYY 1615 GYTFTNYY 1616 GGTFSSYT 1617 GGTFNSYA 1618 GYTFSSD 1619 EFSLDARGVG 1620 GFTFISYA 1621 GFTFSSYA 1622 GFTFSSYG 1623 GFTFSSHG 1624 GFTFSSYA 1625 GFTFSSYA 1626 GFTFSTYG 1627 GFTFSTFA 1628 GFIFGDYA 1629 GFIFGDYA 1630 GFTFSSYW 1631 GASISSGDYY 1632 GGVLSDYY 1633 GGVLSDYY 1634 GGSFSDYY 1635 GGSFSDYF 1636 GDSISSNNW 1637 GGSISSYY 1638 GDSISSYY 1639 GGSISGYY 1640 GGSISSGSYY 1641 DDSISSGSYY 1642 GYSFTSYW 1643 GYSFTSYW 1644 GYTFTSYA 1645 GYTF SFYW 1646 GGAFSSGRHY 1647 GGSFSSYY 1648 GYTLELS 1649 GFTFSDYY 1650 GITVSSNY 1651 GFTFSRFW 1652 GFTFSNYW 1653 AFSFHLHG 1654 GFTFSSYA 1655 GF FDDYG 1656 GFTVSSNY 1657 GGSIGSSSYF 1658 GGSISSSSSYY 1659 GFTFSSYD 1660 GFTFSRSA 1661 GFTFSSQS 1662 GFTF EYS 1663 GYTFGRYW 1664 GYTFSTYY 1665 GGTFSSYA 1666 GATFTTYA 1667 GFTLS SYA 1668 GFTFSNYD 1669 GFTFDDYA 1670 GFTFDDYA 1671 GFTFDDYA 1672 GFTFSSYT 1673 TFIFSNSE 1674 GFTVSSNY 1675 GGSFSGYF 1676 GGSFSGYY 1677 GGSLSSYY 1678 GGSISTFY 1679 GGSVSSYF 1680 GFSFNTPGVG 1681 GFSFSNHG 1682 GFTFSNSA 1683 EFTFSSYE 1684 GYTFTNFA 1685 GYTFTSYG 1686 GFSFSRYG 1687 GFNFNSYT 1688 GFNFNSYT 1689 GFTFSSYE 1690 GYIFTSYG 1691 GYSFNDYG 1692 GYTLELS 1693 GNTFSTYY 1694 GFTFSDVW 1695 GLTFDNAW 1696 RFTFSSYA 1697 GFTFDDYA 1698 GNTFTTYY 1699 GGTFNSYT 1700 GFSLNTPGAG 1701 GFSFNTPGVG 1702 GFTTFSDYY 1703 GFTFSDYY 1704 GFSFSRYG 1705 GLSFSRYG 1706 GFSFNNFG 1707 GFTLS SYA 1708 GFTFSSYE 1709 GFTFSSYA 1710 GGSISPYS 1711 GDSIRSSFY 1712 GYSFTTYA 1713 GGTFSSYA 1714 GGTFSSYA 1715 GFTFSHAW 1716 GFTFSSYE 1717 GFTVSSNY 1718 GGSISSYY 1719 GYTFTTYG 1720 GYTFTNYG 1721 GYTLELS 1722 GYTLELS 1723 GYTLELS 1724 GYTLELS 1725 GYTFTSYA 1726 GGTFSSYA 1727 GFSLSNARMG 1728 GFSLSTTGVG 1729 GFSLSTSGVG 1730 GFTFSSYS 1731 GFTFSSYS 1732 GFTFSSYA 1733 GFTFSSYA 1734 GFTFSSYA 1735 GFTFGSYG 1736 GFTFSSYA 1737 GFTFSIYA 1738 GFTVSSNY 1739 GFTFSNYW 1740 GGSFSGYY 1741 DGSFSGHY 1742 GGSFSGYY 1743 GGSISSYY 1744 GGSISSYY 1745 GYNFTSYW 1746 GYTFTSYA 1747 GFTVSSNY 1748 GGSISSGLYH 1749 GGTFSSYT 1750 GFTFGRHG 1751 GFTFGRYG 1752 GFSLTTRGEG 1753 GYTFTFYT 1754 GFTFTSSA 1755 GFSLSTSGMC 1756 GFTFTTYA 1757 GFAFTTYA 1758 GYTFTSYG 1759 GYTF SRYG 1760 GYTFTGYY 1761 GSGFTFRNAW 1762 GFTFNFYG 1763 GFTFDDYA 1764 GF FDDYT 1765 GYTFTSYG 1766 GYTFTSYG 1767 GDTFNDYH 1768 GGTFSSYA 1769 GGTFSSYA 1770 GFTFSNAW 1771 GLTFTKAW 1772 GFTFSTYA 1773 GFTFSNYA 1774 GFTFSSYA 1775 GFTFSSYG 1776 GFTFSSYG 1777 GFTFSSFA 1778 GFTFSNYG 1779 GFTFSSYG 1780 GFTFSSYA 1781 GFTFHDYA 1782 GVIVSRNY 1783 GFTVSSNY 1784 EFTVSSNY 1785 GFTVSSNY 1786 GFTVSSNY 1787 GITVSSNY 1788 GFTVSSNY 1789 GFTFSSYW 1790 GGSISSGGYY 1791 GGSISSGGYY 1792 GGSFSGYY 1793 GGSFSDDF 1794 GGSISSYY 1795 GYSFTSYW 1796 GDTFSNYP 1797 GFTFSTSA 1798 GFTFSTYA 1799 GFTFFSYA 1800 GFTVSSNY 1801 AGSISSDTYY 1802 GYTFTSYG 1803 GYTFTNYY 1804 GGTFSSYT 1805 GFSLSTSGVG 1806 GFTVSSYD 1807 GFTFRNYG 1808 GFTFSSYG 1809 GFTVSRNY 1810 GFTVSSNY 1811 GFTVSRNY 1812 GLTVSSNY 1813 GFTVSSNY 1814 GLIVSSNY 1815 GIT R S NY 1816 GFTVSSNY 1817 GVTVSSNY 1818 GLTVSSNY 1819 GFIVSSNY 1820 EFI VSRNY 1821 IWYDGSNK 1822 IWYDGSNK 1823 IDPSDSYT 1824 IDPSDSYT 1825 IDPSDSYT 1826 IDPSDSYT 1827 IDPSDSYT 1828 ASYTGTT 1829 ASYTGTT 1830 ISAYNGNT 1831 ISSSGTNI 1832 ISSSGTNI 1833 INPYS GET 1834 VNPNDGSS 1835 ISATGGTT 1836 ISSSGTGV 1837 IIPIFGTP 1838 ISYDGSNK 1839 ISSYGDNT 1840 IKQDESEE 1841 IYYSGST 1842 IYGGDSDT 1843 INTNTGNP 1844 FDPEDGET 1845 ISYDGSNK 1846 ISYDGSNK 1847 IYYSGST 1848 IYYSGST 1849 LYSGGNE 1850 IYYSGST 1851 INPSSGVA 1852 IYAGGGT 1853 ILPVLDTT 1854 VTPIVGVP 1855 ISYDGNDK 1856 IYYSGST 1857 VNPNRGGT 1858 INPDSGGT 1859 ITGSGGST 1860 VFHTGSA 1861 IIPI RLA 1862 IWYDGSKK 1863 IFPGDSDT 1864 IYPGDSDS 1865 IFPSDSDT 1866 IFPSDSDT 1867 VFPGDSDT 1868 IFPGDSDT 1869 FDPEDGET 1870 MKPGDGKT 1871 ISSSSSYI 1872 ISSSSSTI 1873 IYYSGST 1874 wxya 1875 IKSKTDGGTT 1876 ISSSGSTI 1877 ISSSGSTI 1878 IYYSGST 1879 IYYSGST 1880 IYYSGST 1881 IFSNDEK 1882 wxya 1883 IWYDGSNK 1884 IWYDGSNK 1885 ISGYNGDP 1886 ISGYNGDP 1887 wxya 1888 IYYSGRT 1889 IKRIIDGGTI 1890 TNTNTGNP 1891 INPSGSAT 1892 ITWNSGNI 1893 ISQSAST 1894 IYPDDSET 1895 ISGSGDKT 1896 TYYRSNWYN 1897 ISWNSNSV 1898 INWNSDNI 1899 IYTVGDT 1900 IYYSGTT 1901 INRRGNT 1902 IYYSGNT 1903 IKSKTDGGTT 1904 IIPSLRTA 1905 IKSRGSGGTI 1906 ISYDGRNK 1907 VSYDSRQQ 1908 IWYDGSNE 1909 LSNDDRTR 1910 IYSSGDT 1911 INPSGGS 1912 INHSGRT 1913 IYYSGST 1914 IFSNDEK 1915 ISYDGSNK 1916 IRSKAYGGTT 1917 IRSKANSYAT 1918 IDPSDSYT 1919 INPSGGST 1920 IIPIFHIA 1921 IKSKTDGGTT 1922 IFSDWSTT 1923 ISGSGGST 1924 ISYDGSNK 1925 IYSGSST 1926 IYYSGST 1927 IYYSGST 1928 IYYSGST 1929 ISSSSSYI 1930 ISAYNGNT 1931 INSDGSST 1932 IYHSGST 1933 IFPSDSDT 1934 IFPGDSET 1935 IFPGDSDT 1936 IRTRTNRYAT 1937 IYYSGST 1938 INSDGSST 1939 ISAYNGNT 1940 wxya 1941 ISYDGSNK 1942 ISYDGSNK 1943 ISSSGSTI 1944 ISGSGGST 1945 ISFDGSNI 1946 ISYDGSNK 1947 IWNDGNKQ 1948 IWYDGSNK 1949 IFYSGST 1950 ISYSGDT 1951 ISFDGSNK 1952 ISYEGSIR 1953 IYSGGST 1954 ISYEGSTE 1955 ISYEGSTE 1956 IKED GSEK 1957 IIPMLNKT 1958 IIPMLNKT 1959 IYWNDNK 1960 IYYRGST 1961 ISYEGSTE 1962 ISSSSSTV 1963 ISSSSSTT 1964 LNKDESEK 1965 IYSGRNT 1966 IYYSGST 1967 IYYSGST 1968 ISAYNGNT 1969 INPNSGGT 1970 FDPEDGET 1971 INTDNEKT 1972 INTDNGKT 1973 INAGNGNT 1974 INPSGGST 1975 INPSDGST 1976 IIPMLNKT 1977 IIPIFGPP 1978 MNPNTGTT 1979 IYWNDYK 1980 ISGSGGST 1981 ISGSGGTT 1982 ISYDGSNK 1983 ISYDGINK 1984 ISYDGSNK 1985 ISYDGSNK 1986 MWFDGVDK 1987 ISYDEINK 1988 IRGRLVGATV 1989 IRGRLVGATV 1990 IKQDGSEK 1991 IYYSGST 1992 IHRSGST 1993 IHRSGST 1994 ITHSGST 1995 INHSGST 1996 IYHSGTT 1997 IYTSGST 1998 IYHSGSA 1999 LHYSGRS 2000 IYTSGST 2001 IYAGEST 2002 IYPGDSDT 2003 IYPGDSDT 2004 INTNTGNP 2005 IYPGDFDT 2006 IYSGVIT 2007 VTHSGST 2008 FDPEDGET 2009 ISSSGSTI 2010 IYSGGST 2011 IKED GSVM 2012 IKSDGSET 2013 IWFDGSKK 2014 ISSSGGGT 2015 ITWNSGSI 2016 IYSGGST 2017 IYYGGST 2018 IYYSGST 2019 IGTAGDT 2020 MSYDGSDI 2021 ISYDGNNK 2022 VSWNSGTI 2023 INPADSDT 2024 INPSGDST 2025 IIPIFGTA 2026 IFPIFTAA 2027 VSGSGGST 2028 ISSDGNNR 2029 ISWNSGSI 2030 ISWNSGTI 2031 ISWNSEKI 2032 INSGSSII 2033 ISSSDNSV 2034 IYSGGST 2035 INHSGKT 2036 INHSGST 2037 MYNSGST 2038 IYYSGRT 2039 IFYTGTS 2040 IYWDDEK 2041 IWYDGDNR 2042 IYYDGSNE 2043 IDSSSTTI 2044 INTKTGIP 2045 ISAYNGNT 2046 ISHDDSQK 2047 ISYEGSKK 2048 ISYEGSKK 2049 ISSSGSTI 2050 INTNTGSP 2051 ISAYNGET 2052 FDPEDGET 2053 ISPSGDDA 2054 IRSKSDGGTT 2055 VKSKTDGGTT 2056 ISYDGSNK 2057 ISWDGGST 2058 ISPSGDDA 2059 IVPMLGIT 2060 wxya 2061 IYWDDEK 2062 ISSGGDAI 2063 MSSDSDYI 2064 ISHDESQK 2065 ISHDESQK 2066 ISYEGSKK 2067 ISYDGSNK 2068 ITSSGNTI 2069 ISSSSGTI 2070 IYYTGKT 2071 VYNSGTA 2072 IDTNTGKP 2073 IIPIFGTA 2074 IIPIFGTA 2075 IKSNTDGGTT 2076 ISSSGSTI 2077 IYSGGST 2078 IYYSGST 2079 ISAYNGNT 2080 ISTYSGNT 2081 FDPEDGET 2082 FDPEDGET 2083 FDPEDGET 2084 FDPEDGET 2085 INAGNGNT 2086 IIPIFGTA 2087 IFSNDKK 2088 wxya 2089 IFWDDDK 2090 ISSSSSYI 2091 ISSSSSYI 2092 ISYDGSNK 2093 ISYDGSNK 2094 ISYDGSNK 2095 IWNDGSNK 2096 ISYDGSNK 2097 ISYDGSNK 2098 IYSGGST 2099 IKED GSET 2100 IDHSGST 2101 INHSGST 2102 INHSGST 2103 IYYSGST 2104 IYYSGST 2105 IDPSDSYT 2106 INTNTGNP 2107 VYSGGHA 2108 IFSSGST 2109 IIPILGIA 2110 ISTYSGNT 2111 ISTYSGNT 2112 wxya 2113 INTNTGTP 2114 IVVGSGNT 2115 IDWDDDK 2116 ISDSGGSA 2117 ISDGGGSA 2118 ISAYNGNT 2119 ISGYNGNT 2120 INPNSGGT 2121 IKSKNDGGTT 2122 ISYDGNKR 2123 ISWNSGSI 2124 ITWNYATV 2125 ISAYNGNT 2126 ISAYNGNT 2127 INPNSGET 2128 IIPIFGTA 2129 IIPILGIA 2130 IKSKTDGGTT 2131 IKSRSDGGKI 2132 ISGSGGST 2133 ISANG RSP 2134 ISGSGGST 2135 ISYDGSNK 2136 ISYDGSNK 2137 ISYDGANK 2138 MWHDGSNK 2139 IWYDGSNK 2140 ISYDGSNK 2141 ISWNSGSI 2142 IYSGGST 2143 IYSGGTT 2144 IYSGGST 2145 IYSGGST 2146 LYSGGTT 2147 IYSGGST 2148 IYSGGST 2149 IKSDGSST 2150 IYYSGST 2151 IYYSGST 2152 ISHGGKT 2153 INHSGTT 2154 IYYSGST 2155 IYPGDSDT 2156 IIPIVGFA 2157 ISYDGSN 2158 ISYDGSNK 2159 ISGISDSGGNT 2160 IYSGGST 2161 IYTTGST 2162 ISAYNGNT 2163 INPSGGST 2164 IIPILGIA 2165 wxya 2166 ISARGSVT 2167 ISYDGSNK 2168 ISNYGSNK 2169 IYSGGST 2170 IYSGGST 2171 IYSGGTT 2172 IYSGGST 2173 IYSGGST 2174 LYAGGST 2175 IYSGGST 2176 IYSGGST 2177 IYSGGST 2178 IYSGGST 2179 IYSGGST 2180 IYSGGST 2181 QSIASY 2182 QGISSY 2183 SSDVGGYNY 2184 QSISDW 2185 QSISSY 2186 QDISNY 2187 QSVSSSY 2188 NSNIGINN 2189 SGHSSYA 2190 ALPKQY 2191 QSISSY 2192 QGISSA 2193 SSDFGTFHL 2194 AFNIG TNF 2195 QSLVYYDGNTY 2196 QSISRW 2197 QHISNY 2198 ALPKQY 2199 QSVLYSSNNNKNY 2200 GASIASNY 2201 QSVLYSSNNKNY 2202 HSVFFSKVNKDY 2203 QSISSW 2204 SSDVGGYNY 2205 ALPKQY 2206 SSDVGGYNY 2207 QSVSSSY 2208 QSVSSSY 2209 EDIDNH 2210 QSVSSSY 2211 RSNIGSKN 2212 SSDVGSYHY 2213 QSVLYSANNKYY 2214 QSVKSY 2215 KDINSY 2216 QSVLYSSNNKNY 2217 QDISSS 2218 ALSNQY 2219 QDISNF 2220 QAISNS 2221 RDIHNL 2222 NSNIGSNY 2223 QGISTNY 2224 GARYN 2225 QSISNH 2226 QSISTNY 2227 QSISTNY 2228 QSISTNY 2229 ALPKKY 2230 TGAVTSGHY 2231 SSNIGAGYD 2232 KLGDKY 2233 SSNIGNNY 2234 QSVSSN 2235 TGAVTSGHY 2236 QSISSY 2237 SSDVGGYNY 2238 QSVLYSSNNKNY 2239 QSVSSSY 2240 SSNIGNNY 2241 SSDVGGYNY 2242 QSLLHSNGYNY 2243 QSLLHSNGYNY 2244 QSLLHSNGYNY 2245 QSIASY 2246 QGISSY 2247 NIGSKS 2248 KLGDEY 2249 SSNIGNNY 2250 SSDVGGYNY 2251 LSINTD 2252 QGMSNY 2253 QSINSW 2254 QSISSW 2255 QTVSSTY 2256 SSNVGNQG 2257 QSVLYNSNNKDY 2258 SGSIASYF 2259 SGSVSTTYY 2260 QSVSDN 2261 QSLVHSDGNTY 2262 SSNIGNNY 2263 SSNIGSNY 2264 QSLVHSDGNTY 2265 QSLVYSDGNTY 2266 QSVRSNY 2267 QSLRQSQRFSY 2268 QSLLHSIGKTH 2269 HDIR W 2270 QDIGNW 2271 SLETYY 2272 SLRTSY 2273 SSDVGGYNY 2274 SSNIGAGYD 2275 QSVLYSSNNKNY 2276 QSLVHSDGNTY 2277 SSDVGGYNY 2278 QSISSY 2279 SSDVGGYNY 2280 QSISSY 2281 SLRSYY 2282 ELGDTD 2283 QSISSW 2284 QSLVHSDGNTY 2285 QSISSY 2286 SSNIGAGYD 2287 SSNIGSNY 2288 SLRSYY 2289 QDISNY 2290 SSNIGNNY 2291 QSVSSN 2292 KLGDKY 2293 QSISTNY 2294 HSISTNY 2295 QTISTNY 2296 QTINSGY 2297 QSVSSSY 2298 ALPKQY 2299 QSISSY 2300 KLGDTY 2301 QSLLHSDGKTY 2302 QSLLHSDGKTY 2303 QSLLHSNGYNY 2304 ALPKKY 2305 SSDVGGYNY 2306 ALPKKY 2307 ESIS NW 2308 QSVSSY 2309 QGIRND 2310 QGIGND 2311 QSVSGSY 2312 QSVSSSY 2313 QSLLYNFNNENY 2314 QSLLDSDGKTY 2315 QSLLDSDGKTY 2316 QSLLHSNGYNY 2317 QSVSTY 2318 QSVSSY 2319 QDSSKY 2320 QSVSFTSNNKNY 2321 QSLLDSDGKTY 2322 QDISTY 2323 QSISNY 2324 QSVVHSDGKTY 2325 HTISSSY 2326 ALPKQY 2327 SSDVGGYNY 2328 QSISNY 2329 QSLVYSDGNTY 2330 KLGDKY 2331 SSDVGGHDY 2332 SSDVGGHDY 2333 QSLVYSDGNTY 2334 SSNIGNNY 2335 ALPKQY 2336 QSVSTY 2337 QSISSW 2338 VGHDYFT 2339 QDSNTY 2340 NSDVGGYNY 2341 QSLLHSNGYNY 2342 QSISSW 2343 QSLIYSDGNTY 2344 QSVSSSY 2345 QGISSW 2346 KLGDKY 2347 QSISTW 2348 QYVGDN 2349 QYIGDN 2350 ALPKKY 2351 QDVSIY 2352 QSVYDSSNSKNY 2353 QSVYDTSNSKNY 2354 QSVSTY 2355 QSVSSY 2356 SSNIGAYT 2357 QSVSSIY 2358 QSVTSY 2359 QSITNW 2360 SSDVGSYNL 2361 ALPKQY 2362 QSVSSRY 2363 QSVSSSY 2364 QSLLDSDGKTY 2365 QUR 2366 QSVSSN 2367 QGIRFW 2368 SSNIGAGYD 2369 QSISSW 2370 QGISSY 2371 QSVLYSASNKNY 2372 QDISNY 2373 HSLLHSDGKTY 2374 TGAVTSGHY 2375 SSDVGGYNY 2376 QDISNY 2377 SSDVGGYNY 2378 SSDVGSYNL 2379 QSIGKY 2380 QSIEHSDGNIY 2381 SSNTGAGYD 2382 QSLTSSS 2383 QSLLHGNGYTY 2384 NIGSKS 2385 QSVSSSY 2386 QSVSSK 2387 TGAVTSGHY 2388 QUR 2389 SSNIGSNT 2390 SSDVGGYNY 2391 NIGSKN 2392 SSDVGAYNY 2393 QSISNY 2394 QDISNY 2395 SSNVALNA 2396 QSVSSN 2397 SGYSNYK 2398 SSDVGSYNL 2399 QHINRW 2400 QNISRW 2401 QSLLHSDGKTY 2402 ALPIKY 2403 QSVSTY 2404 ELPKQY 2405 SSNIGNNY 2406 QNINVF 2407 QSLNNNQ 2408 QSLNNNQ 2409 SSNIGAGYD 2410 QSISSH 2411 QSVASY 2412 SSNIGSNT 2413 HSLLHNNGNTY 2414 ALPKEF 2415 KLGDKY 2416 QSVSSSY 2417 ALSKQY 2418 QSLLHNNGNTY 2419 QGIRNS 2420 QNISRW 2421 QNISRW 2422 ALPQRY 2423 QGVASY 2424 QNINVF 2425 QNINVF 2426 QSLNSN 2427 SSNIGAGYD 2428 KLGEKY 2429 SSNIGAGYD 2430 ALPKQN 2431 ETIASW 2432 KLGDKY 2433 QSVSSSY 2434 QSVSSSY 2435 QSISSSY 2436 QSVSSSY 2437 SSDVGSYNL 2438 SGSIASNY 2439 SSNIGNNY 2440 ALPEKY 2441 SLRSYY 2442 SSNIGAGYD 2443 SSNIGNNY 2444 SSDVGSYNL 2445 SSNIGNNY 2446 QGISSY 2447 QSIRFY 2448 QSVSSTY 2449 KLGDNY 2450 QDISNY 2451 QDISNY 2452 QSVSSY 2453 wxya 2454 QSISSY 2455 RSNIGAGFD 2456 QGISSA 2457 QDMSNY 2458 SSDVGGYNY 2459 SLRSYS 2460 SSDVGDYDY 2461 SSDVGGYNY 2462 QSVSSSY 2463 QSISSY 2464 QSVSSSY 2465 QSISSY 2466 KLGNKY 2467 SGDVGGYNY 2468 QSISSC 2469 QSVSSN 2470 QSINRN 2471 QSVNRN 2472 SGDVGGYNY 2473 QSISF 2474 SSDVGGYNY 2475 QSISSY 2476 QSLLHSNGYNY 2477 QSLLHSNGYNY 2478 QSISSW 2479 KLGKKY 2480 SSNIGAGYD 2481 TFDVGVYDF 2482 QSLLHSNGNYY 2483 NIGSKS 2484 SSNIGNNY 2485 QSVSSSY 2486 QSISSW 2487 QSISDW 2488 SSNIGAGYD 2489 ALPKQY 2490 QSVSSSY 2491 NSDINSYDY 2492 QGISNY 2493 NIGSKS 2494 QSISSY 2495 QSISSW 2496 NIGSKS 2497 SSNIGNNY 2498 SGHSSYV 2499 QDISNY 2500 NIGSKS 2501 QSVSNY 2502 QDISNY 2503 QSVSSSY 2504 QSVSSSY 2505 TGAVTSGYY 2506 QGISSY 2507 QDISNY 2508 SSDVGSYNL 2509 SGSIASNY 2510 QSVSSY 2511 SSNIGNNY 2512 RSLVHTNGNTY 2513 FSDIGNYDL 2514 QSVSSSY 2515 SSNIGNNY 2516 QSVSNY 2517 QSVSSY 2518 QSVNSNY 2519 QGISSS 2520 SSDVGTYNL 2521 QSIAKF 2522 QGISSW 2523 QGISSA 2524 NSNIGAGYD 2525 QIISSW 2526 HSLVYSDGYTH 2527 SSNIGSNT 2528 SSDVGGYNY 2529 QGISSY 2530 QDISNY 2531 QGISSY 2532 QSISNF 2533 QDISNY 2534 QSISSY 2535 QGISSY 2536 QDIINY 2537 QGISSY 2538 QGISSY 2539 QSISSY 2540 QDINKY 2541 AAS 2542 AAS 2543 EVS 2544 KAS 2545 AAS 2546 DAS 2547 GAS 2548 RSNs 2549 LSSDGSH 2550 KDS 2551 EAA 2552 DAS 2553 EVN 2554 GDQ 2555 KVS 2556 KAS 2557 AAS 2558 KDS 2559 WAS 2560 EDT 2561 WAS 2562 WAS 2563 KAS 2564 DVS 2565 KDS 2566 DVS 2567 GAS 2568 GAS 2569 DAS 2570 GAS 2571 SNN 2572 EVS 2573 WAS 2574 GAS 2575 DAS 2576 WAS 2577 AAS 2578 KGT 2579 DAS 2580 AAS 2581 DAS 2582 KNN 2583 ATS 2584 RNT 2585 SAS 2586 ASS 2587 STS 2588 ATS 2589 EDS 2590 DIN 2591 GPS 2592 QDS 2593 DNN 2594 GAS 2595 DTS 2596 AAS 2597 DVS 2598 WAS 2599 GAS 2600 DNN 2601 DVS 2602 LGS 2603 LGS 2604 LGS 2605 AAS 2606 AAS 2607 YDS 2608 QNN 2609 DNN 2610 DVS 2611 GAS 2612 AAS 2613 KAS 2614 KAS 2615 GAS 2616 RND 2617 WAS 2618 EDN 2619 STN 2620 AAS 2621 KVS 2622 DNN 2623 RNN 2624 KVS 2625 KVS 2626 GAS 2627 LNS 2628 EVS 2629 TAF 2630 AAS 2631 GKN 2632 EKN 2633 EVS 2634 GPS 2635 WAS 2636 KVS 2637 DVS 2638 AAS 2639 DVS 2640 AAS 2641 GKN 2642 QDT 2643 KAS 2644 KIS 2645 AAS 2646 GNN 2647 RNN 2648 GKN 2649 DAS 2650 DNN 2651 GAS 2652 QDS 2653 ATS 2654 ATS 2655 ATS 2656 AAS 2657 GAS 2658 KDS 2659 AAS 2660 QDN 2661 EVS 2662 EVS 2663 LGS 2664 EDS 2665 DVS 2666 EDS 2667 KAS 2668 DAS 2669 AAS 2670 GAS 2671 GAS 2672 GAS 2673 WAS 2674 EVS 2675 EVS 2676 LGS 2677 GSS 2678 GAS 2679 DAS 2680 WAS 2681 EVS 2682 DAS 2683 GAS 2684 EVS 2685 AAS 2686 KDS 2687 DVS 2688 AAS 2689 KVS 2690 QDS 2691 DVT 2692 DVT 2693 KVS 2694 DNN 2695 KDN 2696 GSS 2697 ETS 2698 LEGSGSY 2699 DAS 2700 DVS 2701 LGS 2702 KAS 2703 KVS 2704 GAS 2705 AAS 2706 QDS 2707 KAS 2708 GAF 2709 GAS 2710 EDS 2711 DAY 2712 WAS 2713 WAS 2714 DAS 2715 DAS 2716 STD 2717 GAS 2718 GAS 2719 KAS 2720 EVS 2721 KDS 2722 GAS 2723 GAS 2724 EVS 2725 GAS 2726 GAS 2727 AAS 2728 GNT 2729 DAS 2730 AAS 2731 WAS 2732 AAS 2733 ELF 2734 DTN 2735 EVS 2736 DAS 2737 DVN 2738 EVS 2739 AAS 2740 KIS 2741 DNS 2742 GAS 2743 LGS 2744 DDS 2745 GAS 2746 GAS 2747 DTS 2748 GAS 2749 SNN 2750 EVS 2751 DDG 2752 DVT 2753 AAS 2754 DAS 2755 RDN 2756 GAS 2757 VGTGGIVG 2758 EVS 2759 EAS 2760 KAS 2761 EVS 2762 EDS 2763 DAS 2764 KDR 2765 DNN 2766 AAS 2767 GAS 2768 GAS 2769 GPS 2770 DAS 2771 DAS 2772 SNN 2773 EIS 2774 KDK 2775 QDN 2776 GAS 2777 KDS 2778 EIS 2779 DAS 2780 KAS 2781 KAS 2782 EDT 2783 AAS 2784 GAS 2785 GAS 2786 GAS 2787 GNN 2788 QDT 2789 GDS 2790 KDT 2791 KAS 2792 QDS 2793 GAS 2794 GAS 2795 GAS 2796 GAS 2797 EVS 2798 EDN 2799 DNN 2800 EDN 2801 GKN 2802 GPS 2803 DNN 2804 EGS 2805 DNN 2806 AAS 2807 AAS 2808 DAS 2809 QDT 2810 DAS 2811 DAS 2812 DAS 2813 AAS 2814 AAS 2815 GPS 2816 DAS 2817 DAS 2818 DVS 2819 VKN 2820 DVS 2821 EVS 2822 GAS 2823 AAS 2824 GAS 2825 AAS 2826 QDS 2827 DVY 2828 AAS 2829 GAS 2830 DAS 2831 DAS 2832 EVS 2833 AAS 2834 DVS 2835 AAS 2836 LGS 2837 LGS 2838 KAS 2839 QDV 2840 GPS 2841 DDT 2842 LAS 2843 YDS 2844 RNN 2845 GAS 2846 KAS 2847 KAS 2848 GPS 2849 KDS 2850 GAS 2851 DVD 2852 AAS 2853 DDS 2854 AAS 2855 KAS 2856 DDN 2857 DNN 2858 LNSDGSH 2859 DAS 2860 DDS 2861 DAS 2862 DAS 2863 GAS 2864 GAS 2865 STS 2866 AAS 2867 DAS 2868 EVS 2869 EDN 2870 DAS 2871 DNN 2872 NVS 2873 egy 2874 GAS 2875 DNN 2876 GAS 2877 DAS 2878 GAS 2879 SAS 2880 EVS 2881 TAS 2882 AAS 2883 DAS 2884 VNT 2885 KAS 2886 SVS 2887 SNN 2888 EVS 2889 AAS 2890 DAS 2891 AAS 2892 AAS 2893 DAS 2894 AAS 2895 AAS 2896 GAS 2897 AAS 2898 AAS 2899 AAS 2900 DAS 2901 GLTVSSNY 2902 GFTVSRNY 2903 GVIVSSNY 2904 GFTVSSNY 2905 GVTVSSNY 2906 GI IV SS NY 2907 GI IV SS NY 2908 GFTVSSNY 2909 GLTVSSNY 2910 GLTVSSNY 2911 GI IV SS NY 2912 GVTVSRNY 2913 GITVSSNY 2914 GFTVSSNY 2915 GLTVSSNY 2916 GLTVSSNY 2917 GLIVSSNY 2918 GFTVSSNY 2919 GFIVSSNY 2920 GFTVSSNY 2921 GF IVSRNY 2922 GITVSSNY 2923 GFTVSSNY 2924 GFTVSSNY 2925 GFTVSSNY 2926 GVTVSSNY 2927 GFTVSSNY 2928 GYTFSSYG 2929 GYSFTYYG 2930 GFTFSSYD 2931 GFIVSSNY 2932 EFI VSRNY 2933 GFTVSSNY 2934 GFTVSSNY 2935 GFTVSFNY 2936 IYSGGST 2937 IYSGGTT 2938 IYSGGTT 2939 IYSGGST 2940 IYSGGST 2941 IYSGGST 2942 IYSGGST 2943 IYSGGST 2944 IYSGGST 2945 IYSGGST 2946 IYSGGST 2947 IYSGGST 2948 IYSGGST 2949 IYSGGST 2950 IYSGGST 2951 IYSGGST 2952 IYSGGST 2953 IYRGGST 2954 IYSGGST 2955 IYPGGST 2956 IYSGGST 2957 IYSGGST 2958 IYSGGST 2959 IYSGGST 2960 IYSGGST 2961 VYSGGST 2962 IYSGGST 2963 ISGYNGHT 2964 ISPYNGDT 2965 IGTAGDT 2966 IYSGGST 2967 IYSGGST 2968 IYSGGST 2969 IYSGGST 2970 IYPGGST 2971 ARDLDYYGMDV 2972 ARDLVVYGMDV 2973 ARDLDYYGMDV 2974 ARDLDYGGGMDV 2975 ARPIVGARSGMDV 2976 ARDLGTYGMDV 2977 ARDLGPYGMDV 2978 ARDLGAYGMDV 2979 ARDLYYYGMDV 2980 ARDLDYYGMDV 2981 ARDLDYYGMDV 2982 ARDGYGMDV 2983 ARGGAYYYGMDV 2984 ARDLDYMDV 2985 ARLPYGMDV 2986 ARLPYGMDV 2987 ARARIYTYGPDY 2988 ARVGDSRSWPFEY 2989 ARAPYSSRSET 2990 AREIRVITPVEV 2991 ARGPYPRFDY 2992 ARERGGRFDY 2993 ARDRPAAAIRF 2994 ARDYAGRV 2995 ARELSYSSSSSGVGPKY 2996 ARLINHYYDSSGDGGAFDI 2997 ARIGGVAAAGTADGAFDI 2998 ARERFGISHDY 2999 AKGVVALTGTLLRLDP 3000 ARDRDNGSGSYLGWAFDI 3001 ARDYGDYYFDY 3002 ARDYGDYYFDY 3003 ARDYGDYWFDP 3004 ARSYGDYYFDY 3005 ARDYGDFYFDY 3006 QGISSY 3007 QGISSY 3008 QGISSY 3009 QGISSY 3010 QDINNY 3011 QGISSY 3012 QGISSD 3013 QGISSY 3014 QGISSY 3015 QGISSY 3016 QGISSY 3017 QGISSY 3018 QGISSY 3019 QGISSY 3020 QDVSKY 3021 QDIRNY 3022 QDINNY 3023 QDISNY 3024 QDIRNY 3025 QDINKY 3026 QDIRNY 3027 QDISNY 3028 QDISNY 3029 QDIRSY 3030 QDISNY 3031 SSDVGSYNL 3032 SSDVGSYNL 3033 QSVGSN 3034 QSVRTN 3035 QSISSY 3036 QSVSSSY 3037 wxya 3038 QSVSSSY 3039 QGISSY 3040 QSVSSSY 3041 AAS 3042 AAS 3043 AAS 3044 AAS 3045 DAS 3046 AAS 3047 AAS 3048 AAS 3049 AAS 3050 AAS 3051 AAS 3052 AAS 3053 AAS 3054 AAS 3055 DAS 3056 DAS 3057 DAS 3058 DAS 3059 DAS 3060 DAS 3061 DAS 3062 DAS 3063 DAS 3064 DAS 3065 DAS 3066 EVT 3067 EGS 3068 GAF 3069 EAS 3070 AAS 3071 GAS 3072 GAS 3073 GTS 3074 AAS 3075 GAS 3076 QHLNSYPPIT 3077 QQLNSYPLT 3078 QQLNSYGLT 3079 QQLNSYPHRFT 3080 QQHDNLPVT 3081 QQLNSYLYT 3082 QQLNSDLYT 3083 QQLNSDLYT 3084 QQLDSYPL 3085 QQLNSYLAIT 3086 QQLNSYPPFT 3087 QQLNSYPPA 3088 QQLNTYPPFG 3089 QQLNSYPPMYT 3090 QQYDNLPVT 3091 QQYDNLPIT 3092 QQYDNLPPV 3093 QQYDNLPLFT 3094 QQYDNLPIT 3095 HQYDNLPRT 3096 QQYDNLPVT 3097 QQHDNLPSFT 3098 QQYDNLPPA 3099 QQYDNLPQT 3100 QQYDNLPPT 3101 CSYAGSSTWV 3102 CSYAGSSTWV 3103 QQYNNWYT 3104 QQYNNWPPIT 3105 QQSYSMPPVT 3106 QQYGSTPRT 3107 QQYGSSPRT 3108 QQYGSSPRT 3109 QQLNS 3110 QQYDSSPRT 3111 EVQLVESGGGLIQPGGSLRLSCAASGLTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSTNTLYLQMNSLRAEDTAVYYCARDLDYYGMDVWGQGTTVTVSS 3112 EVQLVESGGGLVQPGGSLRLSCAASGFTVSRNYMSWVRQAPGKGLEWVSVIYSGGTTHYADSVKGRFTISRHNSKNTLYLQMNSLRAEDTAVYYCARDLVVYGMDVWGQGTTVTVSS 3113 EVQLVESGGGLVQPGGSLRLSCAASGVIVSSNYMRWVRQAPGKGLEWVSVIYSGGTTYYADSVKGRFTISRHNSKNTLYLQMNSLRTEDTAVYYCARDLDYYGMDVWGQGTTVTVSS 3114 EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRHNSKNTLYLQMNSLRAEDTAVYYCARDLDYGGGMDVWGQGTTVTVSS 3115 EVQLVESGGGLIQPGGSLRLSCAASGVTVSSNYMSWVRQAPGKGLEWVSLIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARPIVGARSGMDVWGQGTTVTVSS 3116 EVQLVESGGGLIQPGGSLRLSCAASGIIVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNTMRAEDTAVYYCARDLGTYGMDVWGQGTTVTVS 3117 EVQLVESGGGLIQPGGSLRLSCAASGIIVSSNYMTWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMSSLRAEDTAVYYCARDLGPYGMDVWGQGTTVTVSS 3118 EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLGAYGMDVWGQGTTVTVSS 3119 EVQLVESGGGLIQPGGSLRLSCAASGLTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLYYYGMDVWGQGTTVTVSS 3120 EVQLVESGGGLIQPGGSLRLSCAASGLTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLDYYGMDVWGQGTTVTVSS 3121 EVQLVESGGGLVQPGGSLRLSCAASGIIVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLDYYGMDVWGQGTTVTVSS 3122 EVQLVESGGGLVQPGGSLRLSCAASGVTVSRNYMSWVRQAPGKGLEWVSVIYSGGSTDYADSVKGRFTISRHNSKNTLYLQMNSLRVEDTAVYYCARDGYGMDVWGQGTTVTVSS 3123 EVQLVESGGGLIQPGGSLRLSCAASGITVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGGAYYYGMDVWGQGTTVTVSS 3124 EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLDYMDVWGKGTTVTVSS 3125 EVQLVESGGGLVQPGGSLRLSCAASGLTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSVRAEDTAVYYCARLPYGMDVWGQGTTVTVSS 3126 EVQLVESGGGLVQPGGSLRLSCAASGLTVSSNYMSWVRQAPGKGLNWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLEMNSLKPEDTAVYYCARLPYGMDVWGQGTTVTVSS 3127 QVQLVESGGGLVQPGGSLRLSCAASGLIVSSNYMSWVRQAPGEGLEWVSVIYSGGSTYYADSVKGRFTISRDTSKNTLYLQMNSLRAEDTAVYYCARARIYTYGPDYWGQGTLVTVSS 3128 EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGRGLEWVSVIYRGGSTYYADSVKGRFSISRDNSKNTLYLQMNSLRVEDTAVYYCARVGDSRSWPFEYWGQGTLVTVSS 3129 EVQLVESGGGLVQPGGSLRLSCAASGFIVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLRMNSLRAEDTAVYYCARAPYCSSRSCETWGQGTLVTVSS 3130 EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSLIYPGGSTYYADSVEGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREIRVITPVEVWGQGTLVTVSS 3131 EVQLVESGGGLVQPGGSRLSCAVSGFIVSRNYMTWVRQAPGKGLEWVSLIYSGGSTFYTNSVKGRFTISRDNSKNTLYLQMDSLRAEDTAVYYCARGPYPRFDYWGQGTLVTVSS 3132 EVQLVESGGGLIQPGGSLRLSCAASGITVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYSDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARERGGRFDYWGQGTLVTVSS 3133 EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSLIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRPAAAIRFGQGTLVTVSS 3134 EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSIIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDYAGRVWGQGTLVTVSS 3135 EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARELSYSSSSGVGPKYWGQGTLVTVSS 3136 EVQLVESGGGLVQPGGSLRLSCAASGVTVSSNYMSWVRQAPGKGLEWVSAVYSGGSTYYADSVKGRFTISRHNSKNTLYLQMKSLRPEDTAIYYCARLINHYYDSSGDGGAFDIWGQGTMVTVSS 3137 EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIGGVAAAGTADGAFDIWGQGTMVTVSS 3138 QVQLVQSGAEVKKPGASVKVSCKTSGYTFSSYGLSWVRQAPGQGLEWMGWISGYNGHTVNAQNFQDRVTMTTDTSTDTAYMELRRSLRSDDTALYFCARERFGISHDYWGQGTLVIVSS 3139 QIQLVQSGPEVKRPGASVKVSCKASGYSFTYYGISWVRQAPGQGLEWMGWISPYNGDTKFAQKFQDRVILTTDTSTSTAYMELKSLRSDDTAVYYCAKGVVALTGTLRLDPWGQGTLVTVSS 3140 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDMHWVRQATGKGLEWVSVIGTAGDTYYPGSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARDRDNGSGSYLGWAFDIWGQGTMVTVSS 3141 EVQLVESGGGLIQPGGSLRLSCAASGFIVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDYGDYYFDYWGQGTLVTVSS 3142 EVQLVESGGGLIQPGGSLRLSCAASEFIVSRNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLNLQMNSLRAEDTAVYYCARDYGDYYFDYWGQGTLVTVSS 3143 EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDYGDYWFDPWGQGTLVTVSS 3144 EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSYGDYYFDYWGQGTLVTVSS 3145 EVQVVESGGGLVQPGGSLRLSCAASGFTVSFNYMSWVRQAPGKGLEWVSVIYPGGSTYYADSVKGRFTISRHNSKNTVYLQMNSLRAEDTAVYYCARDYGDFYFDYWGQGTLVTVSS 3146 DIQLTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPNLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHLNSYPPITFGQGTRLEIK 3147 DIQLTQSPSSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSSFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPLTFGGGTKVEIK 3148 DIQLTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQRGVPSRFSGSGSGTDFNLTISSLQPEDFGTYYCQQLNSYGLTFGGGTKVEIK 3149 DIQLTQSPSSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPHRFTFGPGTKVDIK 3150 DIQMTQSPSSLSASVGDRVTITCQASQDINNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFIISSLQPEDIATYYCQQHDNLPVTFGGGTKVEIK 3151 DIQLTQSPSSFLSASVGDRVTITCRASQGISSYLAWYEQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISTLQPGDFATYYCQQLNSYLYTFGQGTKLEIK 3152 DIQLTQSPSSFLSASVGDRVTITCRASQGISSDLAWYQQKPGKAPNLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSDLYTFGQGTKLEIK 3153 DIQLTQSPSSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSDLYTFGQGTKLEIK 3154 AIQLTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIFAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLDSYPLFGGGTKVEIK 3155 AIQLTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLNSYLAITFGQGTRLEIK 3156 DIQLTQSPSSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPPFTFGPGTKVDIK 3157 DIQLTQSPSSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPNLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPPAFGPGTKVDIK 3158 DIQLTQSPSSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNTYPPFGFGPGTKVDIK 3159 DIQLTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLNSYPPMYTFGQGTKLEIK 3160 DIQMTQSPSSLSASVGDRVTITCQASQDVSKYLNWYQQKPGKAPKLLIHDASNLQTGVPSRFSGGGSGTDFTFTISSLQPEDIATYYCQQYDNLPVTFGGGTKVEIK 3161 DIQMTQSPSSLSASVGDRVTITCQASQDIRNYLNWYQQKPGKAPKLLIHDASNLETGVPSRFIGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPITFGQGTRLEIK 3162 DIQMTQSPSSLSASVGDRVTITCQASQDINNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPPVFGPGTKVDIK 3163 DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPLFTFGPGTKVDIK 3164 DIQMTQSPSSLSASVGDRVTITCQASQDIRNYLNWYQQKPGKAPNLLIYDASNLETGVPSRFSGSGSGTDFTFTINSLQPEDIATYYCQQYDNLPITFGQGTRLEIK 3165 DIQMTQSPSSLSASVGDRVTITCQASQDINKYLNWYQLKPGKAPNLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCHQYDNLPRTFGQGTKVEIK 3166 DIQMTQSPSSLSASLGDRVTITCQASQDIRNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPVTFGGGTKVEIK 3167 DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASTLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQHDNLPSFTFGPGTKVDIK 3168 DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPPAFGGGTKVEIK 3169 DIQMTQSPSSLSASVGDRVTITCQASQDIRSYLNWYQQKPGKAPKLLIYDASNLETGVASRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPQTFGQGTKLEIK 3170 DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPPTFGGGTKVEIK 3171 QSALTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQRPGKAPKLILYEVTKRPSGVSNRFSGSKSGNTASLAISGLQAEDEADYYCCSYAGSSTWVFGGGTKLTVL 3172 QSALTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQHPGKAPKLMIYEGSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSTWVFGGGTKLTVL 3173 EIVMTQFPATLSVSPGERATLFCRASQSVGSNLAWYQQKPGQAPRLLIYGAFTRATGVPARFSGSGSGSEFSLTISSLQSEDFAVYYCQQYNNWYTFGQGTKLEIK 3174 EIVMTQSPATLSVSPGERATLSCRASQSVRTNLAWYQQKRGQAPRLLIYEASTRATGVPDRFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPITFGQGTRLDIK 3175 DIQMTQSPSSLSASSVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSASGSGTDFTLTISSLQPEDFATYYCQQSYSMPVTFGQGTKVEIK 3176 EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPERFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSTPRTFGQGTKVEIK 3177 EIVLTQSPGTLSLPGERATLSCRASQGVSSFLAWYQQKPGQAPRLLIHGASSRATGIPDRFSGSGSGTDFTLTITRLEPEDFAVYYCQQYGSSPRTFGQGTKVEIK 3178 EIVLTQSPGTLSLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGTSSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSPRTFGQGTKVEIK 3179 DIQLTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLNSFGPGTKVDIK 3180 EIVLTQSPGTLLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAMYYCQQYDSSPRTFGQGTKVEIK

Although the specific embodiments described herein have been described in detail, those skilled in the art will understand that various modifications and changes can be made to the details based on all the teachings that have been published, and these changes are all within the scope of protection described herein. Inside. All of what is described herein is given by the appended claims and any equivalents thereof.

1A - 1C exemplarily show the SDS-PAGE detection results of antigen binding units ABU-174, ABU-175 and ABU190. 2A - 2C exemplarily show the results of the determination of the affinity of antigen-binding units ABU-174 (A), ABU-175 (B), ABU190 (C) and S protein using SPR technology. Figure 3A-3C exemplarily shows the assay results of the neutralization and inhibitory activity of the antigen-binding units ABU-174 (A), ABU-175 (B), and ABU190 (C) to SARS-CoV-2 pseudoviruses. Figure 4 exemplarily shows the CPE assay results of the neutralization inhibitory activity of the ABU-175 antibody against the true virus of SARS-CoV-2. Figure 5 exemplarily shows the PRNT assay results of the neutralization inhibitory activity of the antigen-binding units ABU-174, ABU-175 and ABU190 against the true virus of SARS-CoV-2.

Claims (13)

An anti-new coronavirus antigen binding unit, which comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the sequence of the VH is shown in SEQ ID NO: 3117, and the sequence of the VL The sequence is shown in SEQ ID NO:3152. The anti-new coronavirus antigen binding unit as claimed in claim 1, which is less than 100nM, less than 50nM, less than 20nM, less than 15nM, less than 10nM, less than 5nM, less than 4nM, less than 3nM, less than 2nM, less than 1nM, less than 0.5 The equilibrium dissociation constant (K _D ) of nM, less than 0.1nM, less than 0.05nM, or less than 0.01nM binds to the receptor binding domain (RBD) of the novel coronavirus (SARS-CoV-2) S protein. The anti-new coronavirus antigen-binding unit as claimed in item 1 or 2, which is less than 20 μg/ml, less than 10 μg/ml, less than 9 μg/ml, less than 8 μg/ml, less than 7 μg/ml, less than 6 μg/ml, Less than 5 μg/ml, less than 4 μg/ml, less than 3 μg/ml, less than 2 μg/ml, less than 1 μg/ml, less than 0.5 μg/ml, less than 0.25 μg/ml, less than 0.2 μg/ml, less than 0.1 μg/ml, less than 0.05 μg/ml, or less than 0.001 μg/ml IC ₅₀ neutralizes the novel coronavirus (SARS-CoV-2). A pharmaceutical composition comprising the anti-new coronavirus antigen-binding unit according to one of claims 1 to 3 and a pharmaceutically acceptable excipient. An isolated nucleic acid encoding the anti-new coronavirus as described in one of claim items 1 to 3 antigen-binding unit. A vector comprising a nucleic acid sequence encoding the antigen-binding unit against novel coronavirus as described in one of claims 1 to 3. A host cell expressing the anti-new coronavirus antigen-binding unit as described in one of claims 1 to 3. A host cell comprising a nucleic acid encoding an anti-new coronavirus antigen-binding unit as described in one of claims 1 to 3. A method for producing an anti-new coronavirus antigen-binding unit according to any one of claims 1 to 3, comprising: cultivating the host cell of claim 7 or 8 under conditions suitable for expressing the antigen-binding unit; and isolating The antigen binding unit expressed by the host cell. A conjugate comprising the anti-new coronavirus antigen-binding unit according to one of claims 1 to 3, wherein the antigen-binding unit is conjugated to a chemical functional moiety. The conjugate according to claim 10, wherein the chemical functional moiety is selected from radioactive isotopes, enzymes, fluorescent compounds, chemiluminescent compounds, bioluminescent compound substrate cofactors and inhibitors. An anti-new coronavirus antigen binding unit as described in one of claims 1 to 3, or or the use of the nucleic acid encoding the anti-new coronavirus antigen-binding unit in the preparation of a pharmaceutical composition for the prevention and/or treatment of SARS-CoV-2 infection or SARS-CoV-2 infection in patients in need Diseases associated with CoV-2 infection. A kit for detecting SARS-CoV-2, which comprises the anti-new coronavirus antigen binding unit according to one of claims 1 to 3.

Images